Form 10-Q IsoRay, Inc. For: Mar 31

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

þ

QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended March 31, 2016

or

¨

Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from __________ to ____________

 

Commission File No. 001-33407

 

ISORAY, INC.

(Exact name of registrant as specified in its charter)

 

Minnesota (State or other jurisdiction of incorporation or organization)	41-1458152 (I.R.S. Employer Identification No.)
350 Hills St., Suite 106, Richland, Washington (Address of principal executive offices)	99354 (Zip Code)
Registrant's telephone number, including area code: (509) 375-1202

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨       Accelerated filer x      Non-accelerated filer ¨

Smaller reporting company ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ¨ No x

 

Number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date:
Class	Outstanding as of May 6, 2016
Common stock, $0.001 par value	55,010,619

 

 

ISORAY, INC.

 

Table of Contents

 

 

PART I	FINANCIAL INFORMATION
Item 1	Consolidated Unaudited Financial Statements	1
	Consolidated Balance Sheets	1
	Consolidated Statements of Operations (Unaudited)	2
	Consolidated Statements of Cash Flows (Unaudited)	3
	Notes to the Consolidated Unaudited Financial Statements	4
Item 2	Management’s Discussion and Analysis of Financial  Condition and Results of Operations	12
Item 3	Quantitative and Qualitative Disclosures About Market Risk	22
Item 4	Controls and Procedures	22
PART II	OTHER INFORMATION
Item 1	Legal Proceedings	23
Item 1A	Risk Factors	23
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3	Defaults Upon Senior Securities	24
Item 4	Mine Safety Disclosures	24
Item 5	Other Information	24
Item 6	Exhibits	24
Signatures		25

 

  

PART I – FINANCIAL INFORMATION

 

ITEM 1 – FINANCIAL STATEMENTS

 

IsoRay, Inc. and Subsidiaries

Consolidated Balance Sheets

 

		(Unaudited)
		March 31,				June 30,
		2016				2015
ASSETS
Current assets:
Cash and cash equivalents		$	5,694,339			$	5,226,740
Certificates of deposit			5,910,756				9,362,574
Accounts receivable, net of allowance for doubtful accounts of $30,000 and $30,000, respectively			883,702				1,049,041
Inventory			457,291				403,955
Other receivables			5,098				19,615
Prepaid expenses and other current assets			288,977				263,597
Total current assets			13,240,163				16,325,522
Property and equipment, net			415,675				574,840
Certificates of deposit, non-current			5,191,960				5,106,775
Restricted cash			181,368				181,262
Inventory, non-current			544,363				569,854
Other assets, net of accumulated amortization			222,529				245,031
Total assets		$	19,796,058			$	23,003,284
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$	732,018			$	498,253
Accrued protocol expense			97,679				124,131
Accrued radioactive waste disposal			164,544				129,500
Accrued payroll and related taxes			119,165				212,795
Accrued vacation			98,874				127,515
Total current liabilities			1,212,280				1,092,194
Long-term liabilities:
Warrant derivative liability			45,000				181,000
Asset retirement obligation			1,013,782				947,849
Total liabilities			2,271,062				2,221,043
Commitments and contingencies
Shareholders' equity:
Preferred stock, $.001 par value; 7,001,671 shares authorized:
Series A: 1,000,000 shares allocated; no shares issued and outstanding			-				-
Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding			59				59
Series C: 1,000,000 shares allocated; no shares issued and outstanding			-				-
Series D: 1,671 shares allocated; no shares issued and outstanding			-				-
Common stock, $.001 par value; 192,998,329 shares authorized;
55,010,619 and 54,967,559 shares issued and outstanding			55,010				54,968
Treasury stock, at cost, 0 and 13,200 shares, respectively			-				(8,390	)
Additional paid-in capital			82,727,429				82,467,111
Accumulated deficit			(65,257,502	)			(61,731,507	)
Total shareholders' equity			17,524,996				20,782,241
Total liabilities and shareholders' equity		$	19,796,058			$	23,003,284

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

IsoRay, Inc. and Subsidiaries

Consolidated Statements of Operations

(Unaudited)

 

		Three months ended March 31,								Nine months ended March 31,
		2016				2015				2016				2015
Product sales		$	1,198,701			$	1,158,109			$	3,649,031			$	3,265,795
Cost of product sales			1,132,397				1,102,912				3,472,357				3,303,364
Gross profit (loss)			66,304				55,197				176,674				(37,569	)
Operating expenses:
Research and development			183,187				141,399				385,325				458,636
Sales and marketing			300,995				374,876				833,887				1,032,402
General and administrative			909,144				589,934				2,785,539				1,703,825
Total operating expenses			1,393,326				1,106,209				4,004,751				3,194,863
Operating loss			(1,327,022	)			(1,051,012	)			(3,828,077	)			(3,232,432	)
Non-operating income (expense):
Interest income			53,725				68,954				167,032				214,009
Change in fair value of warrant derivative liability			78,000				28,605				136,000				375,605
Financing and interest expense			-				(100	)			(950	)			(3,551	)
Non-operating income (expense), net			131,725				97,459				302,082				586,063
Net loss			(1,195,297	)			(953,553	)			(3,525,995	)			(2,646,369	)
Preferred stock dividends			(2,658	)			(2,658	)			(7,974	)			(7,974	)
Net loss applicable to common shareholders		$	(1,197,955	)		$	(956,211	)		$	(3,533,969	)		$	(2,654,343	)
Basic and diluted loss per share		$	(0.02	)		$	(0.02	)		$	(0.06	)		$	(0.05	)
Weighted average shares used in computing net loss per share:
Basic and diluted			55,022,668				54,883,551				55,010,619				54,878,297

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

IsoRay, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited)

 

		Nine months ended March 31,
		2016				2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(3,525,995	)		$	(2,646,369	)
Adjustments to reconcile net loss to net cash used by operating activities:
Allowance for doubtful accounts			-				(8,607	)
Depreciation expense			412,170				439,223
Loss on equipment disposals			6,512				-
Writeoff of inventory associated with discontinued product			72,200				-
Amortization of other assets			25,494				34,923
Change in fair value of derivative warrant liability			(136,000	)			(375,605	)
Accretion of asset retirement obligation			65,933				60,278
Share-based compensation			229,442				64,360
Changes in operating assets and liabilities:
Accounts receivable, gross			165,339				(116,817	)
Inventory			(125,536	)			(104,818	)
Other receivables			14,517				43,154
Prepaid expenses and other current assets			111				(9,171	)
Accounts payable and accrued expenses			233,765				(135,198	)
Accrued protocol expense			(26,452	)			38,031
Accrued radioactive waste disposal			35,044				(23,469	)
Accrued payroll and related taxes			(93,630	)			(146,746	)
Accrued vacation			(28,641	)			(5,633	)
Net cash used by operating activities			(2,675,727	)			(2,892,464	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for property and equipment			(259,517	)			(77,963	)
Additions to licenses and other assets			(2,992	)			(14,016	)
Proceeds from maturity of certificates of deposit			9,558,812				10,031,758
Purchases of certificates of deposit			(6,106,994	)			(9,110,673	)
Purchases of certificates of deposit, non-current			(85,185	)			(4,744,580	)
Change in restricted cash			(106	)			(40	)
Net cash provided (used) by investing activities			3,104,018				(3,915,514	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid			(10,632	)			(10,632	)
Proceeds from sales of common stock, pursuant to exercise of warrants, net			-				70,789
Proceeds from sales of common stock, pursuant to exercise of options			49,940				145,274
Net cash provided by financing activities			39,308				205,431
Net increase (decrease) in cash and cash equivalents			467,599				(6,602,547	)
Cash and cash equivalents, beginning of period			5,226,740				7,680,073
CASH AND CASH EQUIVALENTS, END OF PERIOD		$	5,694,339			$	1,077,526
Non-cash investing and financing activities:
Retirement of treasury stock		$	8,390			$	-
Reclassification of derivative warrant liability to equity upon exercise		$	-			$	17,395

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

IsoRay, Inc.

Notes to the Unaudited Consolidated Financial Statements

For the three and nine months ended March 31, 2016 and 2015

 

1.

Basis of Presentation

 

The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries (“IsoRay” or the “Company”). All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10-K for the year ended June 30, 2015.

 

The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading.

 

Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented may not be indicative of those which may be expected for a full year.  The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2016 will be 0%.

 

2.

New Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, Revenue Recognition. The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

 

In July 2015, the FASB issued ASU No. 2015-11 – Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

 

 

In January 2016, the FASB issued ASU No. 2016-01 – Financial Instruments – Overall. The guidance requires an entity’s management to measure equity investments except those accounted for under the equity method of accounting or those that result in consolidation of the investee to be measured at fair value; simplifies the impairment assessment of equity investments; eliminates the requirement to disclose the fair value of financial instruments measured at amortized cost for non-public entities: eliminates the requirement for a public entity to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is not permitted except as contained in the early adoption guidance.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

 

3.

Certificates of deposit

 

The Company has maintained all excess cash in certificates of deposit at certain banks in certificates of deposit and through the Certificate of Deposit Account Registry Service (CDARS), which is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 limit to be fully insured by the Federal Deposit Insurance Corporation (FDIC). The Company ensures that principal amounts of certificates of deposit are fully insured. There may from time to time be short periods following maturity that amounts held in the money market account at the CDARS host bank will exceed FDIC coverage. In cases where the period that uninsured amounts will be held beyond ten banking days, the funds will be transferred to the primary operating account of the Company’s operating subsidiary, IsoRay Medical, Inc. (Medical), that incorporates a sweep function that keeps the funds FDIC insured during that time.

 

		As of March 31, 2016
		Under 90				91 days to				Six months to				Greater
		Days				six months				1 year				than 1 year
CDARS		$	5,910,756			$	-			$	-			$	5,191,960

 

		As of June 30, 2015
		Under 90				91 days to				Six months to				Greater
		Days				six months				1 year				than 1 year
CDARS		$	3,523,167			$	500,064			$	5,339,343			$	5,106,775

 

4.

Loss per Share

 

Basic and diluted earnings per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents. At March 31, 2016 and 2015, the calculation of diluted weighted average shares did not include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company’s net loss position.

 

Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of March 31, 2016 and 2015, were as follows:

 

		March 31,
		2016				2015
Series B preferred stock			59,065				59,065
Common stock warrants			360,800				396,174
Common stock options			2,355,060				2,057,620
Total potential dilutive securities			2,774,925				2,512,859

 

 

5.

Inventory

 

Inventory consisted of the following at March 31, 2016 and June 30, 2015:

 

		March 31,				June 30,
		2016				2015
Raw materials		$	223,588			$	143,669
Work in process			225,978				204,760
Finished goods			7,725				55,526
		$	457,291			$	403,955

 

		March 31,				June 30,
		2016				2015
Enriched barium, non-current		$	469,758			$	469,758
Raw materials, non-current			74,605				100,096
Total inventory, non-current		$	544,363			$	569,854

 

Inventory, non-current is (i) raw materials that were ordered in quantities to obtain volume cost discounts for key components of our brachytherapy seed including titanium lids, titanium tubes, gold wires that are used for imaging markers, and our proprietary seed core, which were ordered based on current and anticipated sales volumes and will not be consumed within an operating cycle; and (ii) enriched barium, which is classified as non-current, and is only expected to be utilized if required to obtain volumes of isotope that is not able to be purchased from an existing source in either the short- or long-term. Management does not anticipate the need to utilize the enriched barium within the current operating cycle unless there is an unanticipated interruption to the isotope supply that requires its use. If such a need were to occur, then management would evaluate the need to reclassify some or all of the inventory as a current asset. As of March 31, 2016, the Company discontinued the GliaSite^® RTS product line resulting in a write-off of GliaSite^® RTS related inventory totaling $72,200.

 

6.

Property and Equipment

 

		March 31,				June 30,
		2016				2015
Land		$	168,459			$	-
Equipment			3,560,891				3,553,774
Leasehold improvements			4,129,977				4,129,977
Other			38,793				5,925
Property and equipment			7,898,120				7,689,676
Less accumulated depreciation			(7,482,445	)			(7,114,836	)
Property and equipment , net		$	415,675			$	574,840

 

7.

Share-Based Compensation

 

The following table presents the share-based compensation expense recognized during the three months and nine months ended March 31, 2016 and 2015:

 

		Three months								Nine months
		ended March 31,								ended March 31,
		2016				2015				2016				2015
Cost of product sales		$	17,757			$	7,972			$	52,947			$	23,917
Research and development expenses			3,567				3,117				10,699				9,352
Sales and marketing expenses			3,744				2,158				10,230				6,475
General and administrative expenses			140,998				8,205				155,556				24,616
Total share-based compensation		$	166,066			$	21,452			$	229,442			$	64,360

  

 

As of March 31, 2016, total unrecognized compensation expense related to stock-based options was $337,350 and the related weighted-average period over which it is expected to be recognized is approximately 1.34 years.

 

A summary of stock options within the Company’s share-based compensation plans as of March 31, 2016 was as follows:

 

						Weighted				Weighted
						Exercise				Average
		Number of				Price				Contractual				Intrinsic
		Options				(Years)				Term				Value
Outstanding at March 31, 2016			2,380,060			$	1.48				5.71			$	289,393
Vested and expected to vest at March 31, 2016			2,294,065			$	1.48				5,66			$	282,800
Vested and exercisable at March 31, 2016			1,966,762			$	1.46				5.01			$	274,200

 

There were 56,260 and 133,564 stock options exercised and $27,469 and $145,275 of intrinsic value associated with these exercises during the nine months ended March 31, 2016 and 2015, respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.

 

There were 482,500 and no stock option awards granted during the nine months ended March 31, 2016 and 2015, respectively. Included in the 482,500 options were 20,000 that were issued in the first quarter of fiscal 2016 and 462,500 issued in the three months ended March 31, 2016.

 

	For the nine months ended
	March 31, 2016
Options issued	482,500
Weighted average exercise price	$0.64 to $1.53
Expected term (in years)	1 to 5
Risk free rate	0.51% to 1.51%
Weighted average volatility	106.21% to 108.26%

 

There were 442,854 and 39,002 stock option awards which expired during nine months ended March 31, 2016 and 2015, respectively.

 

There were 21,608 and 84,236 stock option awards forfeited during nine months ended March 31, 2016 and 2015, respectively.

 

8.

Commitments and Contingencies

 

Patent and Know-How Royalty License Agreement

 

The Company is the holder of an exclusive license to use certain “know-how” developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor’s patent application was ultimately abandoned, only a 1% “know-how” royalty based on Net Factory Sales Price, as defined in the agreement, remains applicable. To date, management believes that there have been no product sales incorporating the “know-how” and therefore no royalty is due pursuant to the terms of the agreement. Management believes that ultimately no royalties should be paid under this agreement as there is no intent to use this “know-how” in the future.

 

 

The licensor of the “know-how” has disputed management’s contention that it is not using this “know-how”. On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time.

 

Class Action Lawsuit Related to Press Release

 

On May 22, 2015, the first of three lawsuits was filed against IsoRay, Inc. and two of its officers – Dwight Babcock (the Company’s retired CEO) and Brien Ragle – related to a press release on May 20, 2015 regarding a May 19 online publication of the peer-reviewed article in the journal Brachytherapy titled “Analysis of Stereotactic Radiation vs. Wedge Resection vs. Wedge Resection Plus Cesium-131 Brachytherapy in Early-Stage Lung Cancer” by Dr. Bhupesh Parashar, et al. The lawsuits are class actions alleging violations of the federal securities laws. By Order dated August 17, 2015, all of the pending lawsuits were consolidated into one case – In re IsoRay, Inc. Securities Litigation; Case No. 4:15-cv-05046-LRS, in the US District Court for the Eastern District of Washington. IsoRay retained Wilson Sonsini Goodrich & Rosati as its and its officers’ defense counsel.

 

On October 16, 2015, an amended complaint was filed with more detailed allegations relating to violations of federal securities laws and requesting damages through a jury trial. Mr. Ragle was dismissed from the complaint.

 

On December 15, 2015, IsoRay filed a motion to dismiss the complaint altogether. Oral argument was scheduled on this motion on April 2016 but was rescheduled at the request of the plaintiff’s attorney to May 12, 2016.

 

On April 1, 2016, IsoRay filed a reply in Support of Motion to Dismiss Amended Complaint for Violations of the Federal Securities Laws. IsoRay believes the lawsuit is without merit and is seeking its dismissal.

 

Property Transaction between Medical and The Port of Benton

 

On September 10, 2015, the Company’s operating subsidiary, Medical, entered into a Real Estate Purchase and Sale Agreement with The Port of Benton (“Port”), a municipal corporation of the State of Washington. The Agreement is for the sale of undeveloped real property of approximately 4.2 acres located adjacent to the Company’s existing manufacturing facility and corporate offices. Medical finalized the purchase of the land in the third quarter of fiscal 2016 and has begun design work on a new production facility.

 

Medical is bound to comply with a Development Plan for a ten year period, the requirements of which include but are not limited to:

(1)

Certain specified site configurations and design with a minimum of 12,000 square feet of warehouse and production space and 4,000 square feet of office space;

 

(2)

Completion of all construction in two years;

 

(3)

Use of facility as primary production facility for ten (10) years; and

 

(4)

Provision of jobs for not less than 25 full-time employees.

 

The purchase price for the property was adjusted in consideration of the Development Plan’s covenants. Failure to comply with these covenants will result in a breach of the Agreement and if not cured, will obligate Medical to pay the Port the difference in the sales price and the appraised value of the property at the time of default. The Benton County 2015 assessed value of the land was $423,720, and management believes this approximates the current appraised value. The difference in the sales price and management’s estimate of the current appraised value of the property is approximately $256,000. This is subject to subsequent changes in valuation of the property.

 

 

9.

Fair Value Measurements

 

The table below sets forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2016 and June 30, 2015, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category.  

  

		Fair value at March 31, 2016
		Total				Level 1				Level 2				Level 3
Cash and cash equivalents		$	5,694,339			$	5,694,339			$	-			$	-
Warrant derivative liability			45,000				-				45,000				-

 

		Fair value at June 30, 2015
		Total				Level 1				Level 2				Level 3
Cash and cash equivalents		$	5,226,740			$	5,226,740			$	-			$	-
Warrant derivative liability			181,000				-				181,000				-

 

10.

Preferred Dividends

 

On December 10, 2015, the Board of Directors declared a dividend on the Series B Preferred Stock of all currently payable and accrued outstanding and cumulative dividends through December 31, 2015 in the amount of $10,632. The dividends outstanding and cumulative through December 31, 2015 of $10,632 and through December 31, 2014 of $10,632 were paid as of those dates.

 

11.

Shareholders’ Equity

 

Warrant derivative liability

 

Based on the guidance contained in ASC 815 “Derivatives and Hedging”, management has concluded that the warrants issued in the 2011 offering should be classified as a derivative liability and has recorded a liability at fair value.

 

A summary of the change in fair value of derivative warrant liability is as follows for the fiscal years presented.

 

		Quantity1				Amount
Balance at June 30, 2014			238,696			$	573,000
Change in fair value			-				(374,605	)
Warrants exercised			(13,209	)			(17,395	)
Balance at June 30, 2015			225,087			$	181,000
Change in fair value			-				(15,000	)
Balance at September 30, 2015			225,087				166,000
Change in fair value			-				(43,000	)
Balance at December 31, 2015			225,087				123,000
Change in fair value			-				(78,000	)
Balance at March 31, 2016			225,087			$	45,000

 

¹ Quantity of warrants either issued or outstanding as of the date of valuation.

 

 

Warrants

 

The following table summarizes all warrants outstanding as of the beginning of the fiscal year, all activity related to warrants issued, cancelled, exercised or expired during the period and weighted average prices by category.

 

						Weighted average
		Warrants				exercise price
Outstanding as of June 30, 2015			385,800			$	1.22
Warrants expired			(25,000	)			2.00
Outstanding as of March 31, 2016			360,800			$	1.17

 

The following table summarizes additional information about the Company’s common warrants outstanding as of March 31, 2016:

 

Number of Warrants				Exercise Prices				Expiration Date
	130,713			$	1.56			May 2016
	199,437				0.94			October 2016
	25,650				0.94			December 2016
	5,000				0.98			June 2017
	360,800

 

12.

Related Party Transaction

 

During the nine months ended March 31, 2016 and 2015, the Company continued to engage the services of APEX Data Systems, Inc., owned by Dwight Babcock, the Company’s former Chairman and Chief Executive Officer, to modify and maintain the Company’s web interfaced data collection application to aggregate patient data in a controlled environment. The cost recorded during the nine months ended March 31, 2016 and 2015 from APEX Data Systems, Inc. for the maintenance of the web interfaced data collection applications in combination with the updating of the Company website was $6,000 and $6,000 respectively. An additional $6,000 was spent on the maintenance of Customer Relationship Management (CRM) software in the nine months ended March 31, 2016 and 2015, respectively. At March 31, 2016 and 2015, services during the prior month had been accrued and remained unpaid in the amount of none and $2,000, respectively. These amounts were each paid in the subsequent month.

 

13.

Concentrations of Credit and Other Risks

 

The Company’s cash, cash equivalents, and investments are deposited with several financial institutions with FDIC coverage. At times, deposits for a limited period of time in these institutions may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances.

 

For the nine months ended March 31, 2016 and 2015, there was a single customer (which was a group of customers supported by a single physician group) that represented between 5% and 10% or more of total net revenue, respectively.

 

At March 31, 2016, one customer accounted for 10% or more of the Company’s total accounts receivable with that customer (a group of seven legal entities) representing 22% of total accounts receivable. At June 30, 2015, one customer (a group of seven legal entities) accounted for 27% of total accounts receivable.

 

 

Accounts receivable are typically not collateralized. The Company maintains ongoing dialogue with its customers about invoice payments. Some of our customers are small outpatient surgery centers that pay invoices for our products at the time they receive a decision regarding payment by the insurer providing benefits which in the case of prostate cancer is predominately Medicare. A qualitative review of outstanding customer balances is performed at least quarterly and the allowance for doubtful accounts is adjusted based on historical performance of the customer and management knowledge regarding specific invoices. Accounts are charged against the allowance for doubtful accounts once collection efforts are deemed unsuccessful. Prior to utilizing an external collection agency and interrupting the supply of our product, customers may be provided the opportunity to continue purchasing product on the basis of pre-paying via guaranteed funds the amount due on their current order prior to producing and shipping the order plus the amount due on their oldest outstanding invoice.

 

Single source suppliers presently provide the Company with several components. Management believes it would be able to locate other sources for these components subject to any regulatory qualifications if required.

 

During the three months ended December 31, 2015, the Company experienced an unplanned supply disruption of radioisotope from its Russian supplier. No customer orders were missed or delayed while the Company increased production at its second supplier to compensate for the unplanned outage. This event has led management to conduct a review of the Company’s current supply interruption plan in such a situation to ensure its ability to continue to produce a sufficient supply of radioisotope at either facility in the case of an extended supply interruption at either reactor. Over the next nine to twelve months, management intends to vet, test and modify where appropriate the Company’s current plan as required to ensure this capability.

 

 

ITEM 2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Caution Regarding Forward-Looking Information

 

In addition to historical information, this Form 10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA.

 

All statements contained in this Form 10-Q, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words "believe," "expect," "anticipate," "intends," "estimate," "forecast," "project," and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties described under “Risk Factors” under Part II, Item 1A below and in the “Risk Factors” sections of our Form 10-K for the fiscal year ended June 30, 2015 and our Form 10-Q for the fiscal quarter ended December 31, 2015 that may cause actual results to differ materially.

 

Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company's views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of the Company’s financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, management evaluates past judgments and estimates, including those related to bad debts, inventories, accrued liabilities, derivative liabilities and contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The accounting policies and related risks described in the Company’s annual report on Form 10-K as filed with the Securities and Exchange Commission on September 14, 2015 are those that depend most heavily on these judgments and estimates. As of March 31, 2016, there had been no material changes to any of the critical accounting policies contained therein.

 

  

Overview

 

Products and Market.

 

IsoRay, Inc. is a brachytherapy device manufacturer with FDA clearance and CE marking for a single medical device that can be delivered to the physician in multiple configurations as prescribed for the treatment of cancers in multiple body sites. The Company manufactures and sells this product as the Proxcelan® Cesium-131 brachytherapy seed. Each brachytherapy seed order is manufactured to the physician’s specifications for a named patient on a specific treatment date.

 

The Proxcelan® brachytherapy seed utilizes Cesium-131, with a 9.7 day half-life, as its radiation source. The Company believes that it is the unique combination of the short half-life and the energy of the Cesium-131 isotope that are yielding the beneficial treatment results that have been published in peer reviewed journal articles and presented in various forms at conferences and tradeshows.

 

The Company has distribution agreements outside of the United States through its subsidiary IsoRay International LLC. These distributors are responsible for obtaining regulatory clearance to sell the Company’s products in their territories, with the support of the Company. As of the date of this Report, the Company had distributors in Australia and New Zealand, and the Russian Federation, with revenues from all distributors combined approximating $17,000 in the nine months ended March 31, 2016.

 

Management is encouraged by the overall growth in revenue from sales of the Company’s Proxcelan® brachytherapy seeds during the prior four consecutive fiscal quarters. The growth from the sales of brachytherapy seeds during the prior four fiscal quarters compared to the same quarters in the prior fiscal year has averaged 20% with minimum revenue growth of 4% and maximum revenue growth of 45%.

 

Management is encouraged by the growth trend in our core business of treating prostate cancer, with three of the past four fiscal quarters experiencing increases over the same quarter in the prior fiscal year. During the prior four fiscal quarters, the prostate segment growth has averaged 18% growth with a maximum revenue decrease of 1% and maximum revenue growth of 44%. The Company has a very small share of the overall prostate brachytherapy market; as such management believes there is significant opportunity for expansion.

 

Net revenue from other treatments utilizing the Proxcelan® brachytherapy seeds during the prior four fiscal quarters has averaged revenue growth of 36% when compared to the same quarter in the prior fiscal year with minimum revenue growth of 18% and maximum revenue growth of 49% during that period. Growth in revenue from treating brain cancer during the preceding four consecutive fiscal quarters compared to the same quarters during the prior fiscal year has averaged 32% with minimum revenue growth of 9% and maximum revenue growth of 139%. Although these treatments are still heavily dependent on the purchasing behaviors of key physicians which has created volatility in revenue, management is encouraged by the upward trend in revenues.

 

Management believes current revenue growth is the result of additional peer-reviewed articles that share treatment experiences. These publications are building awareness in, and communicating the treatment advantages of, our products. Management also believes that as the impact of the Affordable Care Act’s cost containment measures continue to be felt, the payors will have to react by modifying methods of reimbursement to encourage facilities to utilize other modalities that offer equal or better results with a lower total cost of treatment. Management expects cost containment decisions to be favorable to seed brachytherapy as external beam radiation makes up the majority of the overall treatment market for prostate cancer and a significant portion of the market in other body sites in which the Company competes for business.

 

  

When brachytherapy seeds are implanted during a surgical procedure for brain cancer, lung cancer and certain other non-prostate cancers, under Medicare, the brachytherapy seeds are not separately reimbursed when surgery is performed and the patient is admitted to the hospital. Management is developing a strategy to address this gap in the payment system in consultation with consultants experienced in healthcare reimbursement, representatives of the facilities utilizing our products and the final payors for our products. External beam radiation treatments for these same cancers are reimbursed in addition to the cost of surgery as they are administered as separate treatments following surgery with a significantly greater cost of treatment, increased duration of treatment and decreased convenience for the patient. While the cost of external beam radiation is significantly greater than the cost of brachytherapy procedures, the separate reimbursement for external beam radiation treatments results in the hospital receiving a payment in addition to payment for the surgical procedure itself. With brachytherapy performed concurrent with the surgery, the hospital receives the same reimbursement for the surgical procedure whether seeds are implanted or not, resulting in brachytherapy treatment being an additional cost for the hospital.

 

The Company believes that long-term success of the Proxcelan^® Cesium-131 brachytherapy seed is dependent on a number of factors including the following:

·

Increased awareness by physicians of the benefits of utilizing Proxcelan® Cesium-131 brachytherapy seeds;

·

The Affordable Care Act (ACA) implementing cost containment measures in the evaluation of treatment methodologies and reimbursement, particularly in prostate cancer where costly intensity-modulated radiation therapy (IMRT) treats an increasing percentage of the overall U.S. prostate cancer treatment market and growth in the market is expected with the increase in men younger than Medicare age obtaining health insurance;

·

Increased patient awareness of the comparability and benefits of low-dose rate (LDR) brachytherapy when compared to external beam radiation therapy; including comparable urinary symptoms, fewer bowel toxicities, and better sexual function;

·

Increased attention by payors and patients to the increased cost being paid for IMRT and the potential conflict of interest resulting from the in-office referral of prostate cancer patients for IMRT utilizing equipment in which the physician has an ownership interest, which can be allowed through an exception, for in-office ancillary services, to the federal laws that generally prohibit self-referrals;

·

Changes in the reimbursement methodology regarding the utilization of brachytherapy seeds in the treatment of brain cancer, lung cancer, and other cancers;

·

Continued evolution in protocols demonstrating the safety, efficacy and other benefits of using Proxcelan® Cesium-131 brachytherapy seeds to treat tumors throughout the body;

·

Continued publication of peer-reviewed journal articles and presentations at society meetings about the treatment outcomes achieved utilizing Proxcelan® Cesium-131 brachytherapy seeds in the treatment of prostate cancer, brain cancer, lung cancer, gynecological cancer and other tumors throughout the body;

·

Expanded sales through distributors into other countries particularly those in which external beam radiation has not established a significant presence; and,

·

Continued ability of the Company to deliver a product that meets the standards of the Company and the expectations of its customers.

 

As of April 12 , 2016, management had provided a notice of termination of all agreements related to the patent license, supply, manufacture and distribution of its GliaSite® Radiation Therapy System (GliaSite® RTS). The GliaSite® RTS had only resulted in marginal sales but it was the first delivery system available to the Company to deliver brachytherapy radiation in the treatment of brain cancer. Management believes that application of the Cesium-131 brachytherapy seed in a braided suture and using other delivery systems which are being developed by others utilizing the Company's Cesium-131 brachytherapy seed are showing greater success and acceptance in the treatment of brain cancer.

 

 

Results of Operations

 

Three and nine months ended March 31, 2016 and 2015.

 

		Three months ended March 31,
		2016								2015								2016 - 2015
		Amount				% (a)				Amount				% (a)				% Change
Product sales, net		$	1,198,701				100			$	1,158,109				100				4
Cost of product sales			1,132,397				94				1,105,912				95				3
Gross profit / (loss)			66,304				6				55,197				5				20
Research and development expenses			183,187				15				141,399				12				30
Sales and marketing expenses			300,995				25				374,876				32				(20	)
General and administrative expenses			909,144				76				589,934				51				54
Net loss		$	(1,195,297	)			(100	)		$	(953,553	)			(83	)			25

 

		Nine months ended March 31,
		2016								2015								2016 - 2015
		Amount				% (a)				Amount				% (a)				% Change
Product sales, net		$	3,649,031				100			$	3,265,795				100				12
Cost of product sales			3,472,357				95				3,303,364				101				5
Gross profit / (loss)			176,674				5				(37,569	)			(1	)			570
Research and development expenses			385,325				11				458,636				14				(16	)
Sales and marketing expenses			833,887				23				1,032,402				32				(19	)
General and administrative expenses			2,785,539				76				1,703,825				51				63
Net loss		$	(3,525,995	)			(97	)		$	(2,646,369	)			(81	)			(33	)

 

(a) Expressed as a percentage of product sales, net

 

Revenues.

 

Product sales consist primarily of Proxcelan® Cesium-131 brachytherapy seeds manufactured and configured to the physician’s specification. Also included in product sales are GliaSite® RTS device sales.

 

Revenue from product sales for the three months ended March 31, 2016 increased approximately $41,000 or 4% when compared to the three months ended March 31, 2015. Increases in revenue from product sales were due to an increase in the number of brachytherapy seed treatments. No revenue was derived from GliaSite® RTS during the three months ended March 31, 2016. During the three months ended March 31, 2016 and 2015, nearly 100% of product sales came from brachytherapy seed treatments.

 

Revenue from product sales for the nine months ended March 31, 2016 increased approximately $383,000 or 12% when compared to the nine months ended March 31, 2015. Increases in revenue from product sales were primarily related to an increase in the number of brachytherapy seed treatments. GliaSite® RTS revenues for the nine months ended March 31, 2016 were approximately $17,000. During the nine months ended March 31, 2016, nearly 100% of product sales came from brachytherapy seed treatments compared with 98% during the nine months ended March 31, 2015.

 

  

Prostate Brachytherapy.

 

During the three months ended March 31, 2016 and 2015, respectively, prostate brachytherapy was 87% and 86% of total revenues. During the nine months ended March 31, 2016 and 2015, respectively, prostate brachytherapy was 88% and 87% of total revenues. Management believes growth in the Company’s prostate brachytherapy revenue is the result of physicians, payors, and patients increasingly considering overall treatment cost in combination with treatment outcomes and quality of life. Management anticipates that additions in sales and marketing during the three months ended March 31, 2016 will enhance growth in this segment including the addition of a Vice-President of Sales and Marketing with over 15 years of experience in the prostate cancer treatment market. Management also believes the data that has been published in peer-reviewed journal articles on treatment outcomes achieved with low-dose-rate (LDR) prostate brachytherapy with the Company’s Proxcelan® Cesium-131 brachytherapy seeds, indicating it is more cost effective, has faster resolution of urinary side effects and a reduced impact on the healthy tissue surrounding the tumor, when compared to competing treatments such as high-dose-rate brachytherapy and intensity-modulated radiation therapy, is a driver of the recent growth in the Company’s prostate brachytherapy revenue. There is no assurance this trend will continue.

 

Other Brachytherapy.

 

The strategy implemented by management in diversifying the number of body sites being actively treated with the Proxcelan® Cesium-131 brachytherapy seed has continued to provide an additional source of revenue. While individually these treatment sites do not represent a significant contribution to revenue, the sites as a group increased their revenue contribution by 18% during the three months ended March 31, 2016 when compared to the three months ended March 31, 2015. The largest revenue contributions in this classification came from brain cancer and gynecological cancer treatments. During the three months ended March 31, 2016 and 2015, respectively, other brachytherapy represented approximately $139,000 or 12% of total revenue and approximately $118,000 or 11% of total revenue.

 

These treatment sites as a group increased their revenue contribution by 30% during the nine months ended March 31, 2016 when compared to the nine months ended March 31, 2015. The largest revenue contributions in this classification came from brain cancer and gynecological cancer treatments. During the nine months ended March 31, 2016 and 2015, respectively, other brachytherapy represented approximately $285,000 or 12% of total revenue and approximately $219,000 or 10% of total revenue.

 

These other brachytherapy treatments continue to be subject to the influence of a small pool of innovative physicians who are the early adopters of the technology who also tend to be faculty at teaching hospitals training the next generation of physicians. This causes the revenue created by these types of treatment applications to be more volatile and vary significantly from quarter to quarter.

 

Cost of product sales.

 

Cost of product sales consists primarily of the costs of manufacturing and distributing the Company’s products.

 

Cost of product sales for the three months ended March 31, 2016 increased approximately $30,000 or 3% when compared to the three months ended March 31, 2015.

 

Cost of product sales for the nine months ended March 31, 2016 increased approximately $169,000 or 5% when compared to the nine months ended March 31, 2015.

 

Included in the increase in cost of product sales for the three and nine months ended March 31, 2016 were increased payroll, benefits and share-based compensation which were partially offset by a decrease in medical device tax. In addition, for the nine months ended March 31, 2016 material and third-party seed loading costs increased but were partially offset by decreased occupancy and depreciation expenses.

 

 

The Company purchases an excess supply of isotope to meet not only known customer orders but also enough to fill anticipated orders which may or may not materialize. Excess isotope is utilized in the production of upcoming orders where possible considering the decay rates of Cesuim-131. Loss of isotope to decay is also included as a cost of production.

 

Gross profit / (loss).  

 

Gross profit for the three months ended March 31, 2016 improved by approximately $11,000 or 20% when compared to the gross profit for the three months ended March 31, 2015.

 

Gross profit for the nine months ended March 31, 2016 improved by approximately $214,000 or 570% when compared to the gross loss for the nine months ended March 31, 2015.

 

Gross profit improvements for the three and nine months were due primarily to increased product sales that required only minimal increases in labor costs, raw material consumption and utilized isotope that was already available at current purchasing levels to support growth and other fluctuations in demand.

 

Research and development.

 

Research and development consists primarily of the costs related to employee and third party research and development activities.

 

Research and development costs for the three months ended March 31, 2016 increased approximately $42,000 or 30% when compared to the three months ended March 31, 2015.

 

Research and development costs for the nine months ended March 31, 2016 increased approximately $73,000 or 16% when compared to the nine months ended March 31, 2015.

 

Included in research and development costs for the three and nine months ended March 31, 2016 were increases in legal expenses related to intellectual property and increased payroll related to the short-term appointment of the Company Vice-President of Research and Development as interim Chief Executive Officer. In addition, for the nine months ended March 31, 2016 cost increases were partially offset by an adjustment to protocol costs.

 

Sales and marketing expenses.

 

Sales and marketing expenses consists primarily of the costs related to the internal and external activities of the Company’s sales, marketing and customer service.

 

Sales and marketing costs for the three months ended March 31, 2016 decreased approximately $74,000 or 20% when compared to the three months ended March 31, 2015.

 

Sales and marketing costs for the nine months ended March 31, 2016 decreased approximately $199,000 or 19% when compared to the nine months ended March 31, 2015.

 

Included in sales and marketing costs for the three and nine months ended March 31, 2016 were decreases in payroll, benefits and travel expenses related to unfilled positions. The Company filled a senior marketing position in February 2016 and the Vice President of Sales and Marketing position in March 2016. The open territory manager position remained vacant as of March 31, 2016 but was filled in April 2016.

 

  

General and administrative expenses.

 

General and administrative expenses consist primarily of the costs related to the executive, quality assurance/regulatory affairs departments, finance, and information technology of the Company.

 

General and administrative costs for the three months ended March 31, 2016 increased approximately $319,000 or 54% when compared to the three months ended March 31, 2015.

 

General and administrative costs for the nine months ended March 31, 2016 increased approximately $1,082,000 or 63% when compared to the nine months ended March 31, 2015.

 

Included in general and administrative costs for the three months ended March 31, 2016 were approximately $60,000 in increased legal expenses related to the retirement of the Company CEO, the appointment of an interim CEO and the hiring of a new CEO as well as payroll and benefit expenses related to the retirement of the Company CEO and the hiring of a new CEO; approximately $134,000 in option-based compensation for the new CEO; and approximately $79,000 in costs associated with discontinuing the GliaSite^® RTS product.

 

In addition, for the nine months ended March 31, 2016, cost increases included approximately $234,000 in legal fees related to the class action shareholder suit; approximately $300,000 in severance costs related to the retirement of the former CEO; approximately $51,000 in occupancy expense due to a change in allocation of costs; $27,000 in information technology upgrades including computer hardware, computer software and office supplies that are below the capitalization threshold; approximately $26,000 in audit and other services from British Standards Institute, the notified body for the Company related to the quality system; and approximately $21,000 in public company expenses.

 

Operating loss.

 

Operating loss for the three months ended March 31, 2016 increased approximately $276,000 or 26% when compared to the operating loss for the three months ended March 31, 2015.

 

Operating loss for the nine months ended March 31, 2016 increased by approximately $596,000 or 18% when compared to the operating loss for the nine months ended March 31, 2015.

 

Operating losses for the three and nine months increased primarily due to general and administrative cost increases as previously discussed.

 

Interest income.

 

Interest income for the three months ended March 31, 2016 decreased approximately $15,000 or 22% when compared to the interest income for the three months ended March 31, 2015.

 

Interest income for the nine months ended March 31, 2016 decreased by approximately $47,000 or 22% when compared to the interest income for the nine months ended March 31, 2015.

 

Interest income decreases for the three and nine months ending March 31, 2016 were due primarily the excess cash available to invest in laddered CDs in the Certificate of Deposit Account Registry Service® (CDARS) and in amounts that are fully insured by the Federal Deposit Insurance Corporation (FDIC).

 

  

Change in fair value of warrant derivative liability.

 

The warrant derivative liability requires periodic evaluation for changes in fair value. As required as of March 31, 2016 and March 31, 2015, the Company evaluated the fair value of the warrant derivative liability using the Black-Scholes option pricing model and applied updated inputs as of those dates. The resulting change in fair value was recorded as of March 31, 2016 and March 31, 2015.

 

Liquidity and capital resources. The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has historically financed its operations through selling equity to investors. During the nine months ended March 31, 2016 and March 31, 2015, the Company used existing cash reserves to fund its operations and capital expenditures.

 

Cash flows from operating activities

 

Net loss was approximately $3.53 million compared to $2.65 million and net cash used by operating activities was $2.68 million and $2.89 million, for the nine months ended March 31, 2016 and 2015, respectively. The decrease in net cash used by operating activities was due to several factors including unfilled positions within the Company and timing of paying operating expenses. Other factors are as follows:

 

·

Decrease in cash used by accounts receivable of approximately $165,000, the result of the increased collection effectiveness;

·

Increase in cash used by inventory of approximately $126,000, the result of purchases of inventory, consisting of raw materials produced to the specifications of the Company, in quantities to obtain best pricing, pre-loading materials and work in process;

·

Decrease in cash used by inventory, a significant portion of the change is the result of a $72,000 write-off of GliaSite® RTS inventory; and

·

Decrease in cash used by accounts payable and accrued expenses of approximately $234,000, the result of the timing of paying operating expenses and the accrual of severance cost of approximately $300,000 associated with the retirement of the CEO.

 

Cash flows from investing activities

 

Net cash provided by investing activities was $3.10 million as compared to net cash used by investing activities of $3.92 million for the nine months ended March 31, 2016 and 2015, respectively. Investing activities primarily consist of transactions related to the purchase and subsequent maturity of certificates of deposit totaling approximately $3.4 million, with transactional categories showing separately on the statement of cash flows. Other factors are as follows:

 

·

Increase in cash used in purchases of equipment of approximately $91,000; and

·

Increase in cash used in purchase of land of approximately $169,000.

 

Cash flows from financing activities

 

Net cash provided by financing activities was $40,000 and $205,000 for the nine months ended March 31, 2016 and 2015, respectively. The decrease was primarily due to fewer warrants and stock option exercises.

 

  

Projected Fiscal Year 2016 Liquidity and Capital Resources

 

At March 31, 2016, the Company held cash and cash equivalents of $5,694,339, CDARS of $5,910,756 million that mature in the current operating cycle and CDARS of $5,191,960 million that mature within the next seventeen months.

 

		Amount
Cash and cash equivalents		$	5,694,339
Certificates of deposit maturing in less than 90 days			5,910,756
Certificates of deposit maturing greater than one year and less than two years			5,191,960
Cash, cash equivalents and certificates of deposit total		$	16,797,055

 

The Company had approximately $4.50 million of cash and cash equivalents, $6.40 million of certificates of deposit and $5.19 million of certificates of deposit, non-current as of May 6, 2016. The short-term investments mature in June 2016. At the time of maturity, Company management will assess the cash requirements of the Company and reinvest excess cash as it deems appropriate.

 

The Company’s approximate monthly required cash operating expenditures were $298,000 and $321,000 during the nine months ended March 31, 2016 and 2015, respectively, which represents a 7% decrease. As we have filled several open positions both in senior management and sales and marketing and have engaged other third-party experts in marketing and medical reimbursement, our monthly cash operating expenses are expected to show a long term increase from historical levels.

 

Management forecasts that fiscal year 2016 cash consumed in production operations will be similar to the prior fiscal year. Company management is early in the design process of the future facility with the goal of constructing a facility that will have depreciation cost that is less than the monthly rental of the current facility. Management is reviewing all aspects of production operations, research and development, sales and marketing, and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems, and personnel are available to support and drive sales.

 

Capital expenditures

 

·

The Company has not required significant capital equipment investment despite many of the significant items of manufacturing equipment having reached or reaching their depreciable lives this fiscal year. Management believes less than $200,000 will be required to be invested in manufacturing or other capital equipment related to Company operations during fiscal year 2016, but there is no assurance that unanticipated needs for capital equipment or a yet to be determined capital project may not arise; and

·

The Company placed $25,000 in escrow on raw land as disclosed in financial statement footnote 8 Commitments and Contingencies under the section “Property Transaction between Medical and The Port of Benton”. On February 5, 2016, an additional amount of $144,000 was paid to close on the real property. Future cash requirements related to the construction of and moving into the new facility are difficult to project until designs, architectural drawings and contractor estimates of construction costs have been completed. Prior to construction, management has contracted to spend approximately $165,000 to receive a final design, architectural drawings and an estimate of cost to construct the new facility. If the covenants associated with the raw land are not fully complied with in a timely manner, the Company would be required to pay the difference between the purchase price and the appraised value of the property, which management has estimated to be $256,000 as of the date of this Report, but this difference is subject to change with changes in the appraised value.

 

 

Management intends to continue its existing protocol studies and to begin new protocol studies on brain and lung cancer treatment using Cesium-131. Management believes that approximately $150,000 in expense will be incurred during fiscal year 2016 in protocol expenses relating to lung cancer, inter-cranial cancer and both dual therapy and monotherapy prostate protocols, but there is no assurance that unanticipated needs for additional protocols in support of the development of new applications of our existing products may not arise.

 

Based on the foregoing assumptions, management believes that the cash and cash equivalents of approximately $4.50 million, short-term investments of $6.40 million and investments – other of $5.19 million at May 6, 2016 will be sufficient to meet our anticipated cash needs assuming both revenue and expenses remain at current levels for the next three years.

 

Management plans to attempt to attain breakeven and generate additional cash flows by increasing revenues from both new and existing customers in the prostate market (through our direct sales channels and through our distributors), and expanding sales in other market applications which include brain, gynecologic, head and neck, and lung implants, while maintaining the Company's focus on cost control. However, there can be no assurance that the Company will attain profitability or that the Company will be able to attain increases in its revenue. Total product sales have not shown the increases necessary to breakeven during the past seven fiscal years ended June 30, 2015 or for the nine months ended March 31, 2016.

 

For the nine months ended March 31, 2016, revenue from other treatment modalities with brachytherapy seeds increased 30% when compared to the nine months ended March 31, 2015. These newer brachytherapy product sales (including brain, gynecological, head and neck, lung and those reported as other) remain in the early stages of adoption and application in the clinical setting and their purchasing patterns are subject to the influence of a few key physicians who can significantly influence revenue from quarter to quarter.

 

There was no material change in the use of proceeds from our public offering as described in our final prospectus supplement filed with the SEC pursuant to Rule 424(b) on March 24, 2014. Through March 31, 2016, the Company had used the net proceeds raised through the March 2014 offering as described in the table below and held the remaining net proceeds in cash and cash equivalents and certificates of deposit. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.

 

Offering description		Period		Net proceeds				Remaining net proceeds
Registered direct offering		March 2014		$	13,814,742			$	13,814,742

 

The Company expects to finance its future cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing shareholders Management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to shareholders.

 

Other Commitments and Contingencies

 

The Company presented its other commitments and contingencies in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015. There have been no material changes outside of the ordinary course of business in those obligations during the current quarter.

 

Off-Balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements.

 

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and on various other factors the Company believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results could therefore differ materially from those estimates if actual conditions differ from our assumptions.

 

During the nine months ended March 31, 2016, there have been no changes to the critical accounting policies and estimates, as discussed in Part II, Item 7 of our Form 10-K for the year ended June 30, 2015.

 

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

There have been no material changes to the disclosure in the “Quantitative and Qualitative Disclosures about Market Risk Factors” section of our Annual Report on Form 10-K for the year ended June 30, 2015.

 

ITEM 4 – CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-14(c) and 15d-14(c) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act), as of March 31, 2016. Based on that evaluation, our principal executive officer and our principal financial officer concluded that the design and operation of our disclosure controls and procedures were effective. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. However, management believes that our system of disclosure controls and procedures are designed to provide a reasonable level of assurance that the objectives of the system will be met.

 

Changes in Internal Control over Financial Reporting

 

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Inherent Limitations of Internal Control Over Financial Reporting

 

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

 

PART II - OTHER INFORMATION

 

ITEM 1 – LEGAL PROCEEDINGS

 

The Company may, in the ordinary course of business, be subject to various legal proceedings. Legal proceedings are discussed in Note 8 of Notes to Condensed Consolidated Financial Statements (Unaudited), which is incorporated by reference in Part 1, Item 1. We refer you to that discussion for important information concerning those legal proceedings, including the basis for such actions and, where known, the relief sought. We provide the following additional information concerning those legal proceedings, including the name of the lawsuit, the court in which the lawsuit is pending, and the date on which the petition commencing the lawsuit was filed.

 

In Re IsoRay, Inc. Securities Litigation: U.S. District Court for the Eastern District of Washington, filed October 16, 2015.

 

ITEM 1A – RISK FACTORS

 

A description of the risk factors associated with our business is included under “Risk Factors” contained in Part I, Item 1A of our Form 10-K for the year ended June 30, 2015, and in Part II, Item 1A of our Form 10-Q for the quarter ended December 31, 2015, and is incorporated herein by reference. There have been no material changes in our risk factors since such filings, except for the following:

 

Our Revenues Depend Upon One Product. As we discontinued sale of our GliaSite^® RTS product, our revenues depend solely upon the successful production, marketing, and sales of the Proxcelan^® Cesium-131 brachytherapy seed. The rate and level of market acceptance of this product varies depending on the perception by physicians and other members of the healthcare community of its safety and efficacy as compared to that of competing products, if any; the clinical outcomes of the patients treated; the effectiveness of our sales and marketing efforts or those of our distributors in the United States, Australia, New Zealand and the Russian Federation; any unfavorable publicity concerning our product or similar products; our product's price relative to other products or competing treatments; any decrease in current reimbursement rates from the Centers for Medicare and Medicaid Services or third-party payers; regulatory developments related to the manufacture or continued use of the product; availability of sufficient supplies of barium for Cesium-131 seed production; ability to produce sufficient quantities of Cesium-131; the ability of physicians to apply the correct dosage of seeds and avoid excessive levels of radiation to patients; and the ability to use this product to treat multiple types of cancers in various organs. Because of our reliance on this product as the sole source of our revenue, any material adverse developments with respect to the commercialization of this product may cause us to continue to incur losses rather than profits in the future.

 

We Rely Heavily On Five Customers And Have a Single Customer With A Large Payable. Approximately fifty-one percent (51%) of the Company’s revenues are dependent on five customers and approximately twenty-two percent (22%) of our payables are owed by a single customer. The loss of any of these customers would have a material adverse effect on the Company’s revenues which may not be replaced by other customers particularly as these customers are in the prostate sector which is facing substantial competition from other treatments. Failure to successfully collect our large outstanding payables would have a material adverse effect on our revenues.

 

 

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4 - MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5 – OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

Exhibits:

 

31.1*	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
31.2*	Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer
32**	Section 1350 Certifications

 

101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

 

* Filed herewith.

** Furnished herewith. 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: May 10, 2016
	ISORAY, INC., a Minnesota corporation
	By	/s/ Thomas C. LaVoy
		Thomas C. LaVoy, Chief Executive Officer (Principal Executive Officer)
	By	/s/ Brien L. Ragle
		Brien L. Ragle, Chief Financial Officer (Principal Financial and Accounting Officer)

 

 

 

Exhibit 31.1

 

CERTIFICATION

 

I, Thomas C. LaVoy, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of IsoRay, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: May 10, 2016

 

	/s/ Thomas LaVoy
	Thomas C. LaVoy
	Chief Executive Officer
	(Principal Executive Officer)

 

 

 

Exhibit 31.2

 

CERTIFICATION

 

I, Brien L. Ragle certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of IsoRay, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: May 10, 2016

 

	/s/ Brien L. Ragle
	Brien L. Ragle
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

 

 

 

Exhibit 32

 

Section 1350 Certifications

 

Pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of IsoRay, Inc., a Minnesota corporation (the "Company"), hereby certify that:

 

To my knowledge, the Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2016 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: May 10, 2016
		/s/ Thomas C. LaVoy
		THOMAS C. LAVOY
		CHIEF EXECUTIVE OFFICER (Principal Executive Officer)
Dated: May 10, 2016
		/s/ Brien L. Ragle
		BRIEN L. RAGLE
		CHIEF FINANCIAL OFFICER (Principal Financial and Accounting Officer)

 

 

 

v3.4.0.3

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2016	May. 06, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	0000728387
Current Fiscal Year End Date	--06-30
Entity Filer Category	Accelerated Filer
Trading Symbol	ISR
Entity Common Stock, Shares Outstanding		55,010,619

v3.4.0.3

Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 5,694,339	$ 5,226,740
Certificates of deposit	5,910,756	9,362,574
Accounts receivable, net of allowance for doubtful accounts of $30,000 and $30,000, respectively	883,702	1,049,041
Inventory	457,291	403,955
Other receivables	5,098	19,615
Prepaid expenses and other current assets	288,977	263,597
Total current assets	13,240,163	16,325,522
Property and equipment, net	415,675	574,840
Certificates of deposit, non-current	5,191,960	5,106,775
Restricted cash	181,368	181,262
Inventory, non-current	544,363	569,854
Other assets, net of accumulated amortization	222,529	245,031
Total assets	19,796,058	23,003,284
Current liabilities:
Accounts payable and accrued liabilities	732,018	498,253
Accrued protocol expense	97,679	124,131
Accrued radioactive waste disposal	164,544	129,500
Accrued payroll and related taxes	119,165	212,795
Accrued vacation	98,874	127,515
Total current liabilities	1,212,280	1,092,194
Long-term liabilities:
Warrant derivative liability	45,000	181,000
Asset retirement obligation	1,013,782	947,849
Total liabilities	$ 2,271,062	$ 2,221,043
Commitments and contingencies
Shareholders' equity:
Common stock, $.001 par value; 192,998,329 shares authorized; 55,010,619 and 54,967,559 shares issued and outstanding	$ 55,010	$ 54,968
Treasury stock, at cost, 0 and 13,200 shares, respectively	0	(8,390)
Additional paid-in capital	82,727,429	82,467,111
Accumulated deficit	(65,257,502)	(61,731,507)
Total shareholders' equity	17,524,996	20,782,241
Total liabilities and shareholders' equity	19,796,058	23,003,284
Series A Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	0	0
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	59	59
Series C Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	0	0
Series D Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	$ 0	$ 0

v3.4.0.3

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Allowance for Doubtful Accounts Receivable, Current	$ 30,000	$ 30,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	7,001,671	7,001,671
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	192,998,329	192,998,329
Common Stock, Shares, Issued	55,010,619	54,967,559
Common Stock, Shares, Outstanding	55,010,619	54,967,559
Treasury Stock, Shares	0	13,200
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	59,065	59,065
Preferred Stock, Shares Outstanding	59,065	59,065
Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series D Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,671	1,671
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

v3.4.0.3

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Product sales	$ 1,198,701	$ 1,158,109	$ 3,649,031	$ 3,265,795
Cost of product sales	1,132,397	1,102,912	3,472,357	3,303,364
Gross profit (loss)	66,304	55,197	176,674	(37,569)
Operating expenses:
Research and development	183,187	141,399	385,325	458,636
Sales and marketing	300,995	374,876	833,887	1,032,402
General and administrative	909,144	589,934	2,785,539	1,703,825
Total operating expenses	1,393,326	1,106,209	4,004,751	3,194,863
Operating loss	(1,327,022)	(1,051,012)	(3,828,077)	(3,232,432)
Non-operating income (expense):
Interest income	53,725	68,954	167,032	214,009
Change in fair value of warrant derivative liability	78,000	28,605	136,000	375,605
Financing and interest expense	0	(100)	(950)	(3,551)
Non-operating income (expense), net	131,725	97,459	302,082	586,063
Net loss	(1,195,297)	(953,553)	(3,525,995)	(2,646,369)
Preferred stock dividends	(2,658)	(2,658)	(7,974)	(7,974)
Net loss applicable to common shareholders	$ (1,197,955)	$ (956,211)	$ (3,533,969)	$ (2,654,343)
Basic and diluted loss per share (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.06)	$ (0.05)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	55,022,668	54,883,551	55,010,619	54,878,297

v3.4.0.3

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,525,995)	$ (2,646,369)
Adjustments to reconcile net loss to net cash used by operating activities:
Allowance for doubtful accounts	0	(8,607)
Depreciation expense	412,170	439,223
Loss on equipment disposals	6,512	0
Writeoff of inventory associated with discontinued product	72,200	0
Amortization of other assets	25,494	34,923
Change in fair value of derivative warrant liability	(136,000)	(375,605)
Accretion of asset retirement obligation	65,933	60,278
Share-based compensation	229,442	64,360
Changes in operating assets and liabilities:
Accounts receivable, gross	165,339	(116,817)
Inventory	(125,536)	(104,818)
Other receivables	14,517	43,154
Prepaid expenses and other current assets	111	(9,171)
Accounts payable and accrued expenses	233,765	(135,198)
Accrued protocol expense	(26,452)	38,031
Accrued radioactive waste disposal	35,044	(23,469)
Accrued payroll and related taxes	(93,630)	(146,746)
Accrued vacation	(28,641)	(5,633)
Net cash used by operating activities	(2,675,727)	(2,892,464)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for property and equipment	(259,517)	(77,963)
Additions to licenses and other assets	(2,992)	(14,016)
Proceeds from maturity of certificates of deposit	9,558,812	10,031,758
Purchases of certificates of deposit	(6,106,994)	(9,110,673)
Purchases of certificates of deposit, non-current	(85,185)	(4,744,580)
Change in restricted cash	(106)	(40)
Net cash provided (used) by investing activities	3,104,018	(3,915,514)
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	(10,632)	(10,632)
Proceeds from sales of common stock, pursuant to exercise of warrants, net	0	70,789
Proceeds from sales of common stock, pursuant to exercise of options	49,940	145,274
Net cash provided by financing activities	39,308	205,431
Net increase (decrease) in cash and cash equivalents	467,599	(6,602,547)
Cash and cash equivalents, beginning of period	5,226,740	7,680,073
CASH AND CASH EQUIVALENTS, END OF PERIOD	5,694,339	1,077,526
Non-cash investing and financing activities:
Retirement of treasury stock	8,390	0
Reclassification of derivative warrant liability to equity upon exercise	$ 0	$ 17,395

v3.4.0.3

Basis of Presentation	9 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation   The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries (“IsoRay” or the “Company”). All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10-K for the year ended June 30, 2015.   The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading.   Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented may not be indicative of those which may be expected for a full year.  The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2016 will be 0%.

v3.4.0.3

New Accounting Pronouncements	9 Months Ended
	Mar. 31, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	2. New Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, Revenue Recognition. The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.   In July 2015, the FASB issued ASU No. 2015-11 – Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.   In January 2016, the FASB issued ASU No. 2016-01 – Financial Instruments – Overall. The guidance requires an entity’s management to measure equity investments except those accounted for under the equity method of accounting or those that result in consolidation of the investee to be measured at fair value; simplifies the impairment assessment of equity investments; eliminates the requirement to disclose the fair value of financial instruments measured at amortized cost for non-public entities: eliminates the requirement for a public entity to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is not permitted except as contained in the early adoption guidance.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

v3.4.0.3

Certificates of deposit	9 Months Ended
	Mar. 31, 2016
Investments, All Other Investments [Abstract]
Cost-method Investments, Description [Text Block]	3. Certificates of deposit   The Company has maintained all excess cash in certificates of deposit at certain banks in certificates of deposit and through the Certificate of Deposit Account Registry Service (CDARS), which is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 limit to be fully insured by the Federal Deposit Insurance Corporation (FDIC). The Company ensures that principal amounts of certificates of deposit are fully insured. There may from time to time be short periods following maturity that amounts held in the money market account at the CDARS host bank will exceed FDIC coverage. In cases where the period that uninsured amounts will be held beyond ten banking days, the funds will be transferred to the primary operating account of the Company’s operating subsidiary, IsoRay Medical, Inc. (Medical), that incorporates a sweep function that keeps the funds FDIC insured during that time.       As of March 31, 2016       Under 90   91 days to   Six months to   Greater       Days   six months   1 year   than 1 year   CDARS   $ 5,910,756   $ -   $ -   $ 5,191,960         As of June 30, 2015       Under 90   91 days to   Six months to   Greater       Days   six months   1 year   than 1 year   CDARS   $ 3,523,167   $ 500,064   $ 5,339,343   $ 5,106,775

v3.4.0.3

Loss per Share	9 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	4. Loss per Share   Basic and diluted earnings per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents. At March 31, 2016 and 2015, the calculation of diluted weighted average shares did not include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company’s net loss position.   Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of March 31, 2016 and 2015, were as follows:       March 31,       2016   2015   Series B preferred stock     59,065     59,065   Common stock warrants     360,800     396,174   Common stock options     2,355,060     2,057,620   Total potential dilutive securities     2,774,925     2,512,859

v3.4.0.3

Inventory	9 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5. Inventory   Inventory consisted of the following at March 31, 2016 and June 30, 2015:       March 31,   June 30,       2016   2015   Raw materials   $ 223,588   $ 143,669   Work in process     225,978     204,760   Finished goods     7,725     55,526       $ 457,291   $ 403,955         March 31,   June 30,       2016   2015   Enriched barium, non-current   $ 469,758   $ 469,758   Raw materials, non-current     74,605     100,096   Total inventory, non-current   $ 544,363   $ 569,854     Inventory, non-current is (i) raw materials that were ordered in quantities to obtain volume cost discounts for key components of our brachytherapy seed including titanium lids, titanium tubes, gold wires that are used for imaging markers, and our proprietary seed core, which were ordered based on current and anticipated sales volumes and will not be consumed within an operating cycle; and (ii) enriched barium, which is classified as non-current, and is only expected to be utilized if required to obtain volumes of isotope that is not able to be purchased from an existing source in either the short- or long-term. Management does not anticipate the need to utilize the enriched barium within the current operating cycle unless there is an unanticipated interruption to the isotope supply that requires its use. If such a need were to occur, then management would evaluate the need to reclassify some or all of the inventory as a current asset. As of March 31, 2016, the Company discontinued the GliaSite® RTS product line resulting in a write-off of GliaSite® RTS related inventory totaling $72,200.

v3.4.0.3

Property and Equipment	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment       March 31,   June 30,       2016   2015   Land   $ 168,459   $ -   Equipment     3,560,891     3,553,774   Leasehold improvements     4,129,977     4,129,977   Other     38,793     5,925   Property and equipment     7,898,120     7,689,676   Less accumulated depreciation     (7,482,445)     (7,114,836)   Property and equipment , net   $ 415,675   $ 574,840

v3.4.0.3

Share-Based Compensation	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Share-Based Compensation   The following table presents the share-based compensation expense recognized during the three months and nine months ended March 31, 2016 and 2015:       Three months   Nine months       ended March 31,   ended March 31,       2016   2015   2016   2015   Cost of product sales   $ 17,757   $ 7,972   $ 52,947   $ 23,917   Research and development expenses     3,567     3,117     10,699     9,352   Sales and marketing expenses     3,744     2,158     10,230     6,475   General and administrative expenses     140,998     8,205     155,556     24,616   Total share-based compensation   $ 166,066   $ 21,452   $ 229,442   $ 64,360     As of March 31, 2016, total unrecognized compensation expense related to stock-based options was $337,350 and the related weighted-average period over which it is expected to be recognized is approximately 1.34 years.   A summary of stock options within the Company’s share-based compensation plans as of March 31, 2016 was as follows:         Weighted   Weighted             Exercise   Average           Number of   Price   Contractual   Intrinsic       Options   (Years)   Term   Value                   Outstanding at March 31, 2016     2,380,060   $ 1.48     5.71   $ 289,393   Vested and expected to vest at March 31, 2016     2,294,065   $ 1.48     5.66   $ 282,800   Vested and exercisable at March 31, 2016     1,966,762   $ 1.46     5.01   $ 274,200     There were 56,260 and 133,564 stock options exercised and $27,469 and $145,275 of intrinsic value associated with these exercises during the nine months ended March 31, 2016 and 2015, respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.   There were 482,500 and no stock option awards granted during the nine months ended March 31, 2016 and 2015, respectively. Included in the 482,500 options were 20,000 that were issued in the first quarter of fiscal 2016 and 462,500 issued in the three months ended March 31, 2016.         For the nine months ended March 31, 2016   Options issued     482,500   Weighted average exercise price     $0.64 to $1.53   Expected term (in years)     1 to 5   Risk free rate     0.51% to 1.51%   Weighted average volatility     106.21% to 108.26%     There were 442,854 and 39,002 stock option awards which expired during nine months ended March 31, 2016 and 2015, respectively.   There were 21,608 and 84,236 stock option awards forfeited during nine months ended March 31, 2016 and 2015, respectively.

v3.4.0.3

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies   Patent and Know-How Royalty License Agreement   The Company is the holder of an exclusive license to use certain “know-how” developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor’s patent application was ultimately abandoned, only a 1% “know-how” royalty based on Net Factory Sales Price, as defined in the agreement, remains applicable. To date, management believes that there have been no product sales incorporating the “know-how” and therefore no royalty is due pursuant to the terms of the agreement. Management believes that ultimately no royalties should be paid under this agreement as there is no intent to use this “know-how” in the future.   The licensor of the “know-how” has disputed management’s contention that it is not using this “know-how”. On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time.   Class Action Lawsuit Related to Press Release   On May 22, 2015, the first of three lawsuits was filed against IsoRay, Inc. and two of its officers – Dwight Babcock (the Company’s retired CEO) and Brien Ragle – related to a press release on May 20, 2015 regarding a May 19 online publication of the peer-reviewed article in the journal Brachytherapy titled “Analysis of Stereotactic Radiation vs. Wedge Resection vs. Wedge Resection Plus Cesium-131 Brachytherapy in Early-Stage Lung Cancer” by Dr. Bhupesh Parashar, et al. The lawsuits are class actions alleging violations of the federal securities laws. By Order dated August 17, 2015, all of the pending lawsuits were consolidated into one case – In re IsoRay, Inc. Securities Litigation; Case No. 4:15-cv-05046-LRS, in the US District Court for the Eastern District of Washington. IsoRay retained Wilson Sonsini Goodrich & Rosati as its and its officers’ defense counsel.   On October 16, 2015, an amended complaint was filed with more detailed allegations relating to violations of federal securities laws and requesting damages through a jury trial. Mr. Ragle was dismissed from the complaint.   On December 15, 2015, IsoRay filed a motion to dismiss the complaint altogether. Oral argument was scheduled on this motion on April 2016 but was rescheduled at the request of the plaintiff’s attorney to May 12, 2016.   On April 1, 2016, IsoRay filed a reply in Support of Motion to Dismiss Amended Complaint for Violations of the Federal Securities Laws. IsoRay believes the lawsuit is without merit and is seeking its dismissal.   Property Transaction between Medical and The Port of Benton   On September 10, 2015, the Company’s operating subsidiary, Medical, entered into a Real Estate Purchase and Sale Agreement with The Port of Benton (“Port”), a municipal corporation of the State of Washington. The Agreement is for the sale of undeveloped real property of approximately 4.2 acres located adjacent to the Company’s existing manufacturing facility and corporate offices. Medical finalized the purchase of the land in the third quarter of fiscal 2016 and has begun design work on a new production facility.   Medical is bound to comply with a Development Plan for a ten year period, the requirements of which include but are not limited to: (1) Certain specified site configurations and design with a minimum of 12,000 square feet of warehouse and production space and 4,000 square feet of office space;   (2) Completion of all construction in two years;   (3) Use of facility as primary production facility for ten (10) years; and   (4) Provision of jobs for not less than 25 full-time employees.    The purchase price for the property was adjusted in consideration of the Development Plan’s covenants. Failure to comply with these covenants will result in a breach of the Agreement and if not cured, will obligate Medical to pay the Port the difference in the sales price and the appraised value of the property at the time of default. The Benton County 2015 assessed value of the land was $423,720, and management believes this approximates the current appraised value. The difference in the sales price and management’s estimate of the current appraised value of the property is approximately $256,000. This is subject to subsequent changes in valuation of the property.

v3.4.0.3

Fair Value Measurements	9 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	9. Fair Value Measurements   The table below sets forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2016 and June 30, 2015, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category.           Fair value at March 31, 2016       Total   Level 1   Level 2   Level 3   Cash and cash equivalents   $ 5,694,339   $ 5,694,339   $ -   $ -   Warrant derivative liability     45,000     -     45,000     -         Fair value at June 30, 2015       Total   Level 1   Level 2   Level 3   Cash and cash equivalents   $ 5,226,740   $ 5,226,740   $ -   $ -   Warrant derivative liability     181,000     -     181,000     -

v3.4.0.3

Preferred Dividends	9 Months Ended
	Mar. 31, 2016
Preferred Stock Dividends and Other Adjustments [Abstract]
Preferred Stock [Text Block]	10. Preferred Dividends   On December 10, 2015, the Board of Directors declared a dividend on the Series B Preferred Stock of all currently payable and accrued outstanding and cumulative dividends through December 31, 2015 in the amount of $10,632. The dividends outstanding and cumulative through December 31, 2015 of $10,632 and through December 31, 2014 of $10,632 were paid as of those dates.

v3.4.0.3

Shareholders' Equity	9 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	11. Shareholders’ Equity   Warrant derivative liability   Based on the guidance contained in ASC 815 “Derivatives and Hedging”, management has concluded that the warrants issued in the 2011 offering should be classified as a derivative liability and has recorded a liability at fair value.   A summary of the change in fair value of derivative warrant liability is as follows for the fiscal years presented.       Quantity1   Amount   Balance at June 30, 2014     238,696   $ 573,000   Change in fair value     -     (374,605)   Warrants exercised     (13,209)     (17,395)   Balance at June 30, 2015     225,087   $ 181,000   Change in fair value     -     (15,000)   Balance at September 30, 2015     225,087     166,000   Change in fair value     -     (43,000)   Balance at December 31, 2015     225,087     123,000   Change in fair value     -     (78,000)   Balance at March 31, 2016     225,087   $ 45,000     1 Quantity of warrants either issued or outstanding as of the date of valuation.   Warrants   The following table summarizes all warrants outstanding as of the beginning of the fiscal year, all activity related to warrants issued, cancelled, exercised or expired during the period and weighted average prices by category.           Weighted average       Warrants   exercise price   Outstanding as of June 30, 2015     385,800   $ 1.22   Warrants expired     (25,000)     2.00   Outstanding as of March 31, 2016     360,800   $ 1.17     The following table summarizes additional information about the Company’s common warrants outstanding as of March 31, 2016:   Number of Warrants   Exercise Prices   Expiration Date       130,713   $ 1.56   May 2016       199,437     0.94   October 2016       25,650     0.94   December 2016       5,000     0.98   June 2017       360,800

v3.4.0.3

Related Party Transaction	9 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12. Related Party Transaction   During the nine months ended March 31, 2016 and 2015, the Company continued to engage the services of APEX Data Systems, Inc., owned by Dwight Babcock, the Company’s former Chairman and Chief Executive Officer, to modify and maintain the Company’s web interfaced data collection application to aggregate patient data in a controlled environment. The cost recorded during the nine months ended March 31, 2016 and 2015 from APEX Data Systems, Inc. for the maintenance of the web interfaced data collection applications in combination with the updating of the Company website was $6,000 and $6,000 respectively. An additional $6,000 was spent on the maintenance of Customer Relationship Management (CRM) software in the nine months ended March 31, 2016 and 2015, respectively. At March 31, 2016 and 2015, services during the prior month had been accrued and remained unpaid in the amount of none and $2,000, respectively. These amounts were each paid in the subsequent month.

v3.4.0.3

Concentrations of Credit and Other Risks	9 Months Ended
	Mar. 31, 2016
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	13. Concentrations of Credit and Other Risks   The Company’s cash, cash equivalents, and investments are deposited with several financial institutions with FDIC coverage. At times, deposits for a limited period of time in these institutions may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances.   For the nine months ended March 31, 2016 and 2015, there was a single customer (which was a group of customers supported by a single physician group) that represented between 5% and 10% or more of total net revenue, respectively.   At March 31, 2016, one customer accounted for 10% or more of the Company’s total accounts receivable with that customer (a group of seven legal entities) representing 22% of total accounts receivable. At June 30, 2015, one customer (a group of seven legal entities) accounted for 27% of total accounts receivable.   Accounts receivable are typically not collateralized. The Company maintains ongoing dialogue with its customers about invoice payments. Some of our customers are small outpatient surgery centers that pay invoices for our products at the time they receive a decision regarding payment by the insurer providing benefits which in the case of prostate cancer is predominately Medicare. A qualitative review of outstanding customer balances is performed at least quarterly and the allowance for doubtful accounts is adjusted based on historical performance of the customer and management knowledge regarding specific invoices. Accounts are charged against the allowance for doubtful accounts once collection efforts are deemed unsuccessful. Prior to utilizing an external collection agency and interrupting the supply of our product, customers may be provided the opportunity to continue purchasing product on the basis of pre-paying via guaranteed funds the amount due on their current order prior to producing and shipping the order plus the amount due on their oldest outstanding invoice.   Single source suppliers presently provide the Company with several components. Management believes it would be able to locate other sources for these components subject to any regulatory qualifications if required.   During the three months ended December 31, 2015, the Company experienced an unplanned supply disruption of radioisotope from its Russian supplier. No customer orders were missed or delayed while the Company increased production at its second supplier to compensate for the unplanned outage. This event has led management to conduct a review of the Company’s current supply interruption plan in such a situation to ensure its ability to continue to produce a sufficient supply of radioisotope at either facility in the case of an extended supply interruption at either reactor. Over the next nine to twelve months, management intends to vet, test and modify where appropriate the Company’s current plan as required to ensure this capability.

v3.4.0.3

New Accounting Pronouncements (Policies)	9 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, Revenue Recognition. The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.   In July 2015, the FASB issued ASU No. 2015-11 – Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.   In January 2016, the FASB issued ASU No. 2016-01 – Financial Instruments – Overall. The guidance requires an entity’s management to measure equity investments except those accounted for under the equity method of accounting or those that result in consolidation of the investee to be measured at fair value; simplifies the impairment assessment of equity investments; eliminates the requirement to disclose the fair value of financial instruments measured at amortized cost for non-public entities: eliminates the requirement for a public entity to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is not permitted except as contained in the early adoption guidance.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

v3.4.0.3

Certificates of deposit (Tables)	9 Months Ended
	Mar. 31, 2016
Investments, All Other Investments [Abstract]
Schedule of Cost Method Investments [Table Text Block]	As of March 31, 2016       Under 90   91 days to   Six months to   Greater       Days   six months   1 year   than 1 year   CDARS   $ 5,910,756   $ -   $ -   $ 5,191,960         As of June 30, 2015       Under 90   91 days to   Six months to   Greater       Days   six months   1 year   than 1 year   CDARS   $ 3,523,167   $ 500,064   $ 5,339,343   $ 5,106,775

v3.4.0.3

Loss per Share (Tables)	9 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of March 31, 2016 and 2015, were as follows:       March 31,       2016   2015   Series B preferred stock     59,065     59,065   Common stock warrants     360,800     396,174   Common stock options     2,355,060     2,057,620   Total potential dilutive securities     2,774,925     2,512,859

v3.4.0.3

Inventory (Tables)	9 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consisted of the following at March 31, 2016 and June 30, 2015:       March 31,   June 30,       2016   2015   Raw materials   $ 223,588   $ 143,669   Work in process     225,978     204,760   Finished goods     7,725     55,526       $ 457,291   $ 403,955
Schedule of Inventory, Noncurrent [Table Text Block]	March 31,   June 30,       2016   2015   Enriched barium, non-current   $ 469,758   $ 469,758   Raw materials, non-current     74,605     100,096   Total inventory, non-current   $ 544,363   $ 569,854

v3.4.0.3

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	March 31,   June 30,       2016   2015   Land   $ 168,459   $ -   Equipment     3,560,891     3,553,774   Leasehold improvements     4,129,977     4,129,977   Other     38,793     5,925   Property and equipment     7,898,120     7,689,676   Less accumulated depreciation     (7,482,445)     (7,114,836)   Property and equipment , net   $ 415,675   $ 574,840

v3.4.0.3

Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table presents the share-based compensation expense recognized during the three months and nine months ended March 31, 2016 and 2015:       Three months   Nine months       ended March 31,   ended March 31,       2016   2015   2016   2015   Cost of product sales   $ 17,757   $ 7,972   $ 52,947   $ 23,917   Research and development expenses     3,567     3,117     10,699     9,352   Sales and marketing expenses     3,744     2,158     10,230     6,475   General and administrative expenses     140,998     8,205     155,556     24,616   Total share-based compensation   $ 166,066   $ 21,452   $ 229,442   $ 64,360
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	A summary of stock options within the Company’s share-based compensation plans as of March 31, 2016 was as follows:         Weighted   Weighted             Exercise   Average           Number of   Price   Contractual   Intrinsic       Options   (Years)   Term   Value                   Outstanding at March 31, 2016     2,380,060   $ 1.48     5.71   $ 289,393   Vested and expected to vest at March 31, 2016     2,294,065   $ 1.48     5.66   $ 282,800   Vested and exercisable at March 31, 2016     1,966,762   $ 1.46     5.01   $ 274,200
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the nine months ended March 31, 2016   Options issued     482,500   Weighted average exercise price     $0.64 to $1.53   Expected term (in years)     1 to 5   Risk free rate     0.51% to 1.51%   Weighted average volatility     106.21% to 108.26%

v3.4.0.3

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The table below sets forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2016 and June 30, 2015, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category.           Fair value at March 31, 2016       Total   Level 1   Level 2   Level 3   Cash and cash equivalents   $ 5,694,339   $ 5,694,339   $ -   $ -   Warrant derivative liability     45,000     -     45,000     -         Fair value at June 30, 2015       Total   Level 1   Level 2   Level 3   Cash and cash equivalents   $ 5,226,740   $ 5,226,740   $ -   $ -   Warrant derivative liability     181,000     -     181,000     -

v3.4.0.3

Shareholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]	A summary of the change in fair value of derivative warrant liability is as follows for the fiscal years presented.       Quantity1   Amount   Balance at June 30, 2014     238,696   $ 573,000   Change in fair value     -     (374,605)   Warrants exercised     (13,209)     (17,395)   Balance at June 30, 2015     225,087   $ 181,000   Change in fair value     -     (15,000)   Balance at September 30, 2015     225,087     166,000   Change in fair value     -     (43,000)   Balance at December 31, 2015     225,087     123,000   Change in fair value     -     (78,000)   Balance at March 31, 2016     225,087   $ 45,000     1 Quantity of warrants either issued or outstanding as of the date of valuation.
Schedule of Stockholders Equity Note Warrants or Rights [Table Text Block]	The following table summarizes all warrants outstanding as of the beginning of the fiscal year, all activity related to warrants issued, cancelled, exercised or expired during the period and weighted average prices by category.           Weighted average       Warrants   exercise price   Outstanding as of June 30, 2015     385,800   $ 1.22   Warrants expired     (25,000)     2.00   Outstanding as of March 31, 2016     360,800   $ 1.17
Schedule Of Stockholders Equity Note Warrants Or Rights By Exercise Price Range [Table Text Block]	The following table summarizes additional information about the Company’s common warrants outstanding as of March 31, 2016:   Number of Warrants   Exercise Prices   Expiration Date       130,713   $ 1.56   May 2016       199,437     0.94   October 2016       25,650     0.94   December 2016       5,000     0.98   June 2017       360,800

v3.4.0.3

Basis of Presentation (Details Textual)	12 Months Ended
	Jun. 30, 2016
Scenario, Forecast [Member]
Basis Of Presentation [Line Items]
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%

v3.4.0.3

Certificates of deposit (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Under 90 Days [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	$ 5,910,756	$ 3,523,167
91 Days to Six Months [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	0	500,064
Six Months to 1 Year [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	0	5,339,343
Greater than 1 Year [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	$ 5,191,960	$ 5,106,775

v3.4.0.3

Certificates of deposit (Details Textual)	9 Months Ended
	Mar. 31, 2016 USD ($)
Certificates of deposit [Line Items]
Federal Deposit Insurance Corporation Limits On Deposits In Financial Institutions	$ 250,000

v3.4.0.3

Loss per Share (Details) - shares	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,774,925	2,512,859
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	59,065	59,065
Common stock warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	360,800	396,174
Common stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,355,060	2,057,620

v3.4.0.3

Inventory (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Inventory [Line Items]
Raw materials	$ 223,588	$ 143,669
Work in process	225,978	204,760
Finished goods	7,725	55,526
Inventory, Net, Total	457,291	403,955
Total inventory, non-current	544,363	569,854
Enriched Barium Inventory [Member]
Inventory [Line Items]
Total inventory, non-current	469,758	469,758
Raw Materials [Member]
Inventory [Line Items]
Total inventory, non-current	$ 74,605	$ 100,096

v3.4.0.3

Inventory (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Inventory Write-down	$ 72,200	$ 0
GliaSite® RTS [Member]
Inventory Write-down	$ 72,200

v3.4.0.3

Property and Equipment (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Property and equipment	$ 7,898,120	$ 7,689,676
Less accumulated depreciation	(7,482,445)	(7,114,836)
Property and equipment , net	415,675	574,840
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	4,129,977	4,129,977
Other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	38,793	5,925
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	168,459	0
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 3,560,891	$ 3,553,774

v3.4.0.3

Share-Based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	$ 166,066	$ 21,452	$ 229,442	$ 64,360
Cost of product sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	17,757	7,972	52,947	23,917
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	3,567	3,117	10,699	9,352
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	3,744	2,158	10,230	6,475
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	$ 140,998	$ 8,205	$ 155,556	$ 24,616

v3.4.0.3

Share-Based Compensation (Details 1)	9 Months Ended
	Mar. 31, 2016 USD ($) $ / shares shares
Number of Options
Outstanding at March 31, 2016 | shares	2,380,060
Vested and expected to vest at March 31, 2016 | shares	2,294,065
Vested and exercisable at March 31, 2016 | shares	1,966,762
Weighted Exercise Price
Outstanding at March 31, 2016 | $ / shares	$ 1.48
Vested and expected to vest at March 31, 2016 | $ / shares	1.48
Vested and exercisable at March 31, 2016 | $ / shares	$ 1.46
Weighted Average Contractual Term
Outstanding at March 31, 2016	5 years 8 months 16 days
Vested and expected to vest at March 31, 2016	5 years 7 months 28 days
Vested and exercisable at March 31, 2016	5 years 4 days
Intrinsic Value
Outstanding at March 31, 2016 | $	$ 289,393
Vested and expected to vest at March 31, 2016 | $	282,800
Vested and exercisable at March 31, 2016 | $	$ 274,200

v3.4.0.3

Share-Based Compensation (Details 2) - $ / shares	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Options issued	482,500	0
Risk free rate, Minimum	0.51%
Risk free rate, Maximum	1.51%
Minimum [Member]
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Weighted average exercise price	$ 0.64
Expected term (in years)	1 year
Weighted average volatility	106.21%
Maximum [Member]
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Weighted average exercise price	$ 1.53
Expected term (in years)	5 years
Weighted average volatility	108.26%

v3.4.0.3

Share-Based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 337,350		$ 337,350
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 4 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			56,260	133,564
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 27,469	$ 145,275
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			482,500	0
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	462,500	20,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			482,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period			442,854	39,002
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period			21,608	84,236

v3.4.0.3

Commitments and Contingencies (Details Textual)	9 Months Ended
	Mar. 31, 2016 USD ($) a	Mar. 31, 2015 USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]
Area of Land | a	4.2
Number Of Employees Commitment	25
Percentage Of Royalty Rate Payable	1.00%
Gain (Loss) on Disposition of Property Plant Equipment, Total | $	$ (6,512)	$ 0
The Benton Country 2015 [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Land | $	423,720
Gain (Loss) on Disposition of Property Plant Equipment, Total | $	$ 256,000
Capital Addition Purchase Commitments [Member] | Warehouse Space [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Area of Real Estate Property | a	12,000
Capital Addition Purchase Commitments [Member] | Office Space [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Area of Land | a	4,000
Primary Use Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Term of Unrecorded Unconditional Purchase Obligation	10 Years

v3.4.0.3

Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 5,694,339	$ 5,226,740
Warrant derivative liability	45,000	181,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	5,694,339	5,226,740
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Warrant derivative liability	45,000	181,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Warrant derivative liability	$ 0	$ 0

v3.4.0.3

Preferred Dividends (Details Textual) - USD ($)	6 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2016	Mar. 31, 2015
Preferred dividends paid	$ 10,632	$ 10,632	$ 10,632	$ 10,632

v3.4.0.3

Shareholders' Equity (Details) - USD ($)		3 Months Ended					9 Months Ended				12 Months Ended
		Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015		Mar. 31, 2015	Mar. 31, 2016		Mar. 31, 2015		Jun. 30, 2015
Class of Warrant or Right [Line Items]
Balance				385,800			385,800
Balance		360,800					360,800				385,800
Value of warrants issued:
Change in fair value		$ (78,000)				$ (28,605)	$ (136,000)		$ (375,605)
Derivative Warrants [Member]
Class of Warrant or Right [Line Items]
Balance		225,087	225,087	225,087	[1]		225,087	[1]	238,696	[1]	238,696	[1]
Warrants exercised	[1]										(13,209)
Balance		225,087	225,087	225,087			225,087				225,087	[1]
Value of warrants issued:
Balance		$ 123,000	$ 166,000	$ 181,000			$ 181,000		$ 573,000		$ 573,000
Change in fair value		(78,000)	(43,000)	(15,000)							(374,605)
Warrants exercised											(17,395)
Balance		$ 45,000	$ 123,000	$ 166,000			$ 45,000				$ 181,000
[1] Quantity of warrants either issued or outstanding as of the date of valuation.

v3.4.0.3

Shareholders' Equity (Details 1)	9 Months Ended
	Mar. 31, 2016 $ / shares shares
Warrants
Balance | shares	385,800
Warrants expired | shares	(25,000)
Balance | shares	360,800
Weighted average exercise price
Beginning balance outstanding | $ / shares	$ 1.22
Warrants expired | $ / shares	2.00
Ending balance outstanding | $ / shares	$ 1.17

v3.4.0.3

Shareholders' Equity (Details 2) - $ / shares	9 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Class of Warrant or Right [Line Items]
Number of Warrants	360,800	385,800
Range of Exercise Prices	$ 1.17	$ 1.22
Range of Exercise Price One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	130,713
Range of Exercise Prices	$ 1.56
Expiration Date	May 2016
Range of Exercise Price Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	199,437
Range of Exercise Prices	$ 0.94
Expiration Date	October 2016
Range of Exercise Price Three [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	25,650
Range of Exercise Prices	$ 0.94
Expiration Date	December 2016
Range of Exercise Price Four [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	5,000
Range of Exercise Prices	$ 0.98
Expiration Date	June 2017

v3.4.0.3

Related Party Transaction (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Related Party Transaction [Line Items]
Maintenance costs	$ 6,000	$ 6,000
Software implementation costs	6,000	6,000
Due to Related Parties, Current	$ 2,000	$ 2,000

v3.4.0.3

Concentrations of Credit and Other Risks (Details Textual)	9 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Accounts Receivable [Member] | Credit Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage	22.00%		27.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage	5.00%	10.00%

begin 644 Financial_Report.xlsx
M4$L#!!0    ( (6 JDB_N,U_U0$  &X<   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,V9RT[#,!!%?Z7*%C6N[? 490-L 0E^P"33QFH<6[8IY>^Q4T!0%<2K
MTMWDT3N>>Y-QSJ:G=T^.PFAENCY,BS9&=\)8J%LR*I3649^4F?5&Q73KY\RI
M>J'FQ,1DA&^7BE3&K!5AT;A/61EUEG_V,8G"?5A)8HFJX,
M\:FCL,U_K;PZ7]!,/73Q1\8O[Z[TU TUH=7NQ>IRE;J$]-NT2&KXEL/FPJ^2
M:9.'YOKYAQ7Y_I?/LO$2EZ:[\.I1;Q@L=S:F?"Z-TOVV43U:O[BW=O&?VX3R
M4S74C)U/A3[J+;LD%=\D-;#4^D_>KSNEMIZ^99@+=_A1M,I3YRY+D.UY\-?1 #&TX[A,2/<@B0'!(D1P628Q\DQP%(CD.0'$<@.8Y![%    
M*P(   L   !?.0Q(OW[CMB PD.MQ-*O>X^NO ZIK XTHO8<4M?'5$Q^#*G*_=ITJK$"
M2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26M#;3
M"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O]C^AY
M%.!)T:'B1?4C9@,2[2F]@OIZ (4QOCLEFI2"(S>C@KN_V/P"4$L#!!0    (
M (6 JDA>=TD!P0$  -0;   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'/%V< 94 *S=LU1MH8* $^I/.&/7NK2P,_LP7%R3?
MIDW;Y,R[Z9-FNFAC.7\,IRH=NC;6ASY.WII3&^?C_651I]3/G8N;.C15O.GZ
MT(Y/=]W05&F\'/:NKS;':A^KLLAO56BLES->Q#6A:O
MW7",=0@INO-);L8%QL?O??C/\MUN=]B$AV[STH0V_5'AOA8H7#Y(\T%*";)\
MD%&"?#[(4X*F^: I)6B6#YI1@F[S0;>4H+M\T!TEZ#X?=$\)DA+(6'*2$-8<
MK05P+1RO!8 M'+$%D"T M'+T5Z*T<
MO17HK:1O;?2QS=%;@=[*T5N!WLK16X'>RM%;@=[*T5N!WLK16X'>RM%;@=[*
MT=N WL;1VX#>QM';@-Y&VBM!FR4AM'+T-Z&TAM
M'+T-Z&TNGG*?"A@NMT[A2<.?CU5_W\]3/$/?K!][J
M U!+ P04    " "%@*I(I_SFJ=\"  #="P  $    &1O8U!R;W!S+V%P<"YX
M;6R]5DUSVC 0_2L:7TH/B0DEZ90AGDD@G68F:9A"T[,BKT$3(;E:04-^?5BV,4,YAS/":(
MIMW,V#EW]&FGL&B5][^4BSY44W$FC
MDULIK$&3.7;U)$#UXY> P*"3QR 65KI5TBXP95/ C 57,"!?2<850H'Z9PR8
M@9GG7*_BXNM&ZD?\F4_,D#LHLW8WBM-GW$)*3G=.WQH#YMN*\E2>.YAQ/86T
MC'V]N:G%/5CTF9YTCMOTVY9@8R_.!IY*/1UQ:3'I+UUO"<(9NV[3TAW:I=0(
MWW2\GU!\&+$'CN"7Y]&26\FUBQC*9_KL1(7;PAK6*D=GDU_&/N(,P&$_WAK#
MLHPMKV4WZ9X&!*UVD?$VLV1=MIV\O64BG0*\RT;8(
M=J%3=J4=R9%=Z\(5-:]): !N_*N%[\*PUXF]SQH[^
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MNP.K.>?3Z0&/9->/(KBW<=\\A=02P,$%     @ A8"J2%G$(@H^ 0  :0,  !$ 
M  !D;V-0%M9\*/'4]=^395W+@$MOW.K:[^/7<5(*QX3U\.2M X\*PM5!UR8PX1;9
M%M$Q0H+8@N9A$BM,3*ZMUQQCZ#?$<;'C&R!32N=$ W+)D9,C,'<],:M**9CP
MP-'Z#B]%CW=[7R>8% 1JT& PD&)2D*QZ,3MC&U.205^5T7'- RZM5&L%\K8=
MRGZG8F<$K\-)#K)OG_[^Z2%E2-95'H+JJYJFF32S5!<'+LC;\O$YG4VN3$!N
M!$154 Q;!XOLW/EU=G>_>LBJ*2WF.;W)"[HJYHQ>,TK?CY-=^!L,ZVZ(?^OX
M;#!M%Q76,'*W22/37$E6VL;T^I']'%JZJ^ %!+ P04    " "%@*I(F5R<(Q &  "<
M)P  $P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!
MMK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H
M.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVW
MO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?
M-*HU+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='
MU!=*Y \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z"
M>P'_T=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH
M8U=RSTS0LS
M0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^
M VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=
MQXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1
M O)256 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>K
MRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=
M[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71%
M B.5' 86%S+D4.Z2D 83  >LX=SFWJXPD6L_UC6
M'ODRWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=
MX Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%
MFAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'M
MB[\!4$L#!!0    ( (6 JD@4+<>XG (  #(/   -    >&PO#%YOOY\(I<8I06)HE1;^+[4X\APF$4\)+-F2I (DJN0GBY-0&7?R-2',+'
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MG8WRG&X^4++@##NQSC07U=LA^'$/?!2@&A4LA21/.MXV,\0=O0&PO=V]R:V)O;VLN>&ULE9??<]LH
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M#(P/F*B"NI/UJD?U@2AKRMGM4ZMXA^I$?3@?SV!,095#5X,XO9KK,0RFT\!
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ME.^%X!4#G5R)69>4$I+-ZFD^L8$XY:,%;$UR_F:29! &I
MD))[.2@OEC$G;#PX*]@11F$_4.BL+.<<'9L FUA&(7=Y82[(_I3&<8>\V=Z3(:'A>:$
MT.2JS([.91!*>X916&O^_*5U!\,HK#4GM#Z(XB<8A;7FA-9/7=Q&AI-48)\+
MPFPEEKV<;<\COX\@< I31M;[email protected]#"J>*I#7[ZC[)R
M%K?L>/\93G+++!ZWX&35:7T&SR[-)RO2H:0G[\YI;WX"4$L#!!0    ( (6 
MJDA%]=T[5P(  /,'   8    >&PO=V]R:W-H965T&UL?97+
MCILP%(9?!?$  S;71 1IDJIJ%Y5&LVC7#G$"&HRI[83IV]<7(&9DV  V_W\^
MWXY/,5#VP6N,A?=)VHX?_%J(?A\$O*HQ0?R%]KB3?ZZ4$21DD]T"WC.,+MI$
MV@"&81H0U'1^6>B^-U86]"[:IL-OS.-W0A#[=\0M'0X^\*>.]^96"]41E$4P
M^RX-P1UO:.7U# I4%HX/'S&;T2.TYV$=RY2J/ZTYFEDO.C,O>1QD6P4.%&150
M*XZV LR*0,:> = %&.W0LD,7X&0K(C<@<@$B,X/(LL=N>^RRQ\8>6_9D.3ZC
M.-J*U U(-@")9<^< %N1NP'I!B"U[#LGP%: T$W(-@B9[0=+1&H01M*9;0[!
MRCKE&Y#*+860R!F[+0
MP!7*5JX#.Y5AY-J;TZ@Q>Y,D(0A3:]:&%5AW+,'LIFL/]RIZ[W2ILWKG^O8*
M]1W]E)=%CV[X%V*WIN/>F0IYT^MK^4JIP'(HX8L\]K6LP'.CQ5>A/C.5#Z8F
MF8:@_51BYSI?_@=02P,$%     @ A8"J2#B%LI7\!   FQ@  !@   !X;"]W
M;W)K[>MZW[V\[ _
M=H_S;=^?'A:+[GE;'ZKN7GVM5TMF[=^OSO67]M9]W8X5.U_ZWK?G!_G>GY]\&WWNNV'!XO5E\_
M]T,15?CZ49?U?C^4%&K^=RKT5YU#(+^^EO[[I;G!_E/5U66S_V>WZ;?!K9K/
M-O5+];;OOS7G/^JI#68H\+G9=Y?/V?-;US>':\A\=JA^CM^[X^7[//Y2J"E,
M#H I &X!FK(!. 7@7M>-@G*IAS/4#AIY[GG67A^W8
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M1:ZL)\TT(H5&*\_J>QW8U+CE *TYH5&G0U ZT2JN(U^ P82C'&8UYRS)G-6J,2@00ZTP$$KU[0&#E =L&9ET$8Z
MT.!\*D7,@18X:$D&+7!^^J)P!\R[@3B7:1/'6H9(S,8=%X%@D&8L0
MIZ4:72&GKY'0DRM8@;&E7/X*G(GFKO'3>0-LM'>XL)F#)"SOA!"RZ@33($=9
MX)0U=Y2ER5.D 4E3IC2Q$Y&NUSG(Z9KB,^1P"!R'AN3^Y9@S1FEQ&,I81IYE
M.?'I,@=#Y# T,GJ00TY>#Y'D4X$^L1PPAT'D&)3/C&OD?"O @:-$YG*G).NT
M3FQ@F&,A[PN*SK#R&D]I
M8B"C^ CO9%;R80?Z U\=V8D)+&/[*L]OG9M8IV1N,ZN?6$^
MTA>Y_(-LIB^F_9%LNB^FO3$A&7TLV&OD4_5:_U6UK[MC-WMJ^KXY7%X?OS1-
M7X>"U.?0HFU=;6XW^_JE'RY=N&['=^?C3=^&PO=V]R:W-H965T&UL
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M?(*8(NT8B8GZLZ6V[I3!$B,LL9K/?A(==&2E-"24;M2$8P*;,\31U$!4)4Z$1@)2I\
MB0IOHA(A*G6BV$I4ZJO#BJ(G: RN[_F@<2?(1_E[2/+5S
M),L<]HC)@2F4&@X%1P=,?#3S6'69WZISQTP>3'HT]UAUALVP58<%329,>[3P
M6'6&STKR^>GG2N2.F3R8]&CIL?I*/QYWS'S>PMP'AOMB1P?,?>#A/O!S'Q(S
M>=!'2 _W@:_[T*#)A+D//-P'R^YS1$P.S'W@X3Y8=I\C8G)@[@/#?8FC ^8^
M\' ?^+D/B9D\F/O PWV@*\WY?.Y.F328]<##>E LWV=[Q.3 ; <>MH/EASQ'
M9.*(M-?<,SORGZP[5FT?/ NIWIC'U]N#$)*K1N1.K;L39_O;3LT/HI00   \4   8    
M>&PO=V]R:W-H965T&ULC9A-<^(X$(;_"L5]8K6^E2)4#;:W
M=@];-36'W;,#3J &8]9VAME_O_('I$5:WES -D^W]+8:=5NK2]W\:/=EV2U^
M5<=3^[3<=]WY,4G:[;ZLBO:A/IG)2RO#[X?7O==_R!9KY*;
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M?1%&:4<$B648X\8J)<@%SEV0_$Q8'MF0^F(>E=?_
M^*Z/#/=F8J:AA!-^_R,5AB PS>\WW4EC $K&I%'D;I$'H  G?89&5)(U^*H2
MET\Z6S83,VT3?N# 1=A1Q=AP-706,9(+ TP;C4CPY %& @=<9<'7%^G6.P?/5># 1=A1Q=A
MP"4QHDV%24Y264@Y%1$65F"E(ATLD!7XJ@N78$=FR&9BKI&&:&)BSAFI(ML4
MQ@3CS$82$W.^B++H)C77(@#N$1S=(X )5@6J<
MAR37TG<+L7_@7+\ N&%P=,, -AQ+65KEI[ LQ(R+-(HS6*ANKF$ W#'<1W)Z
MB0%WMXS^;8(DTY!T2G,@WT^R$!1*"*?)-YX\)'W,I)"1?.5SK0/'K8.[ZPC<
M]-Z)Z_<7]L XA:6?P[(/&#EH_@&+;*.<;!FF0LIQRX#^8Z$'LA1?XX-+L2,3
M[Z!QQ2(YQD\YN-)U;O[]>I98OG3]I?'7S7A>-=YT]?EZ_'8[ US_!U!+
M P04    " "%@*I(<@TZ*S4%  #H&   &    'AL+W=OGY;+;[JNZ
M[+XTY^KD?WEMVKKL_67[MNS.;57NQD+U<8E99I9U>3C-UZOQWK=VO6K>^^/A
M5'UK9]U[79?M?YOJV%R>YS"_W?A^>-OWPXWE>K6\E]L=ZNK4'9K3K*U>G^=?
MX:E0-$A&Q=^'ZM(%WV>#^9>F^3%<_+E[GF>#A^I8;?NABM)_?%1%=3P.-?F6
M_[U6^MGF4##\?JO]][&[WOY+V55%<_SGL.OWWFTVG^VJU_+]V']O+G]4US[H
MH<)M<^S&O[/M>]@:P'Z
M+*#&GD[.QG[]5O;E>M4VEUD[3<:Y'.8 HV802N"N6OO)["RBU<"V.07&4&BA"AOR,7!8SY@[901DA)9YP2"[VYC$9C:/;+:4PBTQW**,6PHI
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M\OZR+QYO^ZKSL=Q$\7?7.^_5_A_L^-]?]02P,$%     @ 
MA8"J2*,FU'ZB 0  L0,  !@   !X;"]W;W)K&
M<\Z<\:6\:]<\.)$%OW()E]T ,H_Z?51C+G4],1.QA@321)
M06B6/1+)N,)5&6LOIBKUZ 17\&*0':5DYM\%A)[.^(#OA5?>]2X42%62A==P
M"N]V0RC!EHV"O>JIQ\PCW ,@K46
M-GY1/5JGY9V"D63O:>4JKE/Z\S6;:?L$.A/H)P))C:+-;\RQJC1Z0B9M[<#"
M"1Y.U&]$C6PLFC2]-VI]]58=\KPDMR T8VC$7#:8!4&\^M*"[K68Z71%I_OT
M?(^>)X?YQF&Q+U#L"11)H-@('++5L:C6HXH7=55=
M;N<3C6?R :_*@77PBYF.*XNNVOF3CCACU_OTLB8#6A?"+CTVZ
M4BEQ>K@_D.655O\!4$L#!!0    ( (6 JDCT,5+ I@$  +$#   8    >&PO
M=V]R:W-H965T&UL;5/;CILP$/T5RQ^P)@[;I!%!VFQ5M0^5
M5OO0/CLP@+6^4-N$[=_7%\+"BA<\,YQSYHPOQ:C-F^T ''J70MDS[ISK3X38
MJ@/)[(/N0?D_C3:2.9^:EMC> *LC20I"L^P+D8PK7!:Q]F+*0@].< 4O!ME!
M2F;^74#H\8QW^%YXY6WG0H&4!9EY-9>@+-<*&6C.^&EWNN0!$0&_.8QV$:/@
M_:KU6TA^UF>/6Y!=UJ,='I@DZWZ?LM^CXYW*\<'K<%\BV!/ GD*X&O
MZQ$3YK+"Y-FG)F2QIQ),&Z^.194>5+RHB^I\.Y]H/),/>%GTK(5?S+1<6735
MSI]L/(9&:P?>1/;PB%'GW\^<"&A<" \^-NE*I<3I_OY YE=:_@=02P,$%   
M  @ A8"J2*<#KO*C 0  L ,  !@   !X;"]W;W)K#'$CDIQ\^<,$J=3MLMNA5?1]2X4:%72
MA=<(!=H*U,1 >\J>=L=S$1 1\%/ 9%0S;9O 9@);"(^10)-1;/,+=[PJ#4[$
MI*T=>#C!W9'YC:B)C463IO>-6E^]5NRQI->@,T-8A)S7D-V"H%Y\<6!;#C.=
MK1VVZ?LM^CXUN%^[%__Q+[8$BB10W FP^Q$3YGR/V?]C0E=;JL!T\>984N.H
MXSU=59?+^<3BD7S JW+@'?S@IA/:D@LZ?[#Q%%I$![Z)_.&0D=X_GR61T+H0
M?O:Q23U#^3Z.-9,ZGIB6V-\#J2)*"T"R[)Y)QAC!":[@
MQ2 [2,G,OS,(/9[P#M\*K[SM7"B0LB SK^82E.5:(0/-"3_MCN<\("+@C<-H
M%S$*WB]:?X3D=WW"6;   BH7%)A?KO ,0@0AW_COI/G=,A"7\4W]9YS6N[\P
M"\]:O//:==YLAE$-#1N$>]7C+YA&. 3!2@L;OZ@:K-/R1L%(LL^TD0F;6W/P@GNCM1O1(5L+)HTO3=J??5:
M[O*\(-<@-&%HQ)Q7F!E!O/K<@FZUF.AT0:?;]/T6?9\<[E<.#]L"^99 G@3R
ME<#]>L2$.:\Q#_\U(8L]E6#:>'4LJO2@XD5=5.?;^10/D7S#RZ)G+?QAIN7*
MHHMV_F3C,31:._ FLKL#1IU_/W,BH'$A?/"Q25X@F>#["@E,Q\G$'HZXAV^%EYXU[M0
M(%5)%E[#)2C+M4(&VB-^V!U.14!$P"N'R:YB%+R?M7X+R9_FB+-@ 034+B@P
MOUS@$80(0K[[email protected]^J\XK7=_9A8>M?C+&]=[LQE&#;1L%.Y%3[]A
M'F$?!&LM;/RB>K1.RRL%(\G>T\I57*?T)R]FVC:!S@2Z$.ZS:#PUBC9_,L>J
MTN@)F;2U PLGN#M0OQ$ULK%HTO3>J/752Y5G);D$G1E"(^2TANP6!/'B2P>Z
MU6&FTQ6=;M/S+7J>#.;K[L7]MD"Q)5 D@>)&X,?MB ESNL'LL_^:D-662C!=
MO#D6U7I4\9ZNJLOE?*#Q2+[@53FP#IZ8Z;BRZ*R=/]AX"JW6#KR)[&Z/4>^?
MSY((:%T(O_O8I!N5$J>'Z_M8'FGU"5!+ P04    " "%@*I(_**[**0!  "Q
M P  &0   'AL+W=OI-"V3/NG1M.A-BZ!\GL@QY ^3^M-I(YGYJ.V,$ :R))"D*S[!.1C"M0.CIC'-\+[SPKG>A0*J2++R&2U"6:X4,M&?\F)\N
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M_0-02P,$%     @ A8"J2("-C4*D 0  L0,  !D   !X;"]W;W)K&UL;5/);J0P$/T5RQ\0T^XM:M%(Z8RBS&&D*(>9LQL*L.*%
ML4V3^?OQ0A.(N."JXKU7K[SD@S8?M@5PZ%,*9<^X=:X[$6++%B2S#[H#Y?_4
MVDCF?&H:8CL#K(HD*[email protected]"MM"@10YF7@5EZ LUPH9J,_X:7.Z[ (B GYS&.PL1L'[5>N/D/RLSC@+
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MI0$  +$#   9    >&PO=V]R:W-H965T&,"*+]0V2_+W\84E;,4+GAG..7/&EW+2
MYLWV  Z]2Z'L$??.#0=";-V#9/9.#Z#\GU8;R9Q/34?L8( UD20%H5EV3R3C
M"E=EK+V8JM2C$US!BT%VE)*9CQ,(/1UQCJ^%5][U+A1(59*%UW )RG*MD('V
MB!_SPZD(B CXPV&RJQ@%[V>MWT+RNSGB+%@  ;4+"LPO%W@"(8*0;_QOUOQJ
M&8CK^*K^,T[KW9^9A2]73+YA'V ?!6@L;OZ@>K=/R
M2L%(LO>T8'ZC?
MB!K96#1I>F_4^NJERO??2W()0C.&1LSI!K,@B%=?6M"M%C.=KNATF[[;HN^2
MP]VZ^WVV+5!L"11)H+@1R&]'3)C3+>9_EV2UIQ),%Z^.1;4>5;RHJ^IR.Q]I
M/),O>%4.K(-G9CJN+#IKYT\V'D.KM0-O(KO;8]3[][,D EH7P@D 0  L0,  !D   !X;"]W;W)K
M&UL;5/;;J,P$/T5RQ]0$R!I%1&DIJNJ^[!2U8?=
M9P<&L.H+:YO0_GU](10J7O#,<,Z9,[X4H][email protected]$-P:4ZXL[8_$F*J#@0U
M=ZH'Z?XT2@MJ7:I;8GH-M XDP4F:) %&BQG$EXU,H,05'^>
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MC5(6G(GD;H]1Y][/G'!HK _O7:SCE8J)5?WM@&PO=V]R:W-H965T]$US!JT&VEY*9?V<0>CCA#;X5WGC3NE @14XF7L4E
M*,NU0@;J$W[:',^[@(B /QP&.XM1\'[1^CTDOZH3SH(%$%"ZH,#\?L(XPCX(EEK8
M^$5E;YV6-PI&DGVFE:NX#NG/_G&DK1/H2* 3X2&+QE.C:/.%.5;D1@_(I*WM
M6#C!S9'ZC2B1C463IO=&K:]>B\W](2?7(#1B:,2<%Y@)0;SZU(*NM1CI=$:G
MZ_3M&GV;'&X7#A_6!79K KLDL%L(/"Y'3)CS G/(OC4ALSV58)IX=2PJ=:_B
M19U5I]OY1..9?,&+O&,-_&:FX:?$?4$L#!!0    ( (6 JDAFI(3OI $  +$#   9    
M>&PO=V]R:W-H965T&,"*+]0V2_KW]84E4-$7/#.<<^:,+^6DS9OM 1QZET+9,^Z=
M&TZ$V+H'R>R#'D#Y/ZTVDCF?FH[8P0!K(DD*0K/L$Y&,*UR5L?9BJE*/3G %
M+P;944IF_EQ Z.F,+]J_1:2[\T99\$""*A=4&!^N<$S"!&$?./?L^9'RT!OL$\PC$(UEK8^$7U:)V6=PI&DKVGE:NX3NG/
M,9MI^P0Z$^A"^!P))#6*-K\PQZK2Z F9M+4#"R>8GZC?B!K96#1I>F_4^NJM
MRA_SDMR"T(RA$7/98!8$\>I+"[K78J;3%9WNTP][]$-R>-@X_(] L2=0)(%B
M(W#8CI@PERVF^*<)6>VI!-/%JV-1K4<5+^JJNMS.)QK/Y ->E0/KX 1/1PQZOW[61(!K0OAHX]-NE(I<7JX/Y#EE59_ 5!+ P04
M    " "%@*I(A4[? :4!  "Q P  &0   'AL+W=OX@E>#[" E,_\N(/1XQCF^%]YXV[E0
M(&5!9E[-)2C+M4(&FC-^SD^7?4!$P&\.HUW$*'B_:OT>DI_U&6?! @BH7%!@
M?KG!"P@1A'SCOY/F9\M 7,9W]>]Q6N_^RBR\:/&'UZ[S9C.,:FC8(-R;'G_ 
M-,(A"%9:V/A%U6"=EG<*1I)]I)6KN([ISR&?:-L$.A'H3'C*HO'4*-K\QAPK
M"Z-'9-+6]BR<8'ZB?B,J9&/1I.F]4>NKMS(_'@IR"T(3AD;,9869$<2KSRWH
M5HN)3A=TNDW?;=%WR>%NY?!Q6V"_);!/ ON5P'$]8L)
M'8LJ/:AX41?5^78^TW@FG_"RZ%D+OYAIN;+HJIT_V7@,C=8.O(GLX8!1Y]_/
MG AH7 B//C;I2J7$Z?[^0.976OX'4$L#!!0    ( (6 JDBL\B8.I0$  +$#
M   9    >&PO=V]R:W-H965TCK@'%\*K[SK72B0JB0+K^$2E.5:(0/M 3_D^V,1
M$!'PQF&RJQ@%[R>MWT/RW!QP%BR @-H%!>:7,SR"$$'(-_XW:WZU#,1U?%'_
M':?U[D_,PJ,6?WGC>F\VPZB!EHW"O>KI">81;H-@K86-7U2/UFEYH6 DV4=:
MN8KKE/X4NYFV3: S@2Z$^RP:3XVBS5_,L:HT>D(F;>W P@GF>^HWHD8V%DV:
MWANUOGJN\KN?)3D'H1E#(^9XA5D0Q*LO+>A6BYE.5W2Z3=]MT7?)X6[=_3[;
M%BBV!(HD4%P)Y-&UL;5/;;IPP$/T5RQ\0LUXV7:U8I&RJJ'VH%.6A??;" %9\
M(;99TK^O+RR!BA<\,YQSYHPOQ:C-N^T '/J40MDS[ISK3X38J@/)[(/N0?D_
MC3:2.9^:EMC> *LC20I"L^R12,85+HM8>S5EH0,8[
M?"^\\;9SH4#*@LR\FDM0EFN%##1G_+0[7?* B(#?'$:[B%'P?M7Z/20_ZS/.
M@@404+F@P/QR@V<0(@CYQA^3YE?+0%S&=_67.*UW?V46GK7XPVO7>;,91C4T
M;!#N38\_8!KA$ 0K+6S\HFJP3LL[!2/)/M/*55S'].=PG&C;!#H1Z$PX9M%X
M:A1M?F>.E871(S)I:WL63G!WHGXC*F1CT:3IO5'KJ[=R=]P7Y!:$)@R-F,L*
M,R.(5Y];T*T6$YTNZ'2;OM^B[Y/#_RI!-/&JV-1I0<5+^JB.M_.)QK/Y M>%CUKX1E/_3:".9\T?3$ML;8'4D24%HEGTB
MDG&%RR+&7DQ9Z,$)KN#%(#M(R:,GW:G2QX0$?"3PVA7>Q2\7[5^"X?O]1EGP0((J%Q08'ZYP3,($81\XM^3
MYD?*0%SO9_6OL5KO_LHL/&OQB]>N\V8SC&IHV"#B
M_B(J9&/0I.J]4>NCMW)W?"S(+0A-&!HQESO,@B!>?4E!MU),=+JBTVWZ?HN^
M3P[WZ^SY?_+G6P)Y$LCO2CS>EY@PEWO,YW^2D-6=2C!M'!V+*CVH.*BKZ#*=
M3S3VY ->%CUKX0,.O]^EH. QH7MH]^;-%+I
MX'0_/Y#EE99_ 5!+ P04    " "%@*I(5$TG_Z(!  "Q P  &0   'AL+W=O
M?X&GCA7>]"@%0E67@-EZ LUPH9:(_X(3^.-Z;S;#J(&6C<*]Z.DWS"7L@V"MA8U?5(_6:7FE8"396UJYBNN4_GS/9MHV
M@Z/61R]5_B,KR24(
MS1@:,:<;S((@7GU)0;=2S'2ZHM-M^FZ+ODL.=^OLQ7Y;H-@2*)) <5-B?EMB
MPIQN,5]=DM6=2C!='!V+:CVJ.*BKZ#*=#S3VY!->E0/KX(F9CBN+SMKYSL8V
MM%H[\":RNSU&O7\_RT% Z\+VWN]-&JET<'JX/I#EE58?4$L#!!0    ( (6 
MJDCHNA.BL@$  !8$   9    >&PO=V]R:W-H965TF55I0ZY:ZPV;00)M $AR3
M-+W'@C*95&6HO>BJ5*/E3,*+1F84@NJ_9^!J.B6'Y%9X95UO?0%7)5YX#1,@
M#5,2:6A/R=/A>"X\(@!^,9C,:HY\]HM2;W[QHSDEJ8\ '&KK%:@;KO ,G'LA
M9_QGUORP],3U_*;^+73KTE^H@6?%?[/&]BYLFJ &6CIR^ZJF[S"W$!+6BIOP
M1/5HK!(W2H($?8\CDV&LQ%7=)EP:&U?OK@YCJ>V[BP:KC=PN574/T#4$L#!!0    ( (6 JDC/]]BI
MJ $  +$#   9    >&PO=V]R:W-H965T2N9F9GR64Q
M:O-F.P"'WJ50]H@[Y_H#(;;J0#)[IWM0_D^CC63.AZ8EMC? ZDB2@M L^T8D
MXPJ71\09?$Z^\[5Q(D+(@,Z_F$I3E6B$#
MS1$_; ZG/" BX#>'T2[V*'@_:_T6@N?ZB+-@ 014+B@POUS@$80(0K[PWTGS
MJV0@+O=7]9^Q6^_^S"P\:O&'UZ[S9C.,:FC8(-RK'I]@:F$7!"LM;/RB:K!.
MRRL%(\G>T\I57,?T)]]/M'4"G0AT)MQGT7@J%&W^8(Z5A=$C,NEH>Q9N<'.@
M_B J9&/2I.Z]4>NSEW*SOR_()0A-&!HQIQO,C"!>?2Y!UTI,=+J@TW7Z=HV^
M30ZWR^J[_PCD:P)Y$LAO6MS?MI@PIR7&C^T_15!S417:>
MS@<:[^0+7A8]:^$7,RU7%IVU\S<;KZ'1VH$WD=WM,.K\^YD# 8T+V^]^;])(
MI<#I_OI YE=:?@)02P,$%     @ A8"J2)F7@KZ^ 0  >P0  !D   !X;"]W
M;W)K&UL?53=;ILP%'X5BP>HB1/H%!&DIM6T74RJ
M>K%=.W  JS9FM@G=V\\_A$!E]0;;Q]_/.<;'Q235N^X #/H0O->GI#-F.&*L
MJPX$U0]R@-[N-%():NQ2M5@/"FCM28)CDJ8Y%I3U25GXV*LJ"SD:SGIX54B/
M0E#U[PQ<3J=DE]P";ZSMC O@LL +KV8">LUDCQ0TI^1I=SSG#N$!OQE,>C5'
M+O>+E.]N\;,^):E+ 3A4QBE0.USA&3AW0M;X[ZQYMW3$]?RF_MU7:[._4 W/
MDO]AM>ELLFF":FCHR,V;G'[ 7$+F!"O)M?^B:M1&BALE08)^A)'U?IS"SK=T
MIL4)9":03P0R+^=MWA93'0%GY1U;)>HXLT]H[Z"]5(:< FD3[84CO[$BP+#HUQ
MTT<[5Z$YPL+(X=;JRWM3_@=02P,$%     @ A8"J2 OR7N2D 0  L0,  !D 
M  !X;"]W;W)K&UL;5/;;J0P#/V5*!_00(9>=L0@
M=5JMM@\K57W8?^>&/2&V[D$R>Z,'4/Y/JXUDSKNF(W8PP)I(DH+0++LCDG&%JS+&7DU5ZM$)
MKN#5(#M*RE.> LE  ":A<4F#_.\ 1"!"&?^&/6_$H9B&O[HOXS=NNK
M/S$+3UK\Y8WK?;$91@VT;!3N34^_8&[A-@C66MCX1?5HG987"D:2?::3JWA.
MZ<]#-M.V"70FT&\$DA+%,I^98U5I](1,NMJ!A0GF>^HOHD8V!DWJWA=J??1<
MT>RA).<@-&-HQ!S7F'Q!$*^^I*!;*68Z7:?8IN^VZ+M4X6Z=_:[8%BBV!(HD
M4%RU^..ZQ80Y7F'R[%L2LKI3"::+JV-1K4<5%W457;;SD<:9?,&K:?4?4$L#
M!!0    ( (6 JDC*.5Q9O0$  'L$   9    >&PO=V]R:W-H965TW9@ *LVIK8)W;>O
M?PB!BNT%V^/O9\9XG U2O>L&P*!/P5M]C!ICN@/&NFA 4'TG.VCM3B65H,8N
M58UUIX"6GB0X)G&<8D%9&^69C[VJ/).]X:R%5X5T+P15_T[ Y7",DN@:>&-U
M8UP YQF>>"[email protected]/R>&4.H0'_&$PZ-D:>L$,A+(-P(.1C[-7]30
M/%-R0"H<;4?='TP.Q!Y$@;0/JE"]353;Z"4G29+ABQ,:,<1C3G/,#8&M^F1!
MUBQ&.IE;K-,W:_1-R' S=]__1V"[)K - MM%B6198L"#9[1"@:M\$&A6R;WW+S:)3GST0?[MN\#SK
M: V_J:I9J]%9&GM'_86JI#1@DXCO;*F-?0FF!8?*N.G>SE5HCK PLKNV^O3>
MY%]02P,$%     @ A8"J2!Y0;S^P 0  ]@,  !D   !X;"]W;W)K&UL?9/=;IPP$(5?Q>(!8O#N)NV*1D\5%UU2Y"'VHHL)X
M2K+D%G@536M]@!8YG?,JH: S CNBH3XEC]GQ?/"*(/@E8#2+.?'>+XAO?O&C
M.B6IMP 22NL)W U7> (I/<@5?I^8GR5]XG)^HW\+NW7N+]S $\K?HK*M,YLF
MI(*:#]*^XO@=IBT$AR5*$[ZD'(Q%=4M)B.(?<11=&,?XY_ PI6TGL"F!S0G9
M?3 >"P6;S]SR(M&34N>BU8]B6G5P^:-"QH
MSFO-UUE#'7\NPK:*3 "V!+!T&[#; NRCR]T*D&T#]EN 703L5P"V#3C\Q\%A
M!=BMSREJSFO-_I\B='$Q"G03^L^0$HB=8]P7DBHK9\^N+F.?1D7%OO;*YN?>O$74$L#!!0 
M   ( (6 JDBGBTTM*0(  #$'   9    >&PO=V]R:W-H965TJ:A>51K-HUT[B!#0&4]L)T[^O'Y"!
MR*'9X->YQ^<>=*^[email protected]@H^6=7(;UDKUSP#(?4U;(I]X3SM]15GPLV)-1U]%(,]M2\3?%\KXL U1.&V\
M-:=:F0U0%N :=VA:VLF&=X&@QVWX!3U7"!N(1?QJZ"!G\\"(WW'^;A8_#ML0
M&@V4T;TR%$0/%UI1Q@R3OOG/2/IYIPF(5Q3$
M"X+-,LO,^> PG<4D.8)9DOIPU1R'DPBC](Z@9$50LA"4^PG2%4O21RS)5A1D
M:Y:DSI)LEBKT(:HY(H&ZA\1^)9L5)9NY$@S]!/F*%_DC7IBBORO!'/[7C1&T
M9L<"DF",MVTG.HN(PND/AK;G1$Q0]9(JWZB85^(&J&4%CQBA'>0J]
M97,#A&F6W;82,&MN/3G1GT2E1F
MFNFY&UL;5/;;J,P$/T5RQ]0$T.V5420
MFE:KW8>5JC[L/CLP@%5?J&U"]^_K"Z&D@@?L&9]SYHPOY:3-F^T!'/J00MDC
M[IT;#H38N@?)[)T>0/F55AO)G ]-1^Q@@#61) 6A6?:#2,85KLJ8>S%5J47]5_QFZ]
M^S.S\*3%/]ZXWIO-,&J@9:-PKWKZ!7,+^R!8:V'C']6C=5I>*1A)]I%&KN(X
MI96';*9M$^A,H N!)N.I4+3YS!RK2J,G9-+6#BR];';+:6 FFB_?'HEJ/*M[657:YHH\T'LP7O"H'
MUL$?9CJN+#IKYX\WGD6KM0/O([O;8]3[1[0$ EH7IO=^;M*]2H'3P_65+$^U
M^@102P,$%     @ AH"J2%$"97!, @  B <  !D   !X;"]W;W)K&ULC57;;J,P$/T5Q <48W.-"%*35=5]6*GJP^ZS0YR "IBU
MG=#]^_4%"%0FS0NVQV=FSAPTXZRG[(.7A CGLZE;OG5+(;J-Y_&B) WF3[0C
MK;PY4=9@(8_L[/&.$7S43DWM00 BK\%5Z^:9MKVQ/*,7456,.OS0-9O]V
MI*;]UO7=T?!>G4NA#%Z>>9/?L6I(RRO:.HRC[;.XK\
M@=(/=?AYW+I <2 U*80*@>5R)7M2URJ2S/QW"'K+J1SG^S'ZBRY7TC]@3O:T
M_E,=12G9 M4*AVLC
M,W+)RKBT7G.(HLR[JD #!FK,;H[Q)X0GHT\IH"W%X [G*6P)]G-$G-@S(%L&
M9(I BR)B>X# %B P 8)%@&1),C)E&$QK,'$"#"!3*XI  H!5DB4NC?PX6*%D;=V1TJ)W [ 2PMJ:@RX^?$@8:^^-
M+- CPJ!Y4Z P!-&*,@L@".,(?JW+FPVXAK"S'OS<*>BE%6JBS*S3X_(,U8#\
M8M^I1TOGI4G2@61#,&3;,U2/HO3H28GH;:Q
MW#/S4)B#H-WX[DV/;_X?4$L#!!0    ( (: JDBH;".C60(  !P(   9    
M>&PO=V]R:W-H965T]9
MU94\F:X=Q+-*]*GON?K[)#IY6:4PO7:\M/N#<1U9766WN&W;BT&WXD9T>?Y/-
M21O97T/2I.=OOFR'L;SX$70-BP?D4T!^"X!X,0!- >A=0.;)QG5]Y8;7E9*7
M1/F/<>3NF\-'9'=ND^BQ4_GMLBO3MO=,X> $'
M!S@XG(=Z'!S@D)(5,5D3R !F%,1QR (."7!(%(?,YF$LCXJ:N8@0DM,X"UU@
MH0$+C;+0V328L+R$49I !E!)[IP\MH## AP6Q6'S56-[)% 4)Y#1LB XCE,L
MX!0!3A$W*!=N4OF9F^32VUT$-_CAEDRB:>]IR4C\]"[I0J1HDKHBA5GJSH6$
M2QD&?BK%P*4< ]'2QDQ)!L[3!\,4D&B2"600 %"^OTK9+(\?^5[\Y&K?#CI9
M2V.?A#%_[Z0TPKJ!!WLO#_:IOC4ZL3.NRFQ=^&ULC53;CILP$/T5BP]8@PG-*B)(&ZI5^U!IM0_MLP/#1>L+:YNP_?OZ
M0@BIZ*HOV!Z?,^>,&3N?I'K3'8!!'YP)?8PZ8X8#QKKJ@%/]( <0=J>1BE-C
MEZK%>E! :T_B#),X_H(Y[454Y#[VHHIPY"]U(@!DH.9>80'O"SATFOYLAY/TOYYA;?ZV,4.PO 
MH#(N [7#!4I@S"6RPN]SSIND(Z[GU^S/OEKK_DPUE)+]ZFO36;-QA&IHZ,C,
MJYR^P5R"=UA)IOT75:,VDE\I$>+T(XR]\.,4=M+'F;9-(#.!+(1%9YN0SH3T
M1MCY2H,S7]=7:FB1*SDA%?[%0-TO3PZI/;D*:1]4X;AL9=I&+P7)XAQ?7*(9
M0SSFM,8D"P+;[(L$V9*8Z60ML250KA'[QVV%=$MA%XI([XI([C7VP47 B*!!
M;"]OHOT,X$"   P
M"0  &0   'AL+W=OQ%!/+6-%3\>68UOV]#$ X=K]7YHDQ'M"NB,>Y8-:R5
M%6\#P4[;\#/8E( 82:?X6;&[G#P'!G[/^9MI?#]NP]@PL)H=E$E!]>V=E:RN
M328]\N\^Z;\Q3>#T>_ZJ.ZJ)IXS XLA.]U>J5W[^Q?@ZI
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M.@5QQ9FL^5!N"M
M#0./4QSPS$H#WNHPN )7N;*TGP%:X\ITHP*#3A0D!55MQ?U*R7%<98#;]E]$*:0D$>H:'*V7>F9_:#B7+4R
MV'.EC\GN3#MQKIA.%S]IBR[Z]V5LU.RDS"/1S\(>Z+:A^'7X/QE_DG9_ 5!+
M P04    " "&@*I(8?71E%:G<2=:&^R;-H
MS).#;.M"F]OV&*ES*XI]EU17$8YC%M5%V83KK(L]M>M,7G15-N*I#=2EKHOV
MWZ.HY'45HG ,/)?'D[:!:)U%4]Z^K$6C2MD$K3BLP@>TW")F(1WB=RFNRED'
M5OR+E*_VYN=^%<96@ZC$3EN*PES>1"ZJRC*9G?\.I!][VD1W/;)_[\HU\E\*
M)7)9_2GW^F34QF&P%X?B4NEG>?TAAAJH)=S)2G7?P>ZBM*S'E#"HB_?^6C;=
M]=H_6<1#&IR AP0\)4S[P ED2" ?"+.*916""!")(>H+$
M(TA\D;SWHL)P78N9
MNA9>70PF2&><3>]QUC;5FQ+LPR^]'4!]K80RV%L?A1"(VG@H%+,T!=WU8"EQ
M7@*_-K #CK7Y+?#& 2&P?0T&(WR7PV!K&560>QPFKG<\ 5&YA\*(+F"'B>
C\2*PNXP.T[L#B<,?7[)(^=/O1;ML1NG5+"3ET9;CYSH-+(]8#L4
M?(H_HF6.@/C&CGC=$/%!O\[.Q5'\*MICV:C@16HSBG1SPT%*+8SN^)LYE9,9
M0J>;2ART77*S;ONQK+_1\CQ.F=.HN_X/4$L#!!0    ( (: JDBMI(4_C0( 
M   )   9    >&PO=V]R:W-H965T%#V
MQFM"A/?>M3T_^+40PSX(>%63#O,='4@OGUPHZ["0778-^, (/NNDK@U@&*9!
MAYO>+PL]]L+*@MY$V_3DA7G\UG68_3F2ECX./O"G@=?F6@LU$)1%,.>=FX[T
MO*&]Q\CEX#^!_1$@%:(C?C;DP1=M3XD_4?JF.M_/!S]4&DA+*J%*8'F[DV?2
MMJJ2)/\>BWXP5>*R/57_JJ@N$+D*1$9C9!5841"["L2F0&P5@/8D4Z/2Q/0F)D)R[ZXH339 
MB06*G*!D"8)Y'*:)&Y1N@%(+%#M!Z0($\C3-4N@&91MKGUF@%:5H0RFR"J2V
MTMPH14NENQBY*?D&);35LMX*+2UQJ-6.VC%7,!ISXEC^1-!-\<.BE8X6RX&EHU1[.;8
M02L;%CA-/"V]Y6*T]O:V[ DL?Z)/^S$;I2X-"E$>Y6NKXC3HA+(>GWN+T;GP_X)
MZA/N([PL!GPE/S"[-CWW3E3(&PO
M=V]R:W-H965T<@!8PM9VP_?OZ @1'!N4%\'#FG!D/XR'M"?UD)<8:9:2&Z^K
M%K]3P&Y-@^B_(ZY)?W"@,QH^JFO)I<'-4G?R*ZH&MZPB+:#XX/X$8PE1
MB-\5[MGL&,S_Q4OP3Q*^36)P]^<2-H'3
M'+'=V14"FT*@DPB,)!9"#&T$H28(#8*G(&.=AL:T"A/N_,CS;+#3'.;9(XE6
M(HF,2 )30F..)B:TB\0K(K%!$%E%3$QL%]FNB&P-@JV=8+=2U=TK54U6(D@,
M@IV99J+33.;EVL0+FRG/@T49^7*FDUBWTP %WL*7 :VM.NI @P+:=4R0OZ!C
M[==1QSE@
M_$KY3%#TI./.#O<&TZL:>@SDY-9R>9K.K--@??/E<'BR'^7 54/C09.E';KB
M7XA>JY:!,^%B]*@Y<2&$8Q&=MQ&[4(I?@FE1XPN7CV+$ :J'I%YPTHTS?_KQ
MR/X#4$L#!!0    ( (: JD@I.[TGO (  -@)   9    >&PO=V]R:W-H965T
MQ.P^?^9#T\8>W'EXEV>&%/19U.W1"0O
M34/%WQ6K^749@_@V\5H=3\I,).4B&7S[JF&MK'@;"798QL]@O@782#K%KXI=
MI7,?&?@WSM_-X,=^&:>&@=5LITP(JB\?;,WJVD32F?_T0>\YC=&]OT7_UKVN
MQG^CDJUY_;O:JY.F3>-HSP[T4JM7?OW.^G<@)N".U[+[C787J7ASL\110S_M
MM6J[Z]4^*=+>%C; W@ 'PY G;$"] =T->-* >P,>#!!-&DAO( \9$OONW CAV&$JRAQQF&^&^4K:O(BS G"G$BNUK(HQ@)@$,!
ML V O0 S'S*WBV$UK=6@')$T)-M,R#P<,H%#7!SPD,=J-KYFI+C91)+,"_!0
MF,PFR9R7(1G,TI!JZZH 0B3#89I\@B;W:%!P:7,G#\QQ%JS3UE4!3&!.PC3%
M!$WAT>#@VA1.'EQ DH87QY6-_!5F$R0SCX2$4JQF+DDV1K)V97I?2D=H3!L?
MQ3$/'9YL)$2PM?4?*P!?^5I!L"_=*. 7ZM.+@@7R4P5;RRV5UUM 'DZ%W%08
M%B2(M/5T:):F<(1HJEYE=@O@:!^8TYQ'3;Y#U\N3C3(_M)Q;%J9?3&E=YL
MNYWQP+EBFCM]TMWOI(]9PZ!F!V5N&ULC59=CZ,@%/TKQO>M GY,&VLR[6:S^[#)9!YVGZFEK1F5#M!V]M\O'VJE
M0=(7!3SWG'N1 Q0WRC[XB1 1?+5-Q]?A28CS*HIX=2(MY@MZ)IW\U303C.(M:7'=A6>BQ-U86]"*:NB-O+."7ML7LWX8T]+8.03@,
MO-?'DU #45E$8]R^;DG':]H%C!S6X2M8;6&L(!KQIR8W/FD'*OD=I1^J\VN_
M#F.5 VE()10%EJ\KV9*F44Q2^;,GO6NJP&E[8/^ARY7I[S G6]K\K??B)+.-
MPV!/#OC2B'=Z^TGZ&E)%6-&&ZV=07;B@[1 2!BW^,N^ZT^^;^9(G?9@[ /8!
M< R T!N ^@!T#S"5FLQT7=^QP&7!Z"U@YF>LC,O1
M:XG LHBNBJC'0(W93#%@1$22?92 +HD^'$XE8.R2V-J8&1'D$D&F#F010#=!
MXB)(#$%B$2 [2V!F:V- G08EBQF5U*.26BJ)K9(9D70B E.W1N;1R"R-U-8P
MF(V-R=PBN4GW6!)8WT5RR3N<-]69/U>OS%L@[T60=:UD&)<[-Z #UNB='DQ&L).^J;  \J
M>NF$.F FH^-MXU4?L0_C&WD+,2?IG:8LSOA(?F-VK#L>[*B0Y[$^/ ^4"B*S
MBQ=RW9SD/6GL-.0@5#.7;69N#J8CZ'FX"(VWL?(_4$L#!!0    ( (: JDCL
M.>A,70(   T)   9    >&PO=V]R:W-H965T',FM$-<=.DE8 /%Z#0%
M=6T0A6$:=*CI_;*8QEYI69 K;YL>OU*/7;L.T;\ON"7CW@?^//#67&HN!X*R
M"):X4]/AGC6D]R@^[_TOX+D"J91,BE\-'MFJ[4GX R'OLO/CM/=#R8!;?.0R
M!1*/&ZYPV\I,8N8_.NG_.67@NCUG_S8M5^ ?$,,5:7\W)UX+VM#W3OB,KBU_
M(^-WK->0R(1'TK+IUSM>&2?='.)['?I0SZ:?GJ-ZDXBLA3(O@)A-I
M331I7M::R*:H#$6R2 (!L%!$-@JH*"*#(K,G@+8$L4H UP"9R9BI52A)/TF2
M=!=#N+/I*D,716D6AW:>V,$3KWCBW)PG53SQ:IXX"S$&0.>S1VY%MV:,W)'O4GMS!DV_;DZ_FL5MC5Q@,.P?#
MSMC4G3V!+$1W;9$OMWT!UN.O(0#8=D9K7%MQ1V)R6 O S!%M.Z(U6R?&D+F.
M#' 5%+"N*/#>?PQ8:\!L3_R0/:Z3"Y('[$FV[;%+3 YK 9@Y4H<]NKYJC95#
ME]8[$L41K"ZN 5WP3T0O3<^\ ^'B#IPNK#,A'(M$X9-84"V^399.B\]<-C/1
MINJV5AU.AOGC8_D"*O\!4$L#!!0    ( (: JD@,\M/KZ $  #8%   9    
M>&PO=V]R:W-H965TU9L^H)*EB,*+T5#9:# %)9$J,X#L-GS$C7!WEF?6\BS_A)
MT:Z'-X'DB3$B_NZ \G$;1,'%\=XUK3(.G&=XYE4=@UYVO$<"ZFWP&FT.B4%8
MP*\.1KFPD=%^Y/S#;'Y4VR T$H!"J4P$HIGOKE*M%AL&J(*:G*AZY^-WF$I8F8 EI])^47F2BK,+)4",?+JU
MZ^TZNC_IRT3S$^*)$,^$.8^?D$R$Y$I(_TM()T+Z:(;51%C=9<"N=GMR>Z)(
MG@D^(N%N>R"FJ:+-2M]-B:1U"G8
M:Q2L%_UT^$F^AK^#P;2 ,_B6BZ7J(C5[J7;>/5G"O0LL,GW<.M?L3F#85:
M&7.M;>'FVFT4'RZOU/Q4YO\ 4$L#!!0    ( (: JDAV%0[XT0,  $T2   9
M    >&PO=V]R:W-H965T*,X\/N,[9IRPBD"]3N_OL-GR5Z2?-BX7+NR;D?Y$KF9UY\E ?&*N-O
MEN;E[>Q05<./+!=/=KS(XDK<%GNS/!8LWC9.66IBRW+-+$[R
MV6+>V%Z+Q9R?JC3)V6MAE*
M)CPW"K:[G?U$P0OR:TB#^)6PY1@V',M L%""89$AF"Z
MM82S*1GS2?%YJOB\<7QD(L>^*L>^3K/7N_6TB/KIU?;J0&W &!/+ W'WFKC5
M55PK[D$61Q#8U)ID3SID:YG,]ES?A=<@B3;*723*YCO#4ZNLHC2V"H87N
MOH F5"/Y+<#6Q&A"\&SJ!6&=QL*:C:6'6VGB0DU<=!775Q!K55 YN9"MLV,B
MY>Q"RN'5[9EH/)80MB=VN7L9YT[MABL9YZ$)7*B)6TLX0J?T12J /!=Q]X
MIO?9\U5[=+^1RR#[BSAS],F3L6+??/B7QH:?\JKYAV!D'DX7[G#]S?3%OD3!
M(P+L(0J>(7M4GU( ]A4.'B#^$ =/D'V-@V?('N'@!;*+A >12/KW)R)7XDES
M7&!>XF+?9*7QCNOQ&=E\P6XX[QB(L76C7CS#BS>#C&PO=V]R:W-H965T=M%3O-W'
MR(38B%\M':4W!\;\@?,WL_AQW$7(>* =K961('JXTF?:=49)D_],HA],D^C/
M;^K?;+G:_H%(^LR[W^U1-=HMBL"1GLBE4Z]\_$ZG&E(C6/-.VE]07Z3B[)82
M 4;>W=CV=AS=R3J9TL()>$K ZV2=%W"JQ&:8K"-V?LQ\1P!M?J,P"'$E(X7B#0LD(0$$NC*_G@S=K6?SX.(W'@<7>5@@?V T7Q@MED8+9S3WC,8KC,.4X@&E\"D9
M"EY'X5'N(,P;OLLPAQXD#I8R!=UJB3>?0-![FXR*LVU!$M3\TMN.Y^W.;>X)
MV[?]$5Z5 SG3GT2Z0]CG?.)<46T#K?1_K-&->%YT]*3,=*/GPK4F
MMU!\N'7:N=U7_P!02P,$%     @ AH"J2%/+7@[* @  V@L  !D   !X;"]W
M;W)K&ULG5;1;ILP%/T5Q <$; ,)%4%J,TW;PZ2J
M#]NSDS@)*N ,.TWW][.-H79E+*MY"-B<>\^YOCGD5G;>,+
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MSH)MG-.J0W
M&X^"34!O-F:=*%T#Y.8I/3QEP*&7UGGF"]7(M\BS* RQ*#0MFJ=+
M?VO09U 88E#XR: +OW+HLR3T6S+73)\L^?F=DQBC5$>&LQHQ672@MUY-M,;N
M/,8^0C6*?<#KZHK/Y!<>SDW/HCWE8J!3T]>)4DZ$C'0E9%S$H#TO6G+B\G8M
M=8ZCY[C@]#I-TO,X7_\'4$L#!!0    ( (: JD@C>&PO=V]R:W-H965T1JC[,/#MP650;4]N$SM^/%T*@(GD!^W*V:VRG(Q.OVEXH(1I:>BQK(70$I+8A0'OI]@1MK.RU);>Q-9R@=%VP[>
M!)(#8T3\.P'EX]';>=?">ULWRA1PEN*95[8,.MGR#@FHCM[S[I G!F$!?UH8
MY6*,3/8SYQ]F\JL\>KZ) !0*912(?ET@!TJ-D#;^G#1OEH:X'%_57VVW.OV9
M2,@Y_=N6JM%A?0^54)&!JG<^_H2IA=@(%IQ*^T3%(!5G5XJ'&/ER[[:S[]%]
MB:.)MDT()D(P$V:?;4(X$<(;P3I@E\SV]4(4R5+!1R36[0ZA7KD#2
M%H5;+MV9U-5+%N[]%%^,T(0)+.:TQ.QF!-;JLT6P93'1@P4]V#+(EXC]CVV'
M<,LA=$V$JR;N1(RV!"(G$*T$OH71 E646)-E9+.U)#;^)J-M.HC-7^D#9W5]QKD"G\Y_T2C7Z
MGILG%"IEAGL]%N[HNXGB_?4BFV_3[#]02P,$%     @ AH"J2/H+UX$$ @  
M!08  !D   !X;"]W;W)K&ULC53;;J,P%/P5BP\H
MUP"-"%*3J.H^K%3U8??9@9. :F-J.Z'[]^L+(1!945^P?9@9CP=\BH'Q3]$ 
M2/1-22@ZX-B1*_"@(4I_BMO/*
MPM3>>5FPLR1M!^\W5+H1,LZQ.&X
M\5["]3[7" /XT\(@9G.DO1\8^]2+7_7&"[0%(%!)K8#5<($=$**%U,9?H^9M
M2TVM9:/,!AZJX8C/1'ZPX0W&(ZRT8,6(,$]4G85D
M]$KQ$,7?=FP[,P[V39J--#WA0(_F;8C4,7.G=3_U:PZ=;:72-^VN_HV7.]L
M@[K)E$6/3_ ;\U/;"71@4MUE<_&.C$E0YH(G]:$:U9.G!8&CU--,S;EM4W8A
M67]MNE/G+_\#4$L#!!0    ( (: JDB+^PMYYRD  -.R   4    >&POEN&\F9O[-/41A,L!+0HGE3M"<#T#H<)=8QDCS>
MA;$_FF21[)EF-ZOEB[7O"52 /OIU2>A&F0_.:KWG'_JV^_B;UOOTF^/0UG
MZ5H&B9@$)7,?_53OA?KN1Q2\[
M[:/OBG^;P.@YS3CWW67QVX7KQZ5ES!XW,O)"Q---9SOW
MXIGKB_^4;B3.X8\E[!9'JGTKQW[7*_Y%D?%6+KTXB5Q8YLI=EX"]B,-;=^L 
MHF>MFA5. (0(MK\ &G\4OY?;XKB3-(J*!ZI#SM%1>WC4:]=L=>[Y,A(G,&\9
M1J5])K.9A._AVSF/+ ZXC]RY%RS%W78]#?W24>]NZTX8KM? 8'=)./O1$7?$
MZN(Z3>+$#7#!TH'#( Y];TZ0O'9]-YA)F ;R%H.HO+L[%0=?'Q8G_2X-@"W:
MQ/"#.A2Z<0R+O"Q][<8K ;"(&7Z0/Z7>@^O#^!(;G,@H\1;>#""+1;@0<[D)
M8R^IP"0J@5A$XOA\^THE ],0\3*?)(O6%JZ? D*_A&.UV
MFR!2GQU8*M[(6>(]2+]$N8O@ :"M(.EUL@*"9U"4#G03R8WKS87\"'HNAD/A
MGB'-FN5P5N*%, %>;!YS$X'VC( !<%'$Z@;%C3"Q)V)A;!@9># AV
M2T)L5G:W4>C[!% D&1.)^[$>E =WUH"B61D9Q8%OPV!YE,AHW8BQ]VY$NG8.
MNOK!I0/IX65]AG0!Z!,ODJ3GPZGO+1N@;( .59B7X"HL(C.PRZ"Y9# K#T9/
MXF6\<6?R-U^!JQ#+Z$%^]:TH+DEZB,N\YX?.STNF/E0@@W359AY/U!SE^)PS%,1*/A+Y>']^#OQ.GT5:#X29P_AB$DU54I^> $Z26;%94D_G<0_P#
MLE'M''D!B.[&2RH9T8C@7()F*&M9)EI<@<:=Y"6X]YEY!WP&PR<"%.5" A//
MV8R)#Y=R/951R5,JC'/$]T@I<  (TS7+O]Y[>37AY*D33O>>T&1\#VY<%.,5
MB!1X(H?UQGB2,W*GVL@9?7=KV<63:L5<0B3L+6"QNX0@([2BR\;^Q,[9RNN8
M&.FHD;1/V:S2O]EWISLE-M4,4CVVP7P%H$X0&<>#I#6O>G*"^T#L#/
MT\0!H&X.SI@;67\ML>1[Z2U7Y+ ^P,D!X 8CUZR
MPNGL@:HH )59.063!2ZX6FA%.OO*J"6;6ESKW6V(!*3>S-W?]R9C"AV\1.)=WYQ-;DZV44\8TR,
M&:$PJ!GWY*,00G*QX":-XA0%$J@J/\IHYL6V68TKS=QGK1QNB(UVHQ)PN,@,
M=BT.<2(89W18PR[
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M^].?><[?_O2_&*R"-A?PMQ.&"?YXV!+@S(C8P@K!IJ#..
M76#XA8*8'(Y-@=CY?>K0ET$):L1/0?6TD"Z SD\A1KP*4Q^4EQ18WF.7.?@A
M#0@E[':%*9A+M? >U+5RIXLP3((0+9D+.X'B@^,G*XU20[+_P5E!"NM$8.TB
M& 8^[1Q=Q_,P6HM.^^CW!G%;K -)C(_%[]) FMH'X<#"P%/PN,%R !HHVP;@
M9E&JH]1(+C$M1VRB*'4G9^@=Z+S:V<<9FV%*FH+Z0C;!!+_K(:6RBB/I3(48
M:95H!N 80"R2PV2=&EQN*C3*EL(E@<6_C
MLT>)QW@7>":" ?%Z,YG<'%JX 3S.T7>:HZR%:R])2GA"2:[$% H"?)TN5^(1
ME_,]^8"B[R:TLWUVU GN'+0X0&%H;6,-L(6[ 9\"?I>3[QHRV:S%KPA]3G^"[,8TZF[$$R[R#"'E?>;$6#8 !ZV#,6&! U 8&73XS..Y]HQ04D!-H1G0B)
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MVH>7A,C'EWI-M$@0*+#FP*F,._Q*0ITQ%__6YA:?!V'&N8DFY-YD(BG-85(TDJ'&0R#$I^!VF9C AC 
MK95-]<-'YEHL5=*A \I(N3X$':C3*Y<1C RELTB&#\$MH%8=*1-^ABCH%T
M3M#)_'%D'K="LKVXP,F;= I,8G9G9*)#MBB9+)-!KV)9%*;\\%VB,&R)LQ*?
M>O$OA4U=D/"(.'78R*G#HS9Q:F99+@*PCBFK:?CB^H&6,&RN^E.TM3 J4*D;<*Y7JGN1+,)YY92<%4E>6I!_55QH2U6@ V
M3]7QY$)PTQU@JI('.+ \G+B0+&R Q"8.!_@]4,P4"K0
M-?V%AY4LJK-3N809IT-4X%FEP%]Q8M=W(ZV+PS1=IU(=;F$6\QW!,D>8(;>/S774*6H7DQ3*6(14/W-T>9.B
M1_H+,N&C&A.>\S:UJ7+)]&*N(4L)*D=UKKA9G_$?9OFK6D&5A7(H)+HJQ+B'7E6X[88=\3,GC/H]IS.<(3;
MMP$)PSX!TNN-G5Z_QT"UA\YH-"AUI+[532&576Z@(E"'Q%D?7(/05 U^LHCT
M6R(/DBCWI4B]4=8O@_\/VF^FND?!YE&Y5;>^Z'X@:NRR
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M8&'IXT%?5%] 0>-XX!V**(((@80ZG-_],
MTBGV&2]!!X)CF:60 ;Y4!Z\0]BYQ#6I;U5XI[HAM22!R">9=:#^(@*1V#7)G
MY*8OD"=SCPB;K4QQ9ZXZ5/C('&M0(E=5D] 1A"_FVO=U['&88))2IP00
M>FUQIA0X4]/37(6IF.#VN*DD!G3.*(R4'GFLE/%<05!\Q!&8NC*#BL\DG(R]
MR1"9Q4:8"&# 5=R20XJ=6-4D*6!4I $E-A$<"F( WC2P:4:!291N='*?S)U"
M09Q"A+'5N2H5V**O#UP%*F T)@&RL+IMLJ,2M@WV%K57J,3LYSS35?XA=O(,2^\P"&O_X%_V_4Q?LP
MC9?ASNJ:]?0H1]SXKA((,[A![S?/^RQ;,&R):MB;-?%;NKTH.L-CIP]V#1WB
M;";8"#2LH-?ATZ"'=E"\Q>XO]+K0.8K"!U4AZSN=[A@,QLCZQ.%;[]@9C7OH
M>(/!J+YK"-;D>'P,\]KP:7@\=H:C(6R$;=JY^T56"^_!R.D?=YU^?W"(GSN=
MOG/<&Q[6;@/,U!)\:U#_8C>-^N_J^U]%KDO23ACY7BUC806V-A+B+
M <:0-%;7,%3GK&D,;:CJ?N;"3^:<44O4'1IBW$A*'<]VTQ=/K 'O57.;+)G7X;+_6)8U C
MX'Z@*P1191>\D8[V0N*:GFD2N"&XHN@Z=3L@>5WRR<; S_AIB#Y*=53LJ.QJ
M&ICR<&%M!:"=+2,_6,&AO>%'%U'?ZXT 36W1:?7ZPMQ-,!_.=%_I1,4B5R:<
MNJ'(C>[O&^*-_.LBXC8>JCR#!.[[A-+CI@
MJ-4_!@]WA$YE%W1"#Y3(]U@7X=23;>7+I:8GF"N(GS=;@$\
M@*RO.ZU!#RBKT8>TP6LC6Z95!\= P("Y]04*/R6SVZU!Y]?X38<^E#8#/\I-
M.+?>:0];736X?=SJ#G^=.W:_2UYW#\*Y=M?^!N1@V 9Q I3VAB6U7+S9>])P
ML[=Y\'X1VOY+/%G?'K=$\^HW;J*][-\'X>/1;\-'<1MN71^P^Y9O!HC)$FC#
M;WWDD[?(-)P4X;0%)MS\-.9[6SQ7E9ETVO%O?_KSC[C-*GS$%E6E7]4-B4!J
M?VP14JDSYOH-ELFI213Y-!?TJUL>,V["*WRGTC1OW4=PYH KS]VU!Y[F?93B
M1677C+-R.YR>1C:-30.!/HEKL*#<5"Y'L2UD0".%.!/$X CL)C@'LJ-WR1:"
MU)F#KB9>8[:2YF8+!]N+MWQF##BOCQ%2RMECYH7*UYK+J^Y
M4T 8X'GN< #C@@C>6\MH_!?(A!EG;$5(N7=/^]NT*?J]F-#0.5?/!#18M5@R
M#O/KM<1U(.ZP_9(4?)=*#NT16\ EL@DL=@T8PV]9,;9'>8=[XT9V>($AVM1C
M30_1G_+;(KETH[D! G  E'T%'/L(;!=A"(Y]MXFO@@>7>C,H]C%5G$KF@8B 
MBB9N=G7=6@=C@91:7&,=4;(RQ:X[T(\^'N?84=P3<3W']7P=I[@4[F0+,D_J
[email protected]=K1)4^L!M-O41U3E$Y#/C>6T/P=((1CYAPMS*<)$Z]Q/AUL!=VK^/%
M:Y^N6URKCKJN8^4-%U[$?E1"SIG/B[!%YT9D(AB,L7O5N7CP&%*H2WF'!3!8
M1$T3IX^HSL5K=SK#A-E!,87'%\1 39U=<[G]=>1!E'?K8JX?YMN%.:I[XA0^
M0:A[ E4V/:._2U]TQLCU:.2XL)9KA-A(&1U%\L&3CW@J9"_?%(9_@*@;R?PZ
MESFYSKBT,]18 RWHKIG@U,F#A1H+7<19ZQ"TQUPF3'6(0^52MB'GY"9:R4*DAJJV_I2J2R=S=^TN*3FCRR0_X%V2!'-*+7$)&HXQ^<@B
MC8L%]\PDHW4!288GHW]7M
M2==Z?>/I%LX5R0UW(]RE&^JZ1^?8G/54G76B"'UBSHM9L.]S=*,&(T4[JRL>
MQ;&E=U7=WXP\)6.H19%90CC\6D:J(N=AT5_^2#V&B:$@DM8$H_?9K0U8.'G$
M'N]+[#-3,09JDQMUI->8]0CRZKC3MA6 +9I9WL?<.@&!5VMC6):H-"7)YJV$
M#<^H!"OT+3Z^DH,5],RG((FH  HOL^"?\-8*FNMU&I#&]S%Y"#3)22]UZ.,_
MWKOQ"B!,=']8E5
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MJ N!)(2@[7)B\QR[F3@&O\QZBTJADS7LU+KN4A\HU4UX0\0.\<=!5KVJ?ZJ\VG=BQG%!XG,0 *94[SV,P]-R>_"
MTT9/O^;9;HD*D/-N4+V.'5KT5SP,_T$*K>F2 +DZ6"\)*GQ-KN FJ](NM7P
M(Q0K)\(;5^KW2:F79,8MUFW$Q.BXM5LP9FV,JS=[)J&(]VZ KO8I1,$MC
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M'.K,QVN36U6:X\[9TIJ/^_A
M;Y3WPPD4!R .\*E4[$4,'KPH#+(\'C7I&/T\_P1\<[*F!HL[VI/\7:L>D#%)CNL33$HAP>L9>W_[5:%"2=@%6601%FRY(0O6V3>'I:&
M2FXB_9$&O0M488%R*DT5%FLGKC=]GA1AJ_:>T-M%$XXTP?5V*EZGX1;^K/_<
MI20A=3+JQ&$LZ9MWZP&1)[=O1^K5+W.D;"6%/%S.Z,JJ);
M?<'>4Y-S#Y%8^;%>8TX?LE8STS>K;>P!^0*>8YO#YZ0?4/-CKZ%++7)Y'M([&-KME2&EM
MX/5PF2H@D8DS'+M3S)&"Y(3HP*B"')#Z+N1L!S8@6J,!DGA-O5]IHG4W\/!2
MXJ5=RF$J/L-L4<4''Z.
M#;B@P5C(7#%#7RT7ZG8NF57*K6-!)<&5@'?I(H].-.UXJMZSTF^F"KKR8+N(
M4EQJ$]LL96PR-_^I05<]>$)W-W$;G7Z(5]YFHT^F
M1OII_:(8EF/5QN))15$06]:1JM&5T.0A/I2>H6OSA)*\ V*;QZSE.=<&:\R(
MEUC7"E3;+5A_BI_(9\D;Y$Y45D;<,MV
MK1.[T8V-3RG,S'O5>6,)_+@!N>7GOXB+YEZLVVN!U/2VO^ZO)6\1%)WXFW7TFM%^Z;Y56$FUWJ,&V8>
M!E9-4N/0RX!?E$#)SY[.,Q)F6!X5?)QB;.%9VQ2QCI?/.&HW%9""2E93^@V:G7.:)(H!YS%UKH%L2J9Z]4.'0
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MSTC4ZF-,PB.PZV4YJD]^VT&>S5ZV##,KKG=9K?X
MU0_;T^,.GTSS^YQVX<22B@TX\JU]DR![-\! -*^ICU'B;-]FC9?/CTC\(Q^1
M:.+:.B85$S3>ND*[K7IH1$S PL\=_1J!8S^F<&8]S8!_SOT2[J?[R").UW27
M"1M?9@'UB
MY=D^E87^I1[5V/."UU[F*YOK(*)UONBME26ZU E(>H<(?2%D5_[5M<\Q5FRB
MIJ"-'P5MS#^Y5>HNKLIGV5FL[&F^?,8\GWRC9$]DP.=.G-H8*>>&.Y@[M*IQ
MNOW*6MV.XKP 8DFQ\H"4L.Y6^'3;RV[7H!<<)+(*OQE,93\*J/F] SE;!1[>G?\R-I+R"I_PB\'"
MLTU@]@N 5OHP^]FPYTM+_Q\N+34:<^N^8.ZZH"%=B%WW8-J^;%3#G YQ2DQW
M,\TAJ\^4^YG9 CNKW[_D'X/=VHG_PH5 AWM]\1:)8S$DG$]?M;(B)OWC?D%%
M&D]U#$QMC?Y/%:V3BEMC_YV*1[%V@W&];4I]ZJ<6.
MW!*;]_$A'D(74JVKM,5E^PRGZ'+7/P:]FV9%%.9
M260 A @==,'E#/O8/UP2_*6N08;NN@#=A[?HLE_@I:KR(_:F8G;!1>)[]R,P
M4\)=< &V>JK4RPU0A%[R(N^CN$X;Q.'7>U>)%+H.04._NSL5!U^7$&8*)U07
MJ3MOL:Q4\1L6C:?/QHGK1WI%#.P#+E0<..XP(*I\HVA9"U8V!&,.@5%K[6!=
M %*5GL:QNQ!:RW^7^/.B6N)J4%ZW>!,"]4- ^M#-+O32@
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M2##)%PEV;KB+9**SEQ']6KQ0=JC:&F6^KTB9U3IV
M,C_X5=3I^4I.72&G0['JKF=JKEJ
MGUJEO*-B5#+,-16C$BST]YV;916CT@)<0"K;@X^-QU&B4%Z-:E!/YZ;=+N6=
MW)@\PN"+>QK-B83]FSBN0KXU,>=EXRH/YBI, 'N)U>)1X_[_'?95O268R[>N
M!E9S&>@]K5"7[!K01I>ZJ!G(O_-VCMBAT+_D_F]4-CG;_$T4ED/*+[#E
M'?]HX(5YR*X:N1GK6=IZA\?YI4BATZ%_)]J?A]%">@F]3EJ[8?,/,WQ2CLIM
M&C2HS1V:]ZC>!7C%7B>OS:O-U_Q2[:[DZ"22+KKN%![^492 4<[]==;"%EN_
M3E&*;CF!BJ8&9NC?I*!93 C-
MX;R)797VK')C[@MOYD;JT=S&8+EBG1-WX^$6$U4MR-!M,X9>%59X3\5BO$9U
MAQ6)V@TU&7(/<.MS5I#ER8#PRVH[H+A1CT&_R_V 2-UHZE "F)_"BV5'@;+!
M3<\,YYM5K&R#75RW!SE6_XG!0*T_\UU@_P? JEL[\MX?.N4 HM3P4!SQ,Y?VFPBR*Z.T
M*Y6D#U=#E_HD3;&&73?PM2GSZ[N&-AX:\R+E+>H'G_%Z3]VC&;<[(NURB;F<
MZ$?F#!?%TO.>X\1U4&\Z"M7K?9>\?PP;ZA(UV:!X>!_LI+I8M/=[
MF#L]6_.DVVWV@*#E?JAE*][T;*CW4#;^PNK&:,)C>6E3SP=WM#BZVZWR.[NC
MJK]R=[]Z.8?*=+F3Z=>XGG"V0=4VG4)_P8LX3K[]/U!+ 0(4 Q0    ( (6 
MJDB_N,U_U0$  &X<   3              "  0    !;0V]N=&5N=%]4>7!E
M&UL4$L! A0#%     @ A8"J2$AU!>[%    *P(   L             
M ( !!@(  %]R96QS+RYR96QS4$L! A0#%     @ A8"J2%YW20'! 0  U!L 
M !H              ( !] (  'AL+U]R96QS+W=O&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( (6 JD@4+<>XG (  #(/   -        
M      "  :@/  !X;"]S='EL97,N>&UL4$L! A0#%     @ A8"J2'.+4A0%
M!   \ X   \              ( !;Q(  'AL+W=O&PO=V]R:W-H965T&UL
M4$L! A0#%     @ A8"J2 T,9I(Y P  .Q$  !@              ( !8!X 
M 'AL+W=OH
MI00   \4   8              "  <\A  !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#%     @ A8"J
M2*,FU'ZB 0  L0,  !@              ( !%2P  'AL+W=OTM  !X;"]W;W)K&PO=V]R:W-H
M965T&UL4$L! A0#%     @ A8"J2'6ISO>D 0  L0,  !@ 
M             ( !HC$  'AL+W=O&UL4$L! A0#%     @ A8"J2/RBNRBD 0  
ML0,  !D              ( !634  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ A8"J2'@' !>D 0  L0,  !D         
M     ( !ZSH  'AL+W=O&PO=V]R:W-H
M965T&UL4$L!
M A0#%     @ A8"J2(5.WP&E 0  L0,  !D              ( !?D   'AL
M+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ A8"J
M2"3\C8ZF 0  L0,  !D              ( !$D8  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ A8"J2,_WV*FH 0  L0, 
M !D              ( !L4L  'AL+W=O"OKX!  ![!   &0              @ &030  
M>&PO=V]R:W-H965T&UL4$L! A0#%     @ A8"J2,HY7%F] 0  >P0  !D             
M ( !8%$  'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#
M%     @ A8"J2!,@Z2ZI 0  M@,  !D              ( !FU<  'AL+W=O
M&PO=V]R:W-H965T&UL4$L! A0#%     @ AH"J2%G=
M6"32 0  J 0  !D              ( !CEX  'AL+W=OOT,X$"   P"0  &0          
M    @ &78   >&PO=V]R:W-H965T&UL4$L! A0#%     @ AH"J2*VDA3^- @    D  !D 
M             ( !9F8  'AL+W=O&PO
M=V]R:W-H965T&UL4$L! A0#%     @ AH"J2'*9(I61 @  F0D  !D              ( !
MMVX  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%   
M  @ AH"J2'85#OC1 P  31(  !D              ( !,G8  'AL+W=O&PO=V]R:W-H965T



/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em; 
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}







  3.4.0.3
  
  html
  102
  180
  1
  true
  44
  0
  false
  5
  
    
      false
      false
      R1.htm
      101 - Document - Document And Entity Information
      Sheet
      http://www.isoray.com/role/DocumentAndEntityInformation
      Document And Entity Information
      Cover
      1
    
    
      false
      false
      R2.htm
      102 - Statement - Consolidated Balance Sheets
      Sheet
      http://www.isoray.com/role/ConsolidatedBalanceSheets
      Consolidated Balance Sheets
      Statements
      2
    
    
      false
      false
      R3.htm
      103 - Statement - Consolidated Balance Sheets (Parenthetical)
      Sheet
      http://www.isoray.com/role/ConsolidatedBalanceSheetsParenthetical
      Consolidated Balance Sheets (Parenthetical)
      Statements
      3
    
    
      false
      false
      R4.htm
      104 - Statement - Consolidated Statements of Operations
      Sheet
      http://www.isoray.com/role/ConsolidatedStatementsOfOperations
      Consolidated Statements of Operations
      Statements
      4
    
    
      false
      false
      R5.htm
      105 - Statement - Consolidated Statements of Cash Flows
      Sheet
      http://www.isoray.com/role/ConsolidatedStatementsOfCashFlows
      Consolidated Statements of Cash Flows
      Statements
      5
    
    
      false
      false
      R6.htm
      106 - Disclosure - Basis of Presentation
      Sheet
      http://www.isoray.com/role/BasisOfPresentation
      Basis of Presentation
      Notes
      6
    
    
      false
      false
      R7.htm
      107 - Disclosure - New Accounting Pronouncements
      Sheet
      http://www.isoray.com/role/NewAccountingPronouncements
      New Accounting Pronouncements
      Notes
      7
    
    
      false
      false
      R8.htm
      108 - Disclosure - Certificates of deposit
      Sheet
      http://www.isoray.com/role/CertificatesOfDeposit
      Certificates of deposit
      Notes
      8
    
    
      false
      false
      R9.htm
      109 - Disclosure - Loss per Share
      Sheet
      http://www.isoray.com/role/LossPerShare
      Loss per Share
      Notes
      9
    
    
      false
      false
      R10.htm
      110 - Disclosure - Inventory
      Sheet
      http://www.isoray.com/role/Inventory
      Inventory
      Notes
      10
    
    
      false
      false
      R11.htm
      111 - Disclosure - Property and Equipment
      Sheet
      http://www.isoray.com/role/PropertyAndEquipment
      Property and Equipment
      Notes
      11
    
    
      false
      false
      R12.htm
      112 - Disclosure - Share-Based Compensation
      Sheet
      http://www.isoray.com/role/SharebasedCompensation
      Share-Based Compensation
      Notes
      12
    
    
      false
      false
      R13.htm
      113 - Disclosure - Commitments and Contingencies
      Sheet
      http://www.isoray.com/role/CommitmentsAndContingencies
      Commitments and Contingencies
      Notes
      13
    
    
      false
      false
      R14.htm
      114 - Disclosure - Fair Value Measurements
      Sheet
      http://www.isoray.com/role/FairValueMeasurements
      Fair Value Measurements
      Notes
      14
    
    
      false
      false
      R15.htm
      115 - Disclosure - Preferred Dividends
      Sheet
      http://www.isoray.com/role/PreferredDividends
      Preferred Dividends
      Notes
      15
    
    
      false
      false
      R16.htm
      116 - Disclosure - Shareholders' Equity
      Sheet
      http://www.isoray.com/role/ShareholdersEquity
      Shareholders' Equity
      Notes
      16
    
    
      false
      false
      R17.htm
      117 - Disclosure - Related Party Transaction
      Sheet
      http://www.isoray.com/role/RelatedPartyTransaction
      Related Party Transaction
      Notes
      17
    
    
      false
      false
      R18.htm
      118 - Disclosure - Concentrations of Credit and Other Risks
      Sheet
      http://www.isoray.com/role/ConcentrationsOfCreditAndOtherRisks
      Concentrations of Credit and Other Risks
      Notes
      18
    
    
      false
      false
      R19.htm
      119 - Disclosure - New Accounting Pronouncements (Policies)
      Sheet
      http://www.isoray.com/role/NewAccountingPronouncementsPolicies
      New Accounting Pronouncements (Policies)
      Policies
      http://www.isoray.com/role/NewAccountingPronouncements
      19
    
    
      false
      false
      R20.htm
      120 - Disclosure - Certificates of deposit (Tables)
      Sheet
      http://www.isoray.com/role/CertificatesOfDepositTables
      Certificates of deposit (Tables)
      Tables
      http://www.isoray.com/role/CertificatesOfDeposit
      20
    
    
      false
      false
      R21.htm
      121 - Disclosure - Loss per Share (Tables)
      Sheet
      http://www.isoray.com/role/LossPerShareTables
      Loss per Share (Tables)
      Tables
      http://www.isoray.com/role/LossPerShare
      21
    
    
      false
      false
      R22.htm
      122 - Disclosure - Inventory (Tables)
      Sheet
      http://www.isoray.com/role/InventoryTables
      Inventory (Tables)
      Tables
      http://www.isoray.com/role/Inventory
      22
    
    
      false
      false
      R23.htm
      123 - Statement - Property and Equipment (Tables)
      Sheet
      http://www.isoray.com/role/PropertyAndEquipmentTables
      Property and Equipment (Tables)
      Tables
      http://www.isoray.com/role/PropertyAndEquipment
      23
    
    
      false
      false
      R24.htm
      124 - Disclosure - Share-Based Compensation (Tables)
      Sheet
      http://www.isoray.com/role/SharebasedCompensationTables
      Share-Based Compensation (Tables)
      Tables
      http://www.isoray.com/role/SharebasedCompensation
      24
    
    
      false
      false
      R25.htm
      125 - Disclosure - Fair Value Measurements (Tables)
      Sheet
      http://www.isoray.com/role/FairValueMeasurementsTables
      Fair Value Measurements (Tables)
      Tables
      http://www.isoray.com/role/FairValueMeasurements
      25
    
    
      false
      false
      R26.htm
      126 - Disclosure - Shareholders' Equity (Tables)
      Sheet
      http://www.isoray.com/role/ShareholdersEquityTables
      Shareholders' Equity (Tables)
      Tables
      http://www.isoray.com/role/ShareholdersEquity
      26
    
    
      false
      false
      R27.htm
      127 - Disclosure - Basis of Presentation (Details Textual)
      Sheet
      http://www.isoray.com/role/BasisOfPresentationDetailsTextual
      Basis of Presentation (Details Textual)
      Details
      http://www.isoray.com/role/BasisOfPresentation
      27
    
    
      false
      false
      R28.htm
      128 - Disclosure - Certificates of deposit (Details)
      Sheet
      http://www.isoray.com/role/CertificatesOfDepositDetails
      Certificates of deposit (Details)
      Details
      http://www.isoray.com/role/CertificatesOfDepositTables
      28
    
    
      false
      false
      R29.htm
      129 - Disclosure - Certificates of deposit (Details Textual)
      Sheet
      http://www.isoray.com/role/CertificatesOfDepositDetailsTextual
      Certificates of deposit (Details Textual)
      Details
      http://www.isoray.com/role/CertificatesOfDepositTables
      29
    
    
      false
      false
      R30.htm
      130 - Disclosure - Loss per Share (Details)
      Sheet
      http://www.isoray.com/role/LossPerShareDetails
      Loss per Share (Details)
      Details
      http://www.isoray.com/role/LossPerShareTables
      30
    
    
      false
      false
      R31.htm
      131 - Disclosure - Inventory (Details)
      Sheet
      http://www.isoray.com/role/InventoryDetails
      Inventory (Details)
      Details
      http://www.isoray.com/role/InventoryTables
      31
    
    
      false
      false
      R32.htm
      132 - Disclosure - Inventory (Details Textual)
      Sheet
      http://www.isoray.com/role/InventoryDetailsTextual
      Inventory (Details Textual)
      Details
      http://www.isoray.com/role/InventoryTables
      32
    
    
      false
      false
      R33.htm
      133 - Disclosure - Property and Equipment (Details)
      Sheet
      http://www.isoray.com/role/PropertyAndEquipmentDetails
      Property and Equipment (Details)
      Details
      http://www.isoray.com/role/PropertyAndEquipmentTables
      33
    
    
      false
      false
      R34.htm
      134 - Disclosure - Share-Based Compensation (Details)
      Sheet
      http://www.isoray.com/role/SharebasedCompensationDetails
      Share-Based Compensation (Details)
      Details
      http://www.isoray.com/role/SharebasedCompensationTables
      34
    
    
      false
      false
      R35.htm
      135 - Disclosure - Share-Based Compensation (Details 1)
      Sheet
      http://www.isoray.com/role/SharebasedCompensationDetails1
      Share-Based Compensation (Details 1)
      Details
      http://www.isoray.com/role/SharebasedCompensationTables
      35
    
    
      false
      false
      R36.htm
      136 - Disclosure - Share-Based Compensation (Details 2)
      Sheet
      http://www.isoray.com/role/SharebasedCompensationDetails2
      Share-Based Compensation (Details 2)
      Details
      http://www.isoray.com/role/SharebasedCompensationTables
      36
    
    
      false
      false
      R37.htm
      137 - Disclosure - Share-Based Compensation (Details Textual)
      Sheet
      http://www.isoray.com/role/SharebasedCompensationDetailsTextual
      Share-Based Compensation (Details Textual)
      Details
      http://www.isoray.com/role/SharebasedCompensationTables
      37
    
    
      false
      false
      R38.htm
      138 - Disclosure - Commitments and Contingencies (Details Textual)
      Sheet
      http://www.isoray.com/role/CommitmentsAndContingenciesDetailsTextual
      Commitments and Contingencies (Details Textual)
      Details
      http://www.isoray.com/role/CommitmentsAndContingencies
      38
    
    
      false
      false
      R39.htm
      139 - Disclosure - Fair Value Measurements (Details)
      Sheet
      http://www.isoray.com/role/FairValueMeasurementsDetails
      Fair Value Measurements (Details)
      Details
      http://www.isoray.com/role/FairValueMeasurementsTables
      39
    
    
      false
      false
      R40.htm
      140 - Disclosure - Preferred Dividends (Details Textual)
      Sheet
      http://www.isoray.com/role/PreferredDividendsDetailsTextual
      Preferred Dividends (Details Textual)
      Details
      http://www.isoray.com/role/PreferredDividends
      40
    
    
      false
      false
      R41.htm
      141 - Disclosure - Shareholders' Equity (Details)
      Sheet
      http://www.isoray.com/role/ShareholdersEquityDetails
      Shareholders' Equity (Details)
      Details
      http://www.isoray.com/role/ShareholdersEquityTables
      41
    
    
      false
      false
      R42.htm
      142 - Disclosure - Shareholders' Equity (Details 1)
      Sheet
      http://www.isoray.com/role/ShareholdersEquityDetails1
      Shareholders' Equity (Details 1)
      Details
      http://www.isoray.com/role/ShareholdersEquityTables
      42
    
    
      false
      false
      R43.htm
      143 - Disclosure - Shareholders' Equity (Details 2)
      Sheet
      http://www.isoray.com/role/ShareholdersEquityDetails2
      Shareholders' Equity (Details 2)
      Details
      http://www.isoray.com/role/ShareholdersEquityTables
      43
    
    
      false
      false
      R44.htm
      144 - Disclosure - Related Party Transaction (Details Textual)
      Sheet
      http://www.isoray.com/role/RelatedPartyTransactionDetailsTextual
      Related Party Transaction (Details Textual)
      Details
      http://www.isoray.com/role/RelatedPartyTransaction
      44
    
    
      false
      false
      R45.htm
      145 - Disclosure - Concentrations of Credit and Other Risks (Details Textual)
      Sheet
      http://www.isoray.com/role/ConcentrationsOfCreditAndOtherRisksDetailsTextual
      Concentrations of Credit and Other Risks (Details Textual)
      Details
      http://www.isoray.com/role/ConcentrationsOfCreditAndOtherRisks
      45
    
    
      false
      false
      All Reports
      Book
      All Reports
    
  
  
    isr-20160331.xml
    isr-20160331.xsd
    isr-20160331_cal.xml
    isr-20160331_def.xml
    isr-20160331_lab.xml
    isr-20160331_pre.xml
  
  
  
  true
  true







begin 644 0001144204-16-100413-xbrl.zip
M4$L#!!0    ( (: JDB[C9I9W(T  .:E"0 0    :7-R+3(P,38P,S,Q+GAM
M;.R];7.CN+8P^OU4G?_ D[/GS$R5D^;%@.G>,T^EDW3OG)/N])-D9LZ^MVYU
M$9 3[<;@D2!ISZW[WZ\DP 8; \9@"UN[]LPX-DCK74M+:RW]_7]_GWC2"T 8
M!OXO)\J9?"(!WPE=_WM_=2.J9DOSV_1%Y\"W]
MMT3 ]O%;B-$O)\]A.'W[Y@T=$>( V3,ZVALZMZQIRDGRJ ?];[EGZ3!G 7HB
M3\K:&_KS(YDV?9S^ZL+Y"]F'C3?QC_-'5X9^U=BSBF59;]BO\TT[.5A@">S+SQ,J#%7%+'LC?B)]P053!!S*V+7O6&]L
MY*#  V\6#Z>O.T'DAVB6)Q8&SME3\/(F^9'R0SN5E=,%1YP((2)KZ]Y+?J4O
M#O,ON@ 6OT-^*'@>BY^GO] 7]/P+T'\!."Q^)?ZM !O?A@XN?H?]1%]1
M\J]@Z!2_0'XH>CRO1&K^YR8C
MRE&(2H2%_'I"-%:2_D[%_RUF@GT'QA)3A[?A; I^.<%P,O6HU++OGA$8_W)"
M-/HT5=VS[YC(V!LR3FP7+@(_!-]#Z1XX(3$WS":0&6*KX"0_0B+#7V3E*_D_
M1>\AD+6O6OPYAFC^!O!#&,Z2[^;?0I=^/X8 20QJD,,RI?C%]7^?_"J3_YGJ
M2!N9?W^S_'(ZU9NEN7(03 &"@;L, 5%F%!+K"GY-^2,KZ3B+W]*A,NBXF9.$)"T0N
M_:5MRO1%U#*4,;JEC/Y5-OI+&2(V1E>4,;YJ??YZ3T8'^/P+
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MLZ)SS=)S&+$!&R"P/(4(/B732-E_1:EFNA!C-Z6T>H0MRBK4F(I%..'
MP/A$'GX68E(J)H7$.@XY25!^")1_ AL),2D3DR):'8>4,(0? HW^1]B24B$I
M(-4ARLABDR/\DA[[)3O;"@N_I-=^R<[E1/@E/?1+=BXEPB_IG5^RHV#;!DD>
MYP01%WI1"%\ (2>E%GGAZKOC12YP/Z!@SX@'Z+6&=$H6K@Z+>9*DN1/H/&R&B-$*(>1#B'#.$V):([=5DZ@4S )B:
MWTXIT84(\R#":QDCQ'E]V9!P+/@5:/X<"XX+MC(B+1P+CH28!\>B'V(K' M.
M19@WQX(S<5XZ;;OR$23RX;ZW$8PF-,;CAP&:947Y2_1(R/5;"#U&[?DS_9;%
M%)>F1)=G9
MJ8FP) =C23J6F<7J3%'PPE)Y\T*" C)/./OB$0#.???JSPA.
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MWL2L.,]>>%G\>EE%E]];)Z(%S"R^J_E\6EF U%+*L/
M7A9G2?YKQ$=X63WVLOHA8L++ZJ67U0_A$EY6S[TL7L5LHYX1\3?7O@N^ _ )E\BXM[:&%P$DPD,XX3=I)';['9\39:6] F7LH+V9P#/083!_=1VF.RM4\ #/R+(/)#
M-*,+GA#U-J1H#5D/3);6[,*$3!VF3/&\7ULJ^OM@0_2[[47$AMLX0G'E[!WM
M.X2@_Y25Q_F3[V>99S\@\&<$?*?G4E<+N96'2VBV%P.VLY87EV2M@=M#$-PE[8_@QA=0DQ?A7[$FA*YD1/>0+^G
MZ4(T0=6J" L:U$/2MMWL_9/M/*:'^'-*7-@YQ#+G=%%1["A8]ON
MNHT*:\"G-=A9F$98 ^ZMP<[ZRHI0VP%%M';F3XAC0>X"O>)8D$^U$,>"XEA0
MJ(4X%N1++<2QX+XWXL.OEV2,%U;.F-Q4F]?08R]2,-S59EQ( <=2T/$VW!)2T!,IL+J3 D6=U](**>!:"A1U)^ZRD *.
MI6 'I4/Y=!@A#;Q)0V^R181[T1,A:I0^LN25='_'B1 BKH6(LQM,%'EAB82+
MVQ%\2@4EO*B /S
MRVO(X,-K(&20!QF<,^((9? 9 6$)^9#"!2N.3PX_!!$28LB#&"XX<6!2N.[>
M%>$=\BN,>_ .>:[0V4"$A7/)B0COP;D\%!$6OBDW0KP/W_1 Q%BXMKQ(\3Y<
MVQX*\46$PV "4--N"%_9941WX 7X$?@,PHK7EOH-]%62ZW4N*"?M>K%L":(U
MO1T*&29TI.P:,J$C0D=ZESZRVW6$K+F$C+/?,#A_(N[C@M_;DA=Z;1VI$368UJCOWW_W5Z>N6QQ5VZ!P[U
M24]/XT== -]>!DY$?Z,^LY1(^QT8K[5U)PR\#S89R/VJG/RJR*?_Y^]OED=*
ML:+?GY,O759^Z=E/&T^AGOPZMCT,XCER8V4G22?_PE3X*E;OC2?33G*V8NW 
M13-_@-BQO7\"&WT@W^"-YQ[&<^=G71IT_;PQ>,UFUD]^_3]:T;R90;,S7S'+
M?0>>V"68?OC9GFQ.:N/DUVL@+F[+PO0F:_H?VJ'IA>SB_1"?AQ%LCSZI\\R%HYR*IJF$-Y2Y#OGP,4TKWMM?\",-O3
MXOI$'99#:"FRJ1L+"(LF:PC0&I+II0!9FJ'JYG S@!9M<_%G$":6I#Z)C%*(
M1B/-E-4%0(63-85H#8W,4H@4>6C)0V5#D"C]?.+HS<@C]6DS*H5DJ)NJE0$D
M.\>&\Z^AA%4^OZQ9NEYO_MOP&:#M)$65RY5)MD8+6-;/MQ5DQ712E7*)L0Q%
M;P+:%P2F-G23R[V)Z6*OGF,,0KPQ]I9=Z^?<$KXU)"LWZ63)&V4=A4W@2T/?3=P#M=R^ZXI%3$<&KH*YFH&SADKE
MYEXGWJJ996,-<.[(#P@ZQ-M"T"KLQ136
M*A:*D:(::ANP+Y;B!@2NV D,AUK6PA5,U0R:-22KWVBE-M_Q3*)'=-'RTM2[5G7
M(%YNU55-EC5U-*R<-;G^XXL]H_Y8?/DJBH![ ^U'Z,$0@HW]!*W2-+
MCOH@M O]&L)6^/W62-6UCJ"/Q7-K!@S+5PG+-$RK#(-R,#I HY@3PXH%0QTJ
M6=W>%@_V]#94+U\Z%&-(5H\E4]0F5&N(6+Z$**JER_+&4%U-IEXP ^ .L%N:
MMZ%:Q::"N(%&QNVJG+@-2-=0LF*I4533V@;21%!_MQV6M;0Q($L!K:%N^9EA#']UOC4+X.Z=8.D+C8&HGRU6H7C+C<&H?R
MY:T+'!:= -M2B/(E<19<_&E:1J 4;R(&A6QNZ&5C=16@?& 6(+9K D]:J]YJY,T
M F,-/M"ZF/8WA<;NM?^A3V%H>UEZ%B?0!6G\*JIFL-L7+-Z
M[E:@74/'\E5GI X-4U&4;: EOIP-?>!>V2O@KB%N^5)R:BBFINBRN0VXC.3/@><"A.EY1CBK34VS
MXOC'U-6A965S:E;F:@1-,;',UF7FV&SZ-32I"+6IJB(/M5K39^O[
M/@:!BU>.SHL;W.;AJ3CB4:R1*6<%O6#2+0#+YG8N$:HBPJ;H(T6V-@/L(L#A
M[9C]>D_D:G-B5439%$W5LODK2_,U Z>$1!5Q-D56+46M#;;,#0YH^>9F38'8CT]1N566]>5+'-*@+@#&-!;IH@1NJ2W2 4L2R1)
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M7F-@4XHW73FLV@<=2S,U Z2$2E65'?5!^1SX05ZC&U.G:B50S?GQNOB; K*<0,?7EP%BZIF=3YDIA
MR9\,7+):<-_%\0OS8XCKR91,WH!N%84@1C8DM DH':!11O&J"I&VT,BQZOS%
MAAY-K7L(,L'C)/;TWL;0:<"0\H6&"K*9J[/:$*)N$"IC3?EB1)3!4+/1^2WQ
M2RY"AVXUH1?1(N/-&;*T7F4:5&0P40DF\EDV;%\!2#MPE]'=W G<
M?P#X]$R^/W\A5OX)?([H&>GMF+V:*5?>G@W9A7%]#;6J&ME3Q&;0=8IC&BAMXU@C^EJCLEXI7X8U8VCER@]:B@L7]BY<@JQ\32;;:SV7K;I]
[email protected]5F2X#I'*EU%-DS7"PA9"PW5H4Y$';1J&N6UPN Y)*I8O
MS=0-JQ88FP1=Z]"G?!^EC70MNU/H+#YZ;
MLC;*ZE3+<>(Z%"U?,(:R/#2SOL'6@>(Z5*M8-!1K.,J6B+80*:Y#J8I]%.'D
M2,[V.&@E5%R'7%4+BDH46.LD5ER';!4'^P;1 34;%VLU6ER'?!5EG@K1 6MS
M #<+P=8A9%4@S][email protected]KE=!8SKD'-BC)_2V\K;%R#5!5E^_G-64N!
MXSHDJMA+R*J%R'Y.5+2GMH;!=KK<.0BN1B3=G'JJ$/M>&ZHY2NH\: T"IO9 W<:/:Y!^.56 Z5P
MZXWA;B6R6H<-V<6QL@,GA]'C.BS3:N X')FCW#GH=CC&-S8$+Y!V:?\0H#O@
M1@ZMK;@=7P;18SB.O+0+10.F5=;I;#!]>Q"7L:"BI,>@A1(-@$Z9=0FFB S(
M:HEIU&$2H!#^Q?YL0-ZJ-FVJ8N8*QM?.O3V8932M"!YJEJIJC< \=_\5Q7M#
MPH4M:5F^\*KZ,-NY8.W$VT)81L:*#=[0RE*Q/H3K2MUI[PI /S3>T%1T73!T
M2UMNK5@'D+8Q**%Y14L&0U;-Y2Y833 HOENP <$KJYW=ATH6H2\C,85
MO4058Z28;0.>]NA;*8>J1>N*<*6JZ]F3I=+9VP"UC+B5C:1'V29P6X*ZW%:X
M 6DK][email protected],@5^\6AIN2SB;<'.NDV?)F$!0J[#F]._8KN!Z>Y
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MH/J@M(Y$&7_*7033M+)G[BWB<.V'MO\$J:/79B[>F0[^':";1GC
M*G;BFJ7HNE+MBC9$-[NN_&$C>EGPU7> '-@HU;^B)XQ,YND+#7* *IK'#,DRNX:HA0"T!7$)>2O:RBA#7VV,9#GK
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MJ<2ZM ;E^F+-VU!LN5FDOWQWRRPP@1G;\!&#\\V[XE7]HSG&7K8LQ[
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MB@;T/U06Z^FMF;(HVS;CYZ3.TW"RD2;]T-ZHX:9
MT71=-OI,^YR=YY>;_)S8V9J=&?E>SL34/M
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M@] 5YEMHV.L6];M;6^#RO<+T>I3S08L=DB!&ED)%8T_E_O\[0'XDHR"
MBG:@2WT ]TWX[:ULN5>E$U[MQ\P4H]N!F:V*-QG96I.]$Z!E.UO1 U6158TG
M:>_"T%8T455T\K_][ &+#RNWU?BJ+JR:M2?'HAC=]C6^HM.KI>UIV[PN#:-=
MA2]WK(RAN5^W8MBY8U71A)9X+\K6ZCY/* #H!3J@^-W/ [YJXU<_!#$
M]4[SWZFB?P["?]*FS4[PY-/(7?UH=47G6DTSM>RE1IU!O#/2Q%62K-\]^XH^
MIVSNO.KFR:]?E'\./ZF7.Z!.(= K+:YI6LHUQA%P+R-$#$#\%H,"MU.\KNIU
MKC\VU%P/[(W!Z@RQ$G]>KY%3HVB:GLW4;P&S0@DYIUE=3R .HB\>20KHF-@L
M#8RO_7AN)DW7?DB@P= IJ(NMP^2*IK^JF6LDN0L<.*);B0Q5=!1F?1+T?A,N
M9VL# Z\1YT?\Y^J08ETNTV2WH;5.O6HQK0M; (S0,1E3S
MDSIJD:CM8;0C6FD+@B>S,&Y.N//"KTON[6W18&F.T(])F]&%KTE;T%"?[#'4'I*W&J$.%
M7K(IJ4O_!4%G$T+6O253.1N..E'S,CQVK_0M457="U6W0Z]#![TEJFKUJ6IT
MXKCODGP?:7W>?(->D(+9K*(U_N;:=\%W*A\L!H4P38X,UV1=FC5V2\,1[>O3
M'LT+D&]?/*;N6WAK')J.AJK6XX)60E]W\
M3!8]\@99_V['=\',]L(9;4F77(FVP7*>W1XM-\$CJ[A\)BO)7=.E,ZZ<#B-@
MWXYOB,-3'Y;<'0:VDX=%(?;W+'MB/Y^@>.H[8'M7F)X3IS4(I84C2=G$N>NR
MP[E9BT(9K=CJ]#,'_"I2)$R_O!R63+C*MDV7M:
M2.E?T'8 :$;-95=$KFCOK&IFMK]!D29_M*%_0[S.6S^^7R573;31A4R[P[HB
M[40W,5B\^<_ 9L^S$I![VAK"7H6GJ7/
M_,GWL\RS'Q#X,P*^4T2%\JP4754-,]LEOS9"'5/BVI^2;?H-34!3UA!@_O$?
MD&P_B=V:L<>9Y>J2HA7=(WM 494SBM:^&(-#6FJ(,E)R5KX0]A81Y-=L55P]LA\:<6:(*JXSV:,P<69E*NY"V91&
M%_1>@=MQTH3M%MW1L'(F3%^_<8)5(SBKC?3<06/5["U NV;3835H,%D76KI9
M*7R6!>/H533UHV1+4-?IS:C/N]K7 :(6B7/'"_,?2G>3=V!*;"UFQ260H$L
M9=["?\#P.3MB R:5>Q-Y?+L%?L4IBKI .)Z/'JYV.7*\.]G[XF/\SRQT3?F
M-5U0S0]7'JL8H_"P0LM=>%(8TL\M+R68MT"E8>;&'ITK*NF55#*;4BF-S5+3
M$5\2]$3P*/; U\[email protected]?>C]+-XJA;P5ZVYM0.AS2#>]&,%<$07 :OFU\]IU5<_6&JN=R]U1D;
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M3%V7%=E0RB",IZV$KDE 5E/KW*]4#6)9\+@V%=1J+,H5R&UH76H:PO8P
MK+&>MX5A$Z>N/41K53'QL[UI#_%A+Q#?X!K,NHCKO4!\F>,M(+['G7P#'ZD%
MA.O<([AG'ZD%+.MT\MJCC]0"AC5\I*7[('?D)VV/V["&G]0J;IOY2BT@6,-7
MJH%@I_Y2"UC6\)?:Q'*+%?1B>V3[Z3.U@/@>?:8&*V@+"->(]NP[RM "EC4"
M1KN,,G2 80U/:$^[\1:0J^$ [7,WW@*&VP>)=K&R7&Z-Z')[^IZL+"T@7JOQ
M#S?:V4+&&[OZI1@F,N*BI^N?[Q;I^?ZN@RL>*YFX*PY)ZW7*3V7_5<#I%OT
M9/O)1:\7@8\##[IQQQ/?)<3&-%/;2].6?QHNJ3/'T/GWPXA@Z]
M,#3.?J*=V_L8A,_Q2*75[=G;Z_?7BX_43Q
M^RXQCKR3DE]NKCX\Y+Z_N?Y\=?J/J^N/_Z $4/0?WDE_7%\^_(."*/^0QT>Z
ML#WXB.  VSX^Q90@R0,)4@I!*IWIX?9+$0!W\4SS'TZDQP"Y -'$.,D!GH>G
MMD,8/_][:KMN^O7\\O+Z\\<%)2AITR\3(M"O
M$EP3VJ);$HJ)*. KTO479:\ @*KTW Q
MSR/]1#^,B4JD,R[)V$G1,^_/+_[[X]WM;Y\O3R]N;V[OWDHAK>:8VC3!D+VA
MG#$YHR^E ^3_F,^=D\4WH;L%+S:G_B&1_+V-(9:"L92UFEMSX4U&.]XP4]&F
M 2L@\()6[9/H/^W)]-U_*(9<0(K<'UEJ=(2FE(CAOR()Z$P!38Q,+_(,VM[1*=I(=G(-ED19Q,;7]&_:K(MR,7DEV?1*O3$)S0
M13%9>=L(-'&09 \\OI, )J=
M!J\^&01'CQBZT*9>FO133/F1JLKOXG?G7RCOI "1D8&4>>8BAC7ST,]GTCG!
M%B_6^!CV!"N&7\3@),"$F=HRZ=E^ =(C +X$/#@AJ,5XLRF=K,-Q1M!AWP93
MZ)._*:*$FW;<=8V@2>:W7-@,6_+.OR*?D80L.>&S%$1(2@>NP7U"
M5137PQ%L@] /0L)6F\P$0HH^&3 AZ1+K%/,=?=N/;":JY$DR@4=&(7!\"-"$
MB.GI?\\). ,VDH!/L)?^*R+RKLD#B3IG!:M)]RI*7(Z,_F5M21W=/3B+M1TY
M6C1E"X781*V(6M+97&D:(1Q1^Q$&3.90Y(%4P)]H^RYF-1+%O:?])^(>&/2)
MJ^_.,VW#*+&:.8RIU5-C-]?HIK;CUF"L&44L2>[X+(FV1P.*68)GKZF\](
MR/92Q$!_/#__\G.&7(2T+JW5=:EU#B8P#%=(1]>"0N)14TE^CIZ>I5*F#Y(]B=V?A08CX-# %_&6B.82
M%2(:3=4J-7M.4I,6OY];KK,>#/-"R%@X\D)F%6F9:6(C4WV-AYB_1Z:;V#.F
MN8]4F5WHL.K_V*92J_'Z#)UG]A!Y "3=[MEPMC2.R$I _8!"P_JP\#"(U0DA
ML6G,?C'C8N/8H#[email protected] %,P":?B.G!B?*W)2/]8A(!O'>-@S
MIYX]"Z+P[1A^!^Z[REC,?'PT_^3.@V;FJ%T$H)L3?!6Q*FMD5?7H%RX,B;"/%18GPAI
MF#0;Z:PELDG$, 6 16#/;ZX_$DXDJ]0[Z?>KNX?KB_.;](=^.!O4[IWEGXZO__M9S;\J6P-I#NR7?.C
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MDL$6ZD6\8(?L5N-M-1%_"DH28O."U]AD.0$.F<33K2T"A"!_,?^9Z@A!'IVXP&JV ,:%)P&V/8&BP,<:CGL K,.\9(9FT:/
MQ$+,9X^)2D.VXY6=.E/^=?:*6M+\XU5VT#B3KE:,%(%O8:,6BL*/M3HP!3T<
M8]2FOUK/L-G$ 4#,MAFEMLTXE7.V;>& 7OLX1%'LS64>N'UAIQ%MF#[ [M=B
M%C ]>B4N$)B&B8\9.XY)5X*BQC&QZ2+
M&%)Z"!3/#$!Z$!'#Y5)CRTY\F=E\)V&BHQX-M\;VDVHL1 P9FP82,?M(AES%
MY]WB:#KUF^<^,ITT.3$!BT/FV%*3P18J#S.,R()(W%#B@<5)S)@=UM(@]VEB
M-%-;^;8,A#@RFWUCM@)63.:?\,^Q&YJ)JA+LHTE\-YD4X=B-31>798P8.R!.
M9W<3DJ4FGDI\SESFE1TNKD,,A.G]<*0H69*
MN)6\C,6+5#V3'(?%EU[F^H/'60IWW-8SN8,L.=)%DX+AI)\241X0".9GR 1>
M+R!6.#DQ35OS$:4I$M$T,2:7NQ-G7B2'.$4+_CLVN./9*+5%N>?+$0DMP3$DKTZV?*&EB,GT%SC!.8VJ^F29<<)US;T%UE(R3[73:0Z
MQ9$3W[&34'ZG Q_<*5>C4Z:B)OEQ,];KA>>1&7F;#'F5UPQY3)R M]*(1DTD
M13F3E\Y"MAS^I*MM1OR>1%]J_1J%MEGR^
M_ICL& H0B+\6^$]U\Z6T@E!&?H2CJ"58%TC8C)@TB2@^7 $L%N<"L@V!86,*
M\UPGL(?PT!:)_MSDY>TR_:[&RUD7F&XJ)_1JG=B/IIGYU+\F;K]C8Y:*[A3+
M-]UI.DG^W*/M?\.ES[(4,<0269GGO'B./G:9/)9X8](=V2<0;9E1/X:>P4D_
M75R>W]W/ST:)WVY+>(:)=\OB$CWIG97"E,)'1R(+F@:4], RC
M^&"1SD') N),M[^UZ72KNCR0Y7S"F40C2&FZ+LWCH[&*.";S.(NCBX >>WIS
MTEW3G]E^[B) TR Y$?WIP^7UQ<_YXSW@QPG##*DDFYGNM9.T1WJ:L(Z+: D8
M-C#YDN8?LA!'"".T.VQTFX,3V38<(@/=-X%)6\^$@V80]%F+C=\8U=K Z%R#&@%34@
MB94D:9YLYLA/R9K"D![O,E@>P2R@D@MB$:>0N_8,Q_'=<>2[B^?3T^TDTL8F
M(KMB&A)>Y$&F>"31I*("C\7#\[(?6AW$*GVD3_3HAY[LT&HAZ:?DSY\'2;#/
M=Q+6 Z8?KP!,*93.0H:_D:]P!GI&K90$;AI^HV0F#-SD=):CE4/*'_-F/+NE
M8M7M'/.,F9]/8)D_S%^XN+VY.?]R3Z!RB-C;4PS>2;>_7]U]N+G]XZWT C$D
MTV_NFF^>6#??/*C9]+CB+#)ZGQ) J9UZ^.<-R^.F115+'E;(F$!C)(@Q04I.
M1OXC;M:T8NE64_D(8\-@DCSX1P+C4)8S;O0/.4]PZVP^GI!36L"-K(4A.*7"
M -[ZP2NRIW.Y2>4X@5A2%I+5#D5:8*_YPPE5#0(_<8P4984>YWA!D6"\^/R)
MWG:[^%-3!HL_:$#E:"4CNW$0ZL\U@K6=U75VCQ&SUY
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M'BOG1?+H$3-?)(\*?ZTGR(GMFD@>%4P6R:-'R'.1/GA<_!;)H]WX:GR?H"G40ZB#40:C#GIPFT?6Q=$D0B7M'Q6Z1N'>LG!>)>T?,?)&X
M)_RUGB G=FLB<4\P623N'2'/1>K6CZ*-1"J,6>U4)T?6R?]H@;=3E<;I%X92.?
M0(._ '3_;*.MVB$.>6V'B.%?X*TT.M.A+RG*F0S]-H>KTWD<1M%_6#(%%[8''Q$<8-O'IY@R,:_H"NU!F=&A^NF5!:8J-=/S
M+%*:&II^F2209K)%Y3.-FIDEXYY[*4X+)=A++TFCS#"8GBQIX[90Z-D'ZD.Q
M"!U5R6U!YO 2FY;5KH!3:C;=&(NEZKFQ'S)L!8F@(D,<&/;R
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M5S0F$-@AXT$6J^R8T,^0FHUCT[<"3*@<1![A&.$A>7%."3=BW*&H702$X5
MQ,^, \\+7O%;;AFY9_EK5,^T@BO])_;TDI='\H:U2L=4>Z3K(IMMXR0(7E(<
M5"V;XJ"O(%O0^OM8&7I8.:A":QMH[>&D+AUUV_XC8K(H\6QNKODX:=O(@M/0
M.P'F_?*V6IP?\8UN!\>J6U'C6,Y7K8%LB,-5SM$5RB&4@POEX,2E&+/_[H5H;M9.)!S4=@]03C>+&UD.-6!INMD0R0ZJ@HM
M$5JR7DMDW1P8JM 2_AR,W88-'H+0]A89>HN\)SS/L1).Z :&0R.&PPTBU@>9
M'XKP$)K=D& <[^3:C-ZJ ],<#BQU;P%"
M+^I71?UJB_6KNJA?;:]^59K;Y\9$W7WM:@_*E%H%NT5/2LIA/F=^7 B':8%;
M,(ZKUE@=&BUXM0M+1>F],Y(FLV_T_52KK7<)\446? [^U6:T(NIH.V)]$'.
MT16M6W=Z,JAJ WTTZIV4"*402M&94BA#;6 8>SLLYU$I./$;=IL<^$> OM$&
M:%,4. "+1$#.T1755DW3H55]8)E[' W%])#(_RS%>0W1]H*M-3HL.5D4X
M\2EV&R/H\7Y"5#!Q%&85A4M%1G:HFP/54H1J"=42JM6R:LG:P-*/K>Z6?=M-
M'GIMWZBLV)"?+/.N*242V$4">V^0._9\9Y' ?F ,%0GL[44M>**#L,(-E/:@
M_ZK#I7!\>%$]'+ [8N,WWX3@[F)=-GM^G#
MYG!@R,=V4"941*C(!A5SLCR0K;UEP_&H(YQX&+L-5,3M]&':D8T+'X-']W._
M23Q]W+9QD\3#U+/X,HT?:_/XI\%PBT @D -H$O@B3$>AT<&(_
MT3$F-OH&$'F:]OJE,TY1,$40A#9*YG,"! ;2ZS-TGO,X/MITL,"74MK0(2C.
M#IS:M,,PMCTR=XPR9K^^0L\CY RE1\ Z$9,?Z)?A,R&-[4O!E. 94K"S$\A!N.9V,,QY#\9N,LJV*4R!.![\TD\'T*' H4X069/ JA
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M^KU*6[U2YI]H=>>!V?$XD
M-KUW[WY^[=[5=[H4 /<#,3U4OJ/0IGI[.UY[:TN#FU@,7F]BV62UY\73R/JO
M(;)](F[4?!4KWH+1;$5@K?OG[@6S\K;G1![C.34L3$"8Z:7;#[H@OA#K_T07
M'3(+8<)C%,;6VV'6ERQ?\[L3D']51
M-]WT$6#>2U,$Q@#1G0L.R2[TR X,>H!"
M.3AQ*7:;GW\13":!'[L1TJN-D.V'HNL\Y^B*KMP-)1O3E;UW08*&*K2$/P=CMV&#N.AN&H3 #R'Y-,][PO,<*^&$\E(@Q%,#
M[:X)QO%.KM4[= >F.1Q8^[LO1V@9/_(AM*PS+=,5=3#2]W8M+X]:5K=LKC\E
M!.V7!:PO/)B7*US$A38/%)QMR@E,44ZPH\+%N&  TT* I'8JSM>G!4)V6)3=
M3SM>2YK,OM'WD]4_'U^D\8LT_C:/3'A"[M#3^,55"4?&4'%50GO1-9[H(*QP
M Z4]J(Q]499Q!$P691E[/@S9;;9%KL>Q.!KC&UW1!GZG$515&^@CT0:>+(AF]T1:[S3L. AC4P=5$ P#FZ0BF$
M4HC#_5T?[N<*![EP(GIY(MEE:A3?V=2\I$;M-M_:' X,^=A.%H6*"!79H,10
ME@>RM;?T01YUA!,/8[>!BKA/,TQ/PKGP,7AT/_>;]=3';1LW64]<[>STX7"@
M&9I0+:%:0K5:5BW#&HSTO=UMM2?5$@F%'284KDL,7,XIG+_P!X(AN Q>_3JI
M@U\_>M#&Y(6[$'\"DT?"&(PN(::O0C\"[A<4N)$3WD ?G'^'>"G5T#J1(A_&
M,_QV?WDBN<"!1&HQ)P3)=,\UAZ^A10^H%.$+;Y'.;!J_YW!C^!=Y*(YKN
M+"G*F0S]5H>/WZ-^VO-)\<+>,0ZY3.^;Z\]7I_-(C*+_L.297=@>?$1P@&T?
MGS(')^_?*+2]?\;OJ)_D7> YICYSZGZS;/7TRYNK#TL)[/*91KV^)4\[]Q)S
M?RGVTDMR!T$83$^6/)AMH="S#]2'(G5"AZ,J^2JH,%ABT[)Z%'!*S7JB.$2!
M_Y32H:I(P3A;]5[S(]38%M0E:S-V[H)ZZZZQV(R8J5EEUU3,;6IC I?L%KJN
M;=D,[]UMK.J2L07Z9/:Z-VRKVZ3:9CGH8(%'PP%T"4QWZ\D3L984_-Y!O<[0(ZK6I&.\.6W&&@7" L&
MYY#?:7$0UPJ\P^(@8:7YM-(=U8UPH.9=%POUV'(?--,[+1[B6M-WEI.S0H4]
MYN304')WIY@=8""]4(I-E"*T][)
MQR$D[Y:39K?E0?FX_!XD@<C^@>D.';
M[?T%PX&B6@/+-'O'/0Z>42W@]/20]UVM7EL:@Y&UHCLS#J\CEGH!Q?,%_K13#^,D34PS Y[@_5/
M/SAV-78;R;@!&$NVXT23R+-#X$HNF"+@0#N$@2^<4[%]V^7VC0^*%-C0G\S!
M<*0.AD/]9Z$30B>$3L0ZH2C#P4@SA$[P=Q["0\!"&D@^$&&+';9&Y'5;THO6
MB+P2K^@D6M')CFYOP6.A6OQ(AU"MEKN.FL2G&8I@XJZ:_2S:8N6F7_O']C/6
MZ(76TXZGF_3.J]UW;YMN>R:OW?;:[#!%F2&:/XGF3Z*M"&?-!@ZS-Y!H_G3@
M#!;-G]J+I?%$!V&E&RCQ0?G(]G3B>9/0K6$:HGF3\?5_(F1OI_=E];V
M7%JT9;H=7P23*? Q"[W< 1:.N0APB.^?;03>VQBX7^P92R+=IB'3B->&3!C^
M!=Y*(]I 2%*4,QGZK0Y?W?*K+Y.4$:JLQ=.ZUDZ9[V^N/U^=SCV/)9QJ%=FGQRKT4HT#H*[TD?:/"8%HEEC3]6 X
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MT-A77ZX=(,=5<[T5?+?'3]6R#9?T%60?J)%:8!Q;)\'37O/T,_0%2]L[,I]P@?%N&]D*_@K^"B,MC/2!]33M0,WWW;A6,)D/)G?:J/9HF+S-
MR;E0[O[R72@WITS>68[F"A5VE*-9Y)[15 (I&$M3%+B1$TK8]D"'W:@Z0IW7
MFKF..=WC#KR\4J:H+;4Y,/4.N_L(G>""\T(G-M )0Y4NA5Y8%@=
MWD8GQ%N(]Q[%VQIH^MY">#Q*-R=;L]V>_]W3\SZV+YO8Z!L(:0W/OG=E/.[;
M>43W@$S?;J_LT ;FL,.;N(1T"^G>HW2K T4?]8[=0KJ%=-?!N#89<=W/HGW9SLRG9[8/81^ #9'MN7V>X$^A"'R [A"]C[YHS'G7O'
M'8?['+G:8TW"/D.W0WE@67MS@H6."!WA7D=& U7>FZ]&1GE?B%3DGAC&0C;U97J%:_$B'4*V6JU:4P7!_J5%"L_@1#J%9+6N6:@V&
M0Z%:0K6$:K6L6L9PH!DB+Z+>501M]=-G0XMV]9W??S 'ED< SS%MH)2_T6 @
MA2PB$OF9*Q+67*$0W[ =!F2.P/F6A$^"*7T*2Z\VEO[6ILAJFCG0=#E/59IG
M0&]N2(%Y!=1H O?4?@'(?@+2E(P8$*C(G]+K,R28PE""F&'A). _YNZ#(#_:
MTRD*OL,)&=*;M:IWDG*F#?,HS("-<,'5,%G)/F -Z<2BG4LXFDQL-*,"SJ1S
M(9"=$.NK&QFFT*J1TPH@?>AKVJN^LCZVRT9NT3QB
M%AX.HN+F ^$@' ZB1^X@7'T'R($8' *JAZR/%6P\CX,V?Q@,_8*@(QPASF6T@H<7@1\BVPDCV^L[
MID>NC=>$D=#'T#E:/@I_J%\"+>X:JU#IV_@D^6@5^ECX_-,_:6;&ST*G&U0)
M("?.K/J#6^,T^*.)H@MA[@UN0I@Y
M7G[YJ)G::$6^C4(UAF2_*]IZ]U_/MA>0 W!I^%*O?>Z7Q0HF5K!.
M56P_*J6?[:^%K5BL.#*W8K%JVQ<3#QZ5BY/]^6[/CW/[S?I"
M<;,U%PVA&/367?6YGN'@648 ],0O8_[KV?"V^%/OG$G0(_ S@++
M(X /SP !Z97^JTW9DG1CH!H%S?M;G431M(%N+/77S[=_3T))26"IU0L*5',P
M-*Q5%%N=1!GJ ]74\[,$8PFF?4:D%UKI*MD8!PZ,[T2 X3/M=X_!''LLN1&B
MA1FT#;X/?2!-R%C/A#R^2]Y8ZF]/D2 ?](&$ *:9,O %>+,SZ6%-#WTG0@@0
M=*>!!YT9O5 A#,B_,0&+FG+68I]]1UOKX_$LQZ(%C,=[)\)16HCA2!WH1)]/;H;H'K'Y=12MTU&5!_+R;.&S'<93
M,36@ECM$L(H($0>H/ 9@5(6[L@H]$]+VW#Z
MVD(DX^G?,$>_O9L_U-S5'Z.VK_Y(R4WW)WV_!\3,;&B,@MW;G@ISMT?F (JM
M.\6MOZUZ5'T5_0\!*E[G^(CU]HBE_-AW/FY-+;**V4V%8#Y/IJZ[A.J22E%UZF
MX1-IND$?Z,Z(<*"VC^^D]@YL7W<(%QFWO\EGQI &"/^FG.D=5FHZ9+?WB""'
MLLN)+=NMVW8U+\,$:"+]1/;[LTTZL H'CA?F[ [5O/*[FA^2JR<:9FE@X>72F&GNS<3PR^F!3&M?_T<(9
M>/P>YB=A^!=X*XW.=/*%HIR1[_E+$QJJ@Y&^E./7>JJ*9@UD
M6@R0"Q#+\4G@8@OC6YJ!]$YBSYQZ]BR(PK=C
M^!VX[RISA>;CH_DG=R[NV8]H\3%=/?_^)L*G3[8]?7L)L>,%.$+@=DR3:8%/
MLV(#_PYX-'OW(L AOJ<9L^]M#-PO]FQ"/"S\ +Z'[SW"T5___=_^_=\DZ>_I
MX!>H ,68V1G.??((.S3[?@..,&33U3(_4*$*XBG
MGD\D.82]Y(\[,/[EY(ML?I65KU02'@)9^ZJQS\:)!%TBNC81"_>K9EHGORZ)
MPEQKIR'Y)RE]B=DM+8G#(/YB(-U329=..C8>:R1LWUE]JU:)*"WAV2M+>66"
M/26:2$6")_#
M M55SJ.EMYWSN&4 8]]Y4ME-SO"@;X8Z\)M'52U[D8R^@NP#-5(+C&/K)'C:
M:YY^)NN,8&EKP62>Z"!L\0'K;9R /<>X(/U:\%?P]Q#Y*XQT;Y 3MR)7W0-F=PD#4TP>9G)K;;U$:4R0>??57DGM%C&=JJ88H"-W)"
M"=L>:!(S.=@67#RBN_4EV\U[U_6X,5TMRA0U534'IF[V3DB$3@B=Z$PGS(%E
MBA[>G*,K5&*7*J&K [email protected]=4+6!I0B=X&^3V5WU4]$F\PY@P!*^
M:)Z7"UZ %TQIXF&:1[:W#2>/US/QB.[."W\XOIYL(P-(.PCOS?X)Z1;2W;%T
M*_M;W85T"^GN5+H5>6!85N_X+<1;B'<=\;8&FKZW$!Z/TLW)UFRWYW_W]+R/
M[I6HBW$.\ZXFT,AF;_VGP>_JYLMP=F'X$/D.VQ?9GM3J /
M<8ALVAYE[YLS'G?N32^KX5PR=D^00XEM*4-Y8%E[KM#
M9]
M^D#EP_9GL7*.5,5\A]=?(#'U;/*VC>F(2W=!O-KLA_AB"BQNA.C^1HCLA1 C
M<2'$^K5(.^C^MFJV-Z!VP(@>>#?NJB:/Z86KAX#J(>MCNVSD%LTC9N'A("H:
MX L'X7 0/7('X>H[0 [$X!!0/61]K&#C^0M ]E-=+G*+Y1%S\' 0%?Y!>_[!
MH=M;KO&KT-C/T>01H 7*P?AH-?P-$J]+'P^:=_ AOAGX5.-R@6XTK2
M*_C\ -!$*/.!*_/OMA<=;V!1^&"]04Z<6?4'M\;9T$<311?"W!OJ0B/ M$_HR$6CW+?:F0--$L3
MRL'=_K2[/H!%^].XSILU+ =)I;<4!M(+^9J?_6HO&TAV:DJW;J!8%.?*0LP3
MQ3CNN=F%0N3O;GNST_SNW/67DWZPO%S=9<' 2T
M'MH2CDUG33J;[QT&EF$,3$.TP.V_G@EOAS_U.AN*%:S_FB56,'Y53#^3Q5%X
M_U5,+%[<:99J#@?J_K;J/"I720MW=^L6RL6]MWO?&G[7'=M7>L=O.?]'\F"(
MK_VX3_U'%&#E4"AG^!M]*(
MMJ*7%.5,AGZKP\?OT67[^:38TG>,0ZX+_Y+_(R_*PI)?;JX^/.2^O[G^?'4Z
MCU KM$=_;F6_L#WXB.  VSX^Q90]^75;H>MVUEE9G3-QH>8_G&27NOHM_@L\
ME=1)F^-+KQM(OTQ0S=Q ()]I%-HEUR[W4HP"H:_TDES4$ ;3*H%9EH&:?M;&
MT.O9!^I#/[]==52%2,&%%4OBL*RX!1*A)OX/F^#U"9AQL:STYBCE($]GS\J"[ 7^R0\(FQZ;_]
MX/7T'P&=;V9[X4RZ@0Y9_8%T_H0 6_A7<8IVB5W73*D<)_LVCX@^+.XHDB!F
M5Q8]!QY9X>@=1+8O@>^.%V'X B0O86T82!'YCP-0:)/)TYN-5/G=-RH-S\'K
M_"OE'7$<7X 73($K/3ZZ#F4PSH>'.\IBAP(XPWI$7B0B!V5
M9CND@Q!./MM$A!\!\"4_R).;3.0$:!H@FZXX;,X*=*A(LE'' 1F9C)?B1V3)
MC8C$1 A'9->;BFM&VC+XG$F?UH&-\=+(.$CD.(H]H$A5*Z$I,@V(17HBN
MC1.,R;?D9>@S24F4ECU;@5U"]W$4DFU5@6=S %:;,[ ?,FJ>BDD%DYZIHD \
MC6CZRD+TVBB$#J06B^FT'_B/,.[8, $NC(T7 D\V
MB!@$Q*XN
M!HS7EO3)B3TCMFQ"294B;*-'&*(899MZ4#,6?19*U@+8M=W7"\_&6#IW&!>(
MU."(*,8=\.RD..L+(GX(_0+8R64?A^N^<@8V,3:?B-:H*LNZTV/-&T.$P]@L
MDC5.\F*.868%QDP9F24BSUSCX,Z>#:1KWSF+%^G7@+Y(GP[&8V)A46KP%%U^
M)UV^TC,TZ;W]Z-# X4_K[NM$("3.(-F47MW^S,9]CR!Q).[L)P]DQT,+(6(N
M+::O,C&B9I)A)L>890R>S7Y0+.JF$;^'. ^/*784GM*
M)D[6Z7\%$:)VC=(74B*^1\0NS:@/8$]GC./L:V)I0DJLC,$_)^_-,&2NR3TQ
MDR (:4C4(9BEAOF%>*-_ /<)$(7 P%G[W1>R29 N (;1Y%31%"D'! 7URD;>
M[/0^) N5=!,1O"]L8JQ1=DTCWOPE\<_?/T=3@)^E+S:RJ>,^D(BS:'NQ<9US
MGSCTDL,TV7;B2U=MSP-/E*(O,/#L^+MTLT%V%XC9?B="D%EG.A"9:R;=TG >
M\R%=Z3QZ(A(K*68J?V3,!1-B&[Z0/^IDD366Q063U8UPGNYQ',KRC&!&,#O"%7(FY^#,VGX5M%/G9=369>'QNG-W?T@9?AO]](EQ"'Q
MET,BK1$*R5X*L5^N;$RXZ"]^)J#_06A(P X#_RP!@(JSS3SL/Z"'">_N"0[0
MA]+'(' 17009Y/0?HO(TDD]]2I@$9K*ZE%$2ZK6S/91#]G48>&))VXVY3'TO
MQ9B++'$M)K$;0^\6]@BKPXRM9/[2A.Y;7"H&S'Q2Q4D4AIDPYH<%2WJT1H>8
M4-#M,L#L/=>>$!6G>Q 41$_4/_I71#9Y1!ZI"G\B^AV;S=?8@9U 3+>$8Q1,
MF C/0>Y>@/(W!<2E5B.I+UE@A0O*T(4A[FF4?F#H,G
M0,T_V4%0J;'14S3WW7%R*I\$4*C#'X\7+/QNQ9 >H]357[P0[^=3@9O;9C8K
M'(]SRS;91 3(!T3X@@4OV&(;^Q>&,%*[D:>8ITDIQ8HL(3#UF(MP'TVG 6),
M_327K\M$OLX3FW8QES&ZZOV^LM1_2,Q4=GUE2WTR:R;0,OX
MRAYC%_4.OR3B\YY8FL _\+U;[X\>;%\53L#ZW*CO139I]$
M?\IL5'ZF1PN3R&=1+4^:!X\7&[9[-NV2]TTG6C",#W%2.H%D_T!LL\;Q
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MF),/TW6>1F\!\\Q>61)'E/AQF06F'BI<*)C69%X:8X_@=\Z2=%_CDQEM2)%093&$QA,'MI,(<<
M&LR#BEI\0<$+Q(G?^:_@,3Y$8?%=P)(0;+_5&("JYTDSCCSOE*;L2H!XP,$,
M +QT:L!!!P=Q&MDT"7]^\C2EU2CS [KY.1S-1K%=.G*<)$YW/= %^<._Y?.+
MI9S\%^#3A@AGT@<;>A$"RP<@9 B61I<\1[XDVRL$<.2%=$I;>HP3SY/9%B>*
M[)1LS)3!(>.Z@_C5X-&CV85@?MA&YIO:<>$4._.D'UPX'H,X?3XY:(M+8V(Z
M)/4N[ S2AC1?ZX7>=#W/ODG)DR3G,/T@O[E@;!.HXY//Y%CU(HC\_P4<=B),S^)I,A:9
MEJB._\3JJ1C(^13F!.R*,]9#Z#FS6;N*Y687Q"H@=H_\XEF\36\+_3A[6Q2[
MK@?7,Z.%#4\_-S#'O1'!(0K\I[J>C55@=/,C['V3LL\]QV;$I/998@::.%0V
M-<_,TC>F,#\[@%; =>:9DHVZTFY:I%
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MKL%9S!R6VLT';KK^PPD58"*BQ" HR@JF'Q:6UOEFDN 3NZ)JYU
M;>8>XS:4_/49AN"49<^]]8-79$_GJ\5R%VQE<1#7(9E:((N6M0_J"HT>@M#V
MA#P(>4BH<4,]Y@6AFMPA($3C*$2CR=U(0C2.0C0T(1I'=9-AD;=Y8>/GN,R2
M?J!E<603,H],[F;3P?W%&3RB6W9I2L9>;4*-NC?.]/@ZF5J440ON:1H8UG"@
M:5;OY$2HA5 +H19"+81:[$XM3GLG'T(=A#H(=>C'J48KI-GMF<8?-KW2*Y1<
M@,C^,HROA4@.[OX3OX5X"_'F>E47
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MW]YZG(W[5!>1/=P$X2/,^Q+9PT(>2O( 1?:P$ V1/2Q$0V0/]_]<5V0/W^\L3LNMT()%43"G\JVY80TVS%M2JC5#'
ME+BF+;4Q.Z)7UA!@_O$?:>-M]CBE0:<4'?6>HBIG%+5**2IS34N-+UI:T
MO)R'K3+FHOX\6NU++6N7.R01IS9(4OC5)9XLS'#
M5F7I"P)C@(CK=1\2#VN+RUPLG=?+7##\"[R51F5%^>'R2\W5Q\>[CZE<1%FR7
MTQC '%]:])A^F:":J8.4SS0*[5+D(/=2C,+_W]ZU/K>-(_GO5[7_ \XW6Y-4
MR8I(/2P[LZGR(Y[+51)[XV3W]E.*$B&)-Q2I)4C;FK_^N@'P)5%/4Q(H8ZLR
M*TM\H!O=C5\W&MT@'W@RC$]@Z$].9CS"EXZBG;U@_5$D^WW=5=);() STSIK
MF IFUDR.M&XBMD:COJ[DOHR;V\WB/ICV8M5/5BMRXSPZ-O5LM@U/=WI.>S=&
M;^GQZ6**-[*CAR!^U0#O/')#^QPLP9=Q$;?RDD
M?W=&A+QK]XU'L8I^SK5CR"%A^!N$LTFYM8CBT;R(4C
MGP&%5DA9@4E=6!VAHB'4!0A]#LA;4^YEW T2TYB_\]*SQ1?@5U A_PM!OF%*
MD-^> ?F=I<0O82'ZVKJH]V+ TW+PF+QF,KF H[14E_9'E#BJM MCGF()M^
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MU1:D+ABVK"V]+RY]BD 3\_QG7LUVS8P!5(Z;8,Y=3PG^T,D/;+Y8T#1KX+Q#-L$1E.
MO_HAC0NIW 7?T-"^J!G N6X&L%O;@GU81!%_5 I99YZW!W#^A$%@ZYE$GXK5
MIT>'CN?A=_*+3 ^ &G\ 3N8C*F= 7= UFX1^^E"AG3721^?+=?%C4H '=98^
M3QSLAF-' 1\AO& "T^G;O#?+$T41PXXZCS2PAO!;X/1AW+TI/#"D0S^8ZN8#
M^VX^T-;-!Q:"ETX!4-/-!ZI VXK:\<=#Z([:!%2E"< _Y9*2$BW7EE<[KR\/
M!ZO$!VV!MU#>X^GQ$7LG>J*/?*)C+R)E"_<-7NV\*[*IM[O=W2+#?C?GLBI1
MIDW%35\5R55AWZXBZ3]E[APTN^U:5_>S4)W=@*5%HA7J="'#IA9R,E,>LZ
M'T=!"''HD(0:Z<8J8LS#ID*JY)A5-]U8*2>NV6GHR(;6L2-)-U9*M8RZ<; T
M?A7U:MUDX^JDDVZ=^!EGD#HLV/@A5]./^,I/O#G/@H^X0\57TI09-U98Q02H,T6BC>M[VZ=
MHTJ!B/VW"B0(5<&O[Q:X]RD#O>SJ\$7%HS-5.J2CX*FE*KK 
M!1A)%\VM +E'!)'V'M_I5FZVM7"OADB\K W (QV:WA4\>OGQCN-."JK4Z2$5
M\H;T,:("^*4/Z%6"7)4 F!+T%H&M"L^O%N?5D*O"]![FV./<>:>8RE]GCB?]
M6ON5X6FZ7^=(28^[5;@]QSZ.0J%\!R?H\MEA,\8YX
M QM9 84+;-IW0.K9WTX^?;T]^6 VNYWS3GKB=-6H2Z2R71*5YAI4FNU&]VRO
M5)Z73&5312H-4Q[P+8O*EHI4IL>82Z*RO3LJT=)]8BS"WB[^0!S993@,QP.Z
M/-K'XTE/3CB2QWCCFLW,HZ$_<.2=?9^%3(QLP>GNUG>_=$7NK&:+T30;Y\*>
METIEEGTQ"XNIZ@+V*"1RONRP;Z0L+(M\_ERPCJ=/1%6MC$V&LL),YO[FK&2[:]A
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M594P'.N$'\_/6\U#Q9X5,2MG:P2OVYUV0R$N[=_D=%/L]
M][T@3F13;41<K%G\QID:=CYE(/0GQ0E6\J"H V9
MBKE)\D1\*U9:G<]6@(\]_&"8=?[07G&RP,IW96O=%KY RC[APD\RTK_F:Y6A#_<-K2'EOX,U>,2RF5AD^/+^X_^2&RNTR,.4A70,0_KD]>LU
MXC]Y<&-O2FZ>T'B2*ZO7!_-76UC0& L? S:^'EE. !3R,5V/'#H@8./[$<;;
MR-U@ "\.:CB@L6\#J?RRL>5X(?Q;^.PGVB,.UG <6'T8E8WCQ6J[8FN26).)
MZ_1%U65XLC4;IC@%^-7Z!#*DH^^/>XXG",:-6?Z,
M: *WX9#E,V,Q@&Z!X*&GES_>W+6UBJ!N$3
MX!@B97X#!9^A/EQ\9:+F&4F>! X((7\3&5F@WY0"__K] *T$WAI0I C^B+R)
MY=CQ *VQ'R'1 ^+Y,-32I]F<8_4LI:"@+!X'&@1@'K6 \.PH6=1C]-\1\IF3
M6*]@5KP5KO@WA_U1"HQM*MMF@(%_<4&ZB*.(8=0;,W#JI8\7
M]V&.[>AD3I#V0<,+\?CG3U\_GB:'A@PL79]3U6L '[W J3$0LE,F@'AV> 9F
MX&Z*PC-JM3X@+X"R\=&0A%XLY!]_*4G-U/9OU)LXVID#);F;! G 7_(H45<,
M[1<#ZHU'TL/XHXO3E5G>5!!208&%49"/O@UMS>?KF'9Q@N'E$._4"RI\EGGR/**0'@P2CW6OC- #8%A$.N]*CK4$P?"4=6
M2$#\G>09/A-^*SZ"P30YX#E:,+0 U$*";Z"E9[DX1E9@D106H(K*_:WT7S<+
M1P3"\[1@%KTAX)A^["*]>1HY<)?X<1CXT03E+OX9_*QH,O$0ADMLGHRES
M0$,\<4*C")W1KRO1/VKF)^BNGL,SGPZ>9-W W+1 ! C\$
M@^!1)/.1>A&=\8UV+D3Y5DJ+.T/M6A]6/F3%8L.P(\4CL:D#[%-8>=!ED: CT(U6ZC*KAHN,1EP[A=E =)W0H>YNJ
M$L8,2I5QTYR5\<'BP?,%CF\T-QLU:4URO%I-29Z;Y9)RM@DIE;+R%5V<+@OD
M'X%6.)T <'#=*0<6O$5;B% +]R3S ":.0@,<]X8^2K\-0,P?1E*1$&&EJY/H
M[@>PSG<0(UE3CNWJY %^1FGPHR![-8R$C6$8V.!>'=#20
M@ XOZ%&/#I NL13+,!H@6$X"7,^ (P5(#@#TV#[8PP]P\)#OH#+T@?2
M0%?)OR/@:@I2B)<\.F"P86KQ !F:Y,BS6=;GL.&)XG8'-2<(>)0=HT@R
M:@VO%J\1M-L$8^N3F#)YI1LM?BB>48;IR3(]?MHUWP>
M:!$O9_'V'*.91^*6PO^!7L6>*!B%"!80'ZPV-WB#=%=N #^"UP\&4J_W>QAV
M9GL\Q+2MO$.:I&I*H#VS,YZ/4>!>%ZQ(N.LE[:/M,&XUP72 $0LLV_$=YH?^
MA(H=7EPROT6,H1L:"VV=?/73986;([E/-7887Y-@':"N-<68S\AQ\R+M>/V 
M\J5+FE)NR4/^)D;!Y-K)BX0-EIE6--E53HD  \G,$][\Q*
M)RPYM]I69L5>V*]86F3)H71E@7'BB], #WCJ891LQE,..C@=5@]6KIDU)#'J
M"&%8A/D!3N8UL]P'CE"':^W ZHNGS8 6N2AR*2@::_H$X'K
MF,H9:+'$@F08%^(D]JV)9-X*V[+Z#_5W/M?9OERYY7E/ _P"ILQ8*[U VTW'NQZOI]^F$9RS^?+!;/
M:F2/\2TCO 0FM3),:JO$)',)DPQDDK$=CV#QDM@>9/H^\#WXV.=JS^Y]U^E/
MQ7]?LH_>5'4?O>1<.^4S[&9A1EJ;ZE16I HQ\6)BH8W>\HY/'I%'B%H"@MPF
M.SRIG)$']$? VV3DRH?_(V]N+Q^NWA(LK0&+0>&%/S#;BY(WEP\_WO+'GS;.
M:T3JED IUYCK9F'8@ /FZ\3)PYOB>][6I/,/BR7\1FTJ'"@9:N;Y<$./YU?%
MRY/8Q8)U%T=9/+IK7 GCE#QXW?5;\MV?@ O=:;3347Y+GRU",26PL#]*S%,T';&7@C00)O!._P)SE"A);\:A\=#OZE*Q9T!Y$)
M.,S>, 9M/D 6,2#NSLH1S;#BR7%=_JC!0$3\Q3:?YX'_@<%:<,VY!\YW^QA<
M.70\C[O( X ]*1)&#(QG=FJ(-=U(NK]PB3-.;D8YX2P06RJY1\M]S)@RGI)(
M,6$L#/QT,Z(F9(U:/'Z3R:<0"YQ8K-*AC!KWZ=_WIJ&#%CVHWWY).'7A-X^8O,4F*1XOP7BCT.1H5W7?Q(FBV_#D
M*0_Y@DWE;^[email protected]+7T%F>^,QRA8$0
MGFS>\!\'@/M!??$089)%LH27-7[[*#G;JY..
MCS%ZZ0FLS0V;!0 @F,I=Y"6VK7/:R-FV%(!^\E@81 +-92ZXXW%5MPS31WD]
MT%SR$R8;34*ILOD=V@B/" H#)NX;4[B,9S!9*:D\6 R01Y[OG4JC
M&=O*BV5#$"EAV3NF<\,2;'Z#.^8(0S/)5D!]-)Z( '6=.D[@WUL<#5-)UD4>3LD,68=B%PI#A9LRX
MF).)9J]:3QNK@ZX[3-$*,;O\(-QP>/(&RG*>(0&EGKQ
M(!BOZX,5EJ=DXAP#4)HB$24R*(_,X.L]3@I(GY!,SI*"!5^+0"!.65,'(^2*B7]7%M*
M=4RCDMBQPA7'MXW.SD9WBTL57&*5  %>KJ;I)?^;R"29$U"Q@O_,Z)Y^\
M>RYZOP<^6U;@+PF
M9'G0.U#2H="0=394[D%% 9_^8/1R&% ^T&RX_[/O#?&U\=.!-M V0&LEM8>+/']?X)QBG[Q"W$97G!PWP]W-T.?I95-Q'][F6UF,T?>XA?.:7IA5X)R#D)VE=_ R>17%.\&YXX4EG! 4!_XJ]Z!
M/]!^,,)KG_HS"B!%_A&O^NC?9MPD?,F6]BF#HHFP55MS6I_]>^&PG77'+VM+
MP6H55Q-.G>)YBAP5:*OHE*P:]E6<\1UFO+5Z.W
M]=_4!E]QF%QAO,_E?(V$]X<;ISPK6N[6R(X8+(Z[2K<00(-!?'!R>7Q)^NT]
MBJX]8^C;VX2?>BL2'CZ:$4\&DY5HK$7A%IUHNH]AEQSI3PB_)"P:HX^4G$E(
MHG7Y$%]&2J2\900"SSY@I 1#/DD.%@R;Y'?J,\@.(QX+*G',
MT8K_ZF8[?/E_7W)&RW2^Y)J!)Q9?27?!HY(3U%8: 7GO\46)-$
MF&:;[F:ZU9;#D1(X "Q 48?Q>YBX.LN.OT>6B"$C>(XF,=&HYJ?\\X48J? ^
M! B.)AOX&EHTJBH:ESS][M5.\W9MW]7ISKJ5Y;^2VV=6_M1W:PLI.-K>M"J2
M^](>ZGMLM%W5-O-&8YY'9K-;ZYQW*BJAV_:*58I!3MLV921[1*4K*G
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M5PR4>G(YO:!U[\:$1K5I%JM5JZ]C(8EPSTZ5 %Z1>-&Q96WIQ
M XI5-737(=&8ITP6W27KW$[BHKY8MCRIC4\=WAE.ELCW ^)'(>]TQANSL;C\
M.>]G#Y^3/G8KRI7OI"C[+N4N>?[:32:62=Q>6TIL/O2XC,N!!UY-75>B60')
M48YM#$67 =ZP4!3"Y_T+G#^QA8;KI@I?K-]I,T;Y1:9)08T_ !ML/8I&IDE[
MRID.&S721^_0=?%C4B$(C0I]GO"VLW;:U%5TB.0--9XH@@ULIH'=C8
MFR8]075WA'UW1VCK[@@+T56G $GJ[@A5H&U%7QZM5XH.VP%LH[_$T(B8R\B90OW#5[MO"NRZ[B[[>44AAUTZR<
MB.@LIG+Q1*:*/0]+'TH@5-S^/6B>Y^[$H*IYGCOD2%&>IWG8$EE:(5ZG0APZ
MHV@C)3'K.F%(00AQZ)"$&OG0*F+,P^9JJN2853C%S@4LEX)HU'D:X=)$987R)S-6+-XA7IY1&0N9N'I5@N7D^<**0C]YQ%GI
M:94+Q[.V*U;M# *SGYYB
MKB>^ZA-OSK/@(^[J\)4T9<:-%58Q:>A,D0C=^MY/>TOO9_?>3N>HT@9BGZ<"
M2355\(6[!:YPLU$[,YJ5E8R]3?VK#2$=>7S(;!7%A]IZ;T-Q*XET$;!KU
M\U;E9EL+]VKDRAH*L45@>];!P4JAAZ41'-5LZMW02]F.U:IZT3AA0G
M]XC R^YXH!IXT<*]0_"2=(#2L9#;DJ3*\"C5/B/SB+^*&AGA_8-."'>>*D
M?!S,!9XW>B].C9VZUM2/PHN!\TSM]VO56A?8+_EDQY_>93\&Z<=XQ+^]B]CI
MT+(F%P^AW_]CY+LP./;QWY$33K_Z(;UQ6-_U6130[_0YO'+AF@]_^8^__ RNX"QY"[!CP#^PX>T^#AY$54-+WO1#N_T8'?SNYOV1W7J/S
ML]GXB04=3XAC_^WD%CL.V#];S?,3$GF.N/+'P\W/"0U^\F><$)OV'9 =A@=_
M/C3JC8:1CGZ-0RZ_S=
M7WC@-F+X8/[J,?7":]=B[&[ +[A\=EB>TE8C0RGC;\^2^.GK+1"9$KAXM+-T
M/?1'U(Y<"F_&JZXL1NU[:XHCNGRR O& NPD>F6#_B#N\7,*CQN*[[R@;R6SG
M>=$X^]G@?&A_]U.>S!!FG'R0"C5_0B[$4W)"(X76DIDS>S7Q18T@GP^&($>K9HK9A+WC'K^?GPE-&-8U:^L>6&XR'YHLJ
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M3V?&Y1W([ZY+;VAFYK5+(A4'E11%M 7S_VSM\A'.!_^7C
M_W]02P,$%     @ AH"J2.&T,3E[#   'X,  !    !I'-D[5U?;^,V$G\OT._ \P&'O0?'<9+=:W*;%OFS*0(DZR!QKST<#@4MT3:Q
M,NF25!*CN.]^0TJR)8ND)"?-"G=ZZ]G\97_>]ZZ(?OO_WFXY_Z??0C841@14(T6:%+K/!8X."+
MS/C1<&^X=XSTPW[_%J_Z!_O##^A?P_V3@_V3HP__1K^?W?X'?7H8HSYZ>GK:
M"T&",A+V KY _;[N1P9SLL!(83$CZC->$+G$ 3GMS95:G@P&FH]*+O!*\PQT
M#_N'AT/0.B(+PM05%XM+,L5QI$Y[O\4XHE-*PAX",YD\H5)42S*D!;*GPSTN
M9D"R/QS\O64*T9\L3O!TGCFC3R
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M\'$W^\$Y $0>P'LD12
M%03_M<.P&L.U:^5H.EKJC!#TL$PS!YT?NR,?=AN)B$_11F:'6C/4+K"<7T7\
MJ0*T#9D?L_?U,=,BD9'986;'[!Q+"KZ_RYF;H&1K\./R06<35 81E[$@\,.(
MT##DA71 V('X3)[. K-=@ ,'H-D)"> ^ C\P/QM&Q@0A3:R4%%8!Y C
MNA&A8'NO-RM*$B9@.#CL<-US*.R(>YI!0
M)2@4WOB=?[SM?,V+8(%'AKOSN=WGU^P1S(2==N+PS4^OMX?[V]Y>,W:.MCL:
M(C(,1K72V_O?8KK4@3GQN;7%[_[AMOLS&0CK+7\FI$D?:4A8*+.UI/3>#\3[\DJ22D!K$1T(GF5DSJ.0"*G77+7*+2'%
M]WX02MOLO(2__/GP^.\HD=,A84?BGD2Z5'2'(04:"PR+;;!9T5V-?DQ*.^Q4
M##)R4$Y0!XJS=AB G6F%=32]@*!"]>>MD9H3<4_EETWUL)+0#U9YYUT0:>J&
M1JA9\(U89.1VV#4N7=WQB&[RLCJ$?NQ*&W=O*0N]R\1V7UJ:5+7&>!*MK@]*VWU'A0N\2<1U&-4I=>6@L[_V(E"H!Q;)7!T3=^E<>A>V7?@A*F_\U
M>^?]'8IB>2 \[7Y,MC_@V^MC'3X[%I<*1:G4#K8F>YW4>9[-3D;A!ZON]_PU7!U,.\!4F%]U"/V@E^E$HU0QR&]8.@&8 %**7J]$/
MAZ]^T,6HW0L)A2GB(_##4SH_X*HE=%-GEV)" 24_B1^G!N6$#JD7(#6L =6P
M JM25:$2*S3LT-H%K8,::!U4H&6O,GC1.NC0V@6M0C91B]*/7*G<4(UY'TG+"P7.*L8/S1:7S0D[BI?"#5JI%.(OG74;2]+RC;;)54GGA
M.BI5)RQG(;N9M?L'CW*J;VWV@U0J7K@_>723:D>$AA405:3W1_8_A_!AU*7W
MS5$ZJ$"I(JT_*A4VJE'JTOJ&)Y!MJU0]4C]VI6*'\W1RMV"]XGEE>X;?E,T/
M;:DV4OJ]\3Z;(7#]VHF]V.NU)NEA&^MHR\VX."=UICTK1SVYK
M^Q5LWGM>1!F%[L!S#YH9*-MN2OO-1*1W6?EO1P,AIHH,F[5!IGL/#5[/+L"C
MJ5U%"%MI580G3:T"%A*UUB 8_$T-VIHOKVM6,M?R%Y[!K_R%:.856,6%0LQZ
MNZ+KYL#D8L8;'AA1'A;]JY_Q]?6K_O"@?SC<>Y;AQOE-E-C8V$R)C&\')>SW
M,M;L/F/0_;ZOVZ/W8D5'QZ93*^. 1$IF;_H;48WL]UQRZ%/(PI8^]S=I!A?*=G&:Q862F]Q7U(E3@V?&$LTIM2&(TB
M?: \HY4Q,%,5Z]8?!8^762<4Q"?[9$A[?ZVGI,/".\$?J;XF_(J+>Q+&IKPQ
MFE[R>**F<93^R:@L&KG@$ BP6-G,G.)(-K0SH9TD-X">]@*S$:]M?FT+'!YX
MF -31$93RS%T<[[_S0$.U"5OR6)"1&9@NR,]8"*SOGQ7W=#97\GSUZ1E"%)7D#KHC]YC-DC^NUG72
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MSG8% (=6#ALN(BPEGZ;#EPMC.\_%@+:855_15\M&;B@S^EQ3FS36[,^I__>!;3\LF@_LIS2EPDE-DTWRI<]UVC_9ZFC?Q
M!4D<25FBO*^#-:M,>=>S0B]+R_2O=[_"X'AEFRIBO9%NM%[H<@#$GA7LGNN.
MES_.%57Z.)N-RJG7Q*BY(*W&JJ!@ \.N
M>-R:^E^5?NZ 0>8\EN1!?^)IBS%VK1PFC*93L+55^EM42"BR47*>(P,>6(I23RFEU1
M!C040@9;:_:F7[Y#,FE0I7E%$UV36'\Y8A?)R3Q]9*(MJX93,5>](UXNDQ+7"57*@/SQ\XQ">\$U\Z9O'P(@O(44=-.'.HKAS:ME,\LNS:C]^D.Y0CV'43]&%-8P1>[;4QJW
MJ%3]J=GZ]257PC.5V^2KC93Q(GG7MD7WE>RI_%[71&9[%O 7ZZ_]\G&0G/@S
M+OHO4$L#!!0    ( (: JDB!QU%T%0H  %*8   4    :7-R+3(P,38P,S,Q
M7V-A;"YX;6SE76UOXD@2_G[2_0ET&C5V
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MI,SOO=N>CT$_"-/3OA#8Y/?%KC*, !TM-I=@M
MNX"T:Q*O"ZF?>T4H.T7*\KY8O"'M^8:(#]+N+^'U$4)3T0VV/C1P&//E$^FV
M#_5F:]$+_K1X_*/->=KYS"6':(##]'T_U@F6OBA#O:N$L31@+%J^T664S4#7
M9GF]$?.7(L7/#=SR8\J"HL&3R2255B>BJUGR#QF=J/VV>"$UZIMP\6HZE6)1
M6/,H"S 3DP4Q5WC!9#2.Q>^R$)#=J&@<\A_90)Y1*+O7=GR%&)N)2!2:Z]&YQ0".CWL
M8Q%5@Q#S;SBV=WP:^JK@HU%?#= 9!(#>YE5"7P,N>;*JP)'76HW"SQ!0Z,9C
MS(JV%1-351 RV:#&ZP,$O!X8GB(27+].<<2Q&$!3.UQG=T[<54'0R1@UE!]A
M0#E?,3V(E4N<73:9.T0S&QCP]*B9U <\H;BCTD!@^.4FO T)(1
M7ZS_UCM/),0AC76\ISOGO[4;"Z4D <5P_AM)'3$=Y3S]C,BH9Q>/](K.IG0J!]3
M_VE,0^$[_@5QXAOBI["D,#1?F=!0K V&Q#2DY*@ 0&$(J'5 36J)@< C2*@-G+:2MT!8W-%>=P=IJKV1<=LVBQ:IZP&(AMJV_,!]?)'DT4&
MRFDL6=$"0*1 ]Z4P #(V8AF,A3?D K@C&GA(TQ330G=S+L#$!PFS]:A39 ),
MI@#NYOHX%#)'0O%[Q)YPQEC30&1@JA)L)CL 9T?G!9>A4+L=3$A$>"S-?<9V
MX*R<54+/:@[email protected]&M'\@& 'S\ # #:GE9+!!,#M;96AG^M\&\68B2>6+*F:
M!0)4MN!394_5U@ >V;Y'#*.0_(F#KXA$,BJ[40!96^,K XRE+ OHMZ.?1"]'0V$9T5'R'$'S_\U)78*
MB2EM1T3J]\"HC)S@R^P[QT*YMTETVQ?=.XD)Y@(I\2 1S[(G8DQ;*#L)!M!$
MMPD#Q8;+3FX /$&J]&;:'H*^C+VUC;- XL&/U YY5/*&LAX.$E^^LSOLT&00
M#Y.P[?LT45= %>(^.. *60\Y@]K!4X9],L._AW,D^)B8''L<,V\!PLK :; 1\7./#.JV-+QI[:A?U@H748BX.403-BV@8;,6.@:*5<42QH?6!
M)AQ Y/\T9BP.S^\4#BH9QQ8.*A]HP@'(H=MU,ZXGTY#.,.[A4&ZF;QL1)C%'
M%!0F-VCB D1>41/>>PH.JZPCBA"K+S1A B)!FS@F+"VXZ0Y",II#)89%
M+'_8:^4*R#C8L"C@ TTX_ (A'/ICQ/ 7$=;!%9U(?6U;$3J&@P5:9[ &U4\0
M4-5X8EZ-_0ZU7Z:E\T4O$K75<#A!H"C P#7GFW$<-$8<.,_W!!PLQ]RX=F&"?+ZP7C["%"R
M'T\ *,VWEZM!VL/*WUY8*(VTSGJPN-M-MQ>QE8>YQB/SFZHP(RA.WP[DI@_J2A\-W^ Y9=@Y!.'T:.0- !!LI\&I!M,"GD#]-(R
M,T/^'3$FR_%?,?.)^9XF,]OAPF\T&W).*;L0DE'93=7D2^U-=Z0Y\!X%X!K;
MG4>"_]>Q[HT/L95PBGO7CY:4H6H/O=PCL3 @*#3OS"KI 30!E=.U1W7RV@,^
MZKPZ7$39DZQ)%"W2>.99QU UA-;4!SRZO*E\(Z_R&N,@O9G2!:(UAJI!M*8^
MN*' ]+')$D:%]_Z2"P13TMM;MS%FP0B@";C Y/RYFH59@ >8MN\GDR2M(
M4!>_P[2*9.VD^C:[L?M[147#8W\.@'V-4NF?U\U4P0F_9:^RDCZ,9X8@M;.6
M5"!5Q B+VF6U&5=8-DJ?%)2 N])\+LSVI5XE-0"PW.%16@ 8G\P%=];/*&^0
M5@J93?4!KY\>Y59%PF9.P*B(*P6-R@#(MV2V@X#,%7M )+B-KM"4Q"C,1)AI
MYN? 7"GT7 P"_,&\GES]1CBX1BPBT8CG)J9#XAL_J^/"7"DP70P"?)&/VU$:
M:(=DMIT+.AQP 3&:9?2T?VE910P+(PKD!18.%J^DEW(
MLDKAK#ERO0W8-E$51]QF'N!.-U6]$+I:CDJ!J+4"<(&6_N"J'34'WDKAYV /
MX-7$HJ_X#?FI5YRZ5"5#I3#3&0%XI;"ZS#!CIM/7N:VX!XCCUR?\ 4$L#!!0    ( (: JDAS )O:_"T 
M %'U @ 4    :7-R+3(P,38P,S,Q7V1E9BYX;6SM?5MSX[B2YOM&S'_PU#R[
MRY(L7SI.[X3*EQK'N,H.V]6U)R8V�)R9RF2#5(NDIG8__[)*B[A"M)$"F=
M?NFN4A%@?ODE@40BD?C;O_\[D]
MOOAP].__^U_^U]_^]?CXZ#-)"/5S$AZ]3H^N_=Q_H7[P1[9H?]3YI?/+Y1'[
MP\GQ%W]ZW#WIG!W]5^?DU^[)KZ=G__?H_PV^_/^CF^>7H^.C'S]^_!)"#WG9
MPR]!.CXZ/F;OB:/DCU<_(T<@6)+]]N$MSR>_?OS(GO_Y2N-?4CKZV#TYZ7U<
M//AA]N2O/[-HX^D?O<6SG8__Y\O]<_!&QOYQE&2YGP2K5JP;7KO.Y>7EQ_)?
MX=$L^C4KV]^G@9^7JE+*=21\@OWM>/'8,?OIN-,][G5^^9F%2[G@F3!?OF:]
M@_['V3]^ '4='?V-IC%Y(L.C4M9?\^F$_/8AB\:3F&$L?WNC9/C;ARBC)2$G
MO=F;_NTZ#8HQ2?)!$MXD>91/[Y)A2L0\?0;YZ$EZE29;&4WPC),SWQ),TMRO;H4U#)&\FCP(]K"KK5
M5[-2/\/71QA]VZJ2_K)S^+H,]'
M2C+HO=3!-R,^\T#4%C6X:T"NA>30$F\H)O.N:3-(LRN>OT52IM(=&
MF \ _]R6@"I*PHB-,P_P-="G*/LCJZ+="MW6QW*?9MDCH<]O\#$;*9G;L+X\
M=\D[Z""E4R-A=EO5E^2)Q.R;A%$NGX(KD61^4/6[T>RJOLPE&V]I'(+/<_-G
M 9.>D1HES2W*UJDI7,>J=-V:TG6;D.Z1IC!WY5/FRT#G$S9'&#$K[: A[3&'
M,;Q*QQ,"!KYFWP8*%'=A64:CSUFO)\L2FWPUDCZ:L$TR)!3FJNOH/0I)$E::
M_-2]U)?TUH_H[WY0Q.>Q7@6O!&I
MZ%%H=V?7;S.36J>CYCT-(QF%C2U_]2:SD:2/I90^#1:"SO^XWO5R81\E^<
=>UA2W[.1Z3\2NA34JZV6]=,=] (AH4K^1XJ8(&A>7V7E?D),T'
MC7Y+BPZ7@H'%1DG$/O][Z&[C13!FP41+PL6KF$350VIEP ]>&*?!QEMB%I5,
M*1=/B24CP2^C]/UC2"+ U#EE?V!#XNGQ26<>>/PW^,E;O'WMI0")W.5DG"UZ
MC_U7$I?O]%1-O-.5EEH6^\5_71&L%KE\W.MMB+NB=4 W!0?36G0]MS*C\7Q(
MT[&^ N.%7P)9,3^
ML/KW.(4I[;DHI=XK@@
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M!3IO:;T\'R;3\3A-GO,T^*/BISESC)1Y?.$I*'7V;O%M28H 65SN #U
MX^8V@8W- W'":^6=@Z&?O9:Z+K+CD>]/F.'T/Y(XSQ:_, OJKUG0_&=OF6DI
MVT$0/^QU:\8K&I!N0^AIW,^3P(T
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MEE:%=! (NG 4B%O4!'F-_=KQK421 /DO)FGD]! %:[965$HF ,6>!
MB/LT&>G[XIRGO1Z"D(0V/R(  EJ0#H:!3D)^>N\KVD2:/CENIUXO7T*
M7QCB$NP*.XMIK%Q:'1(Y3WL]-/$*#;9$  2T. M+K+D[6L1PG_=Z: (3&M2(
M(0C(<1:2F FI].Z\4S1!!^TP;"FS0-_.P@OWD?\:Q: YPDJ^E)LI&U6I-.+D
MNEUXIPC"$D9[&D;(!,PZBU>L":^_YR%NY)TBB%<8$:+DE(=0P**S$,8@"-(B
M8<53IRSB JCA%UJ0';-#4[\4[11#24) D&&4-00JH=A??V)%_-FTWPK>\
M*^\4092D(=(UD J8=Q9-*44V(EC0PCM%$$.IQ*,,D( N9Z&4F_$D3J>$S,NT
M&A&G;.N=(@BS5*)0#YJ 3'=9(;.1XG=_5@M?:VSE-/!.$016JHZ@(CR"+&YG
M 16C+XUG?PC"*94X$F 1\.,LLK(F9CF>O[SYR2(0>TU>\U7LP6PIHMF9=XH@
M)M/L$L4$N< :G(5RK@F-WF%,>2=K@+0B;HJ67A]!\*XV@TNXI BV.=YEX?0<2H4:*U40O8QA!-TANSO3-X@@%5>50@%+#H,#5F
M_62**F^=\[371Q",4RB=SY0(C( B9P&@^Z#2)YV
MIFKLG2'8-*[$IR8V 9_.8BZ[6(U<1^\,P>9O);X$6 3\H$VWJ9%FXYTAQ<7=5J)?5?U5@#JQ:V;E5'[V!:F5,YX(U,!_-@54K.^_L2[4R0Z;^B:J5
M72!PQ 5?BV (5( Y^&IE%PC<[PJ,B<$><(YLG:G*UAP58XC2>N
M_$81S9;>.8)C!+69VP:$K:;:VJYLA;E/H[5WCN"D@1&-NJ"P567;N94SG:"%=X$BVZ<.56M L)5;,[PR2Z>9=X$BO:<.
M8=MHL!5FV\@CFXFLFT$W>]J[0)&R8\"1"(2\ EO[.0)+4-G#\&%"Z.SR#M)"O(Y3<-,7B:7][AWB7.71#*9B5 @2P6X2K/\
M85A*^)S&\G7HQI/>)<[M#3$E/ #(MOD_TS3+'FDZE!X]6'O*N\2Y02%F85MX
M9-OV\[5),II7B->YO4K8QL-PF-B('3D49!OV3R0CH Q6&_D:1MHX+6N0SR67
M\"5MYUTBV(20T\"G3HT*V3[\,XFASQ'(^\6G?Y UN-($&5$C[Q+!MD,5XA20
ML&VU?R8)8(Q9A)8+-ARH$ZN#"MNF^@]-D?O,Z)P@V
M'ZI0)8"";8M]*>9=$J1C<@\NDPX_JZ1^]12)(PFXF]!'LWGL@]29-N0!$(8B-&1)K#PW8!VH8I#M[]*&;[
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MWV!PODN6&Y>#((_>9_=4E?)<2T@FSR:1(\NPK1AZ
M[2)8\C?)BE:\MBN,"KB[F#;\[V*V,9J]I$\$/+8@BLF&W"^III8TA@ ;KP.]
M(D@&L6],]G376))RE%%F:&*0Z;9F]3^D3"(F#O>1AN%U?B6(U!
M:P""(,)@CZ)-DS!6#++4YFLRH22(2MMG>87CE.;1/\J_2@8/22M B2!%I2WZ
MM16"+"5ZE;'!S@\]#$$- #R?/L9^DK,*\).QO/:<7@=>'\-5,6T;@XENL"5=
ML_2L!/J>?J=13J[3'[)A8/=A (7  VB;<)$>L.5BK_0",Y7F4"]L PI!D,'6
M-M4*=6#+[[:8O]A%D [7-OM:2L&61BZ\#9?=24_8']09=MI]@ H09-RU/BJ8
MJ0=;AOHB92]MYG1Z"1;XM:G> 8LNXYP#/WPA=F:(9L=N- 32"%;TM=OEHL67R
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M,^ T!^ (PI0.K$"H"X$1((I>/H' - I@Q9PFN,3%'=R%N;D(QB 15,Z
M!4/]W8\+$ZT0R<@%]GT<@7-IX4=%JZ*+.#GB&[YO4+R=]25NZCD&Y9ZS3W^F<(
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MQXV3AFS ;)0]U7#I;!=L(?5M2@DL,&&-O[X.E5"XV0 P(DBO47Q 0*J6#A>ZQ"?VM9I[*PB&D77N?2V6Z.0D;E)50:S;W.1>L1
MEFH4B 9(78R'$'A9(7MFQ0=#GTZOX)L*5:QGM!J#^JRN5E@=KV5-KU\
M\S  C"Q2LX;RTU0@O-*EU>\$OC&KV_7:"Q,#QE24ZV%&%NIQP#NNM4W+!F A
M5L3=(_GBYP6-\ND]R;*7-S^Y/+GVIYEP1:-J J(CV-$U_=9V=TW4&!L+!TEI
MN>RP][ZD9U_ #7C3XX7;!H1&L"/;'#$2D(W%?*3,S%_\DG;^3GRJ10RO"8B,
M( C0'"]BC';O>5J\OWSM2]IC_]/[7#@M0& $IU*:(T4($5FL9H7XX4="PD'.
MO&LM?V+M>4"&X/1 $XM("3P,P94P(<%(21OFB>.A3E/V1US 
M KN<["X9IG2LS$W1:.5U'5[SO;2I70'U@RZ"MN"Z.KL,7*EO59!%BND0(BP;
M'QO[MCY-/Y$D>!O[5'5?N*HI* G/M>%ZC/+-00\HLGC*KM +D=575RN: EX<
MEXWK$:-+*@\DLF")95)Q!49LLXLV:V;W!@SE1K"H"\Y[V^W="T?GL,O 
MS8[TREE1V@[F?03[#$OP!!#MZ58G4P8;M
MRNI9_MWJK'$:Z.70"%N!A@[#V5%BQ'87M4!@C40)23L8@*RFF!KDQ"CH,&)Q
M'1RV^Z2M\8C+\;%%J,KU<7<-]!?_OU.ZF"4RQ1"[^S" 0YB36&%D%4'#=IOS
M5W\, #>D57Z$PC8 $E(:)0U@PD%P;JBXLZS&IC\RN1V,C3NTXQ5"7M^\REQ>"IFD.11&,4%.UOT
M3 *6D121[.9G$!> AE5!O$K'DV)V5.EA>./3)$I&2\GO-1(VFGJ%UW5W=^5J
M_JZ)1C\5I(D7P6=B,WU FC?2+.V"31(+VCJ$C)2:VO@TY7>@<,$MOA6H<5Z_
MP*;1"?9M;2L46;X-7USFEBF=4E53&$5PQ&6L<*U5$!L&
MVBR?9T)!V$^;Q?G5&2/B5H 602E3O8]5X!*IP"%+]YG7:U22MO$<($&P@5F'
M)@X<9&D]BUNEUZK@*TD2M@&$"$Y2U2%, 0U9)D_-R4190+B1_D%S"$YRM;%.
M;5!=THRC=D)7[.A3 H8[=1BW6LJ@$X':?=CKGCH;6)?27!4P02>Y*B3$?1X 
MV%S/2",[(G6*-B"%XA]"J.6Q>(VCX%O.BDW#-[U$JXB5R)J!J.:&#-"MR$BBQVT0"NN^(%=?MLJ>7*3T(C%5S_Y
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MCP''(!RS)6!Y@..=W/R
7K8&59T\<^Q3A.;"5)V#:EY6G
M,5EM)9)<$QJ]EX[J?#B07S@A>MSK8=@A$-G]IN+5.)"M"+GC]4.19[F?A+#T
M,/4[UIJ"?A"D_33LA^S@LWN;SEV6%2R:D [!!Q_#THZ97Y2 BY.0P'$Q(G@ZC>[QQ!*I YZ9848?=2G\7X
M\KL?%V3PRL(" 6_U+'S6ZYWA&5H-V9( 0I92LI!TD(0EM$QO?)4U YP.0Z@*
M]?.'4S4<9#DFWQ)*_#CZ!PD_@S)8L9B'9#6WRU9JBI;@".P;>5J(FLM-D8YV
M8#*T-*#%&!PJAKS=!@#5H6MBQ( .$ QI)\+08.>@8H/G[FK\-QT;/'=V>DU'
MR>:QP?,#.<[6<&SP',U!-A5YQK'!**YX[#%J8
M,U,UNG@NC&0T%5WDRG#SD\^KA;($@@=DSCMCKV(?;BNO4FXUH[.!#ENF*9"_A<@^V
ME@R9UP/=4N)L&9HN![)QFN1O8)!3XHM&:7DCD!M!>4-SLG218]T+9_/9QM7@?#GU+PV5=P$P;>9$2./T
MNB0(5OY&" \A*6F#KU\$]&&C"QN+D:L=5.!
MNC6@MKHVU;^!0IA:M'7*XF)#%9X40
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M=4E5-06\"&)PE1G5@XML 1YD(:X&.,(5S&J0++3Q
MJ]F9RCOPXGZ2\"5EM[,LBU%IY-_K-/=Z?32E;5H96O65@BQ4IA)<^57K=>#U
MNSANA=YZHQWUUNZ2(^L3I4K\XR%;4!I C.DIM\
MB7Q>%0"1Q=->HIQ-8@ X>H_"PH\5\S3W>4!FTRO&-S%+M( L'75'TN5M\R!@
M]A9-7M*;)&<%0U7CM&%/7O_<:H1<>VZ6<*5)K@Y0;)FC3GG'-5&W80"J*;KC
M+']Q-J"I%V ;SP$DA(E=%@=T#GH!DJ@7X%+0I8R_=4?5RW'6.]U7M_N
M%1/:VO:?).LIS,4&8O
M:>['Z__.]K>_IOG?2;[:^:Y[+*'*.[W>F<.[<]K9.+2L/(%].@MA6H,[R\RX
M3>G\)_:P\PAZ"B"E(+%"M,8'M=
M-,=(.F8'2+C%W)_E>U=KJ\!!D$?O43Z]EQP$J=FCUZOB]32$2W1THT9O@*?U
M6S0;H6#S&ZNM@;_.8.RD59\[3Q2NS:HHJ"3%?&BG+2[0G[8X%R9XBO 6W-8-^2==WF]'H(2*_MGL0)%(CM7U*!>OQ-V
M42!\I.^$^B.R>6,KZ'S8IO.J*8S7ZSLT[OUP;(U4B>Q854MJ<&_3H/U]SFRM
M:75.OX&9ZK$=++/O<#GZ(.H)!F3M4
M2I0?A)'JFSN_*-@!KH=E"\ 387R"FJ_2)*=^P HXOA Z'KQFY5^%.\>M2@%+
M+8?A0FM[SPYTB/+XXTXFR*X27HT'"I$^NJHQNEUI@!:'.<;.[% R4+O0/[93
MFG458>S"B?0C.R&'1T@@T6%9\ /[B)JF!=L)4TOZ$3N)B+ZM"D("B-![_2D]?-R*@4*/AF.W'^=@/M8"AT:#0M5H8I/3+6C@MXZT>T]$J_$#\KZ*RH[=P+
M=.'^+>499!G),]#2_1C' 9;>0ES*&#\D3"0I*9Y<@[email protected]
MB6DV^A[OM.]LF&T"B,I?;>P=WFG79CJFU-6UP#A_.&A86W\YV#O3;==F"J.1
M@]TPU\:^>5>84;B_OGG7:L)3$[XYT[J^N]<5)A#MKV_>[>^-;VY*%EK??#G6
M?)JN.6NWE/Q9@%\Y50RG&JT!O*=V#P!6F=J5Q!F,!7+$
MB:!6O55"-Y!B.T]YY6=OX'VR_]W\643O?KP!_3K*V"X*J$06)M7M Z8Q3&3;
MW@XSU NVXX#7A(+,>?1.UO0C,0/N\P -03W3UBB7Z$!^(JV=G(>K=#R.\G)T
M8X:9)CF@(TD 0KK/?_W&%,[4$GY+@C0)HYFJ'@L8>OV,/+S&T
MF=?O.5L/:TNKREO5.K9RN,HF]5C(%O5K64@2P[08Q%@$09>JG8
M(VC':F4Z[3A<+79-#49#)5/HMR/!^%L",Z4@0)^
M \"(H')?K4];M$ 4PVTL\8);O^*11F.?3K]E9#"BI'1PA.1(GP=A$418&^1&
M RVRE(DGXLA4D6P3TL];[579]"
MC+2YS PN&P_#811H4+'S'$B'(&NN:1X$,)M+A>"2\ EG
MG%VV^#"\&4_B=$I(MHIZ"OQ*20L87A#DZ33#CA;4YJJ9\@/LX'[!N_P1^,%/
MZ=2/\^D3,Q!_*LC@4#<"HT)0(*8YBG308JNGJ9BLRH&\;]6S=S+.K7#)BS>V
M3\AG4,9]FF4/R;,?KZTY'V,?O*$_BV@B& _-.@#P"+:YFB75!+F =F0WMEL]:B^U51\
MK9"C#G&"&(<<%K)DR[IEAOI6S[(W40JJU#J?*A$>9/F-#7"$+'+8'%D64@JY
ML][\>#X(W"590?TD(%PNN8T2>";R8W@\C_*B
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M6&#P\06[UUV;R"3;^VFD;\!J@3@XAOO#$+@%5G0Q=/ .P
M;< $8;#5=NFSF>"(SFRBSJ^^#_U.%A_#I @R++3Y6!7
MK>\_T9'F3[@8^$1FGXF::9=).A^;>!5AVFTEKR.:WK"UF%"27.S CH
M=Q*-WMCU\^^$^B,ROW2>/-(HD&YCMB<%L."PRJUKJVU:C\B"3?SPQNY7^[H-
M?[T$[4+C-S\G) #T+ &WHS)>*R\%'3M,9V[#5BVJ#=FE*I4G%![M*Q':33:/HMYRDW],8>HNCV7')MNQ8*@20X'A_;7MF-ZKU
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MHE%\MRE--;XMR:HYSGEOM0>5&,Z+_OB8\=+C#GW(<
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MN9!2K$%O\6-(=Z=Q_L';B":6X:9&\2'@M@^-"_% M?6 AAX?@5H*!LBUA*1IB[@03#:/""D0ST7(LYV
M:=J9PN0K3W%SH[B0<-V'1MFTL\QP8PVJ&OHV0F#C/J_;N PCG)Z1CSXFJ=QI
M]%I:K74YS&R@W\H6"
ME-#&JD$NB6@)P:@0(UN@@A"U*%WP$1 =#2POP K21=C:RQZ8.+OLY-'SMA1F
M/WR+HSRK?D/Q]D,+;^6O_WZ7$Q=&MT:K]648>[$?DOU1DH6*$U,]F\M$5XF."
M8]()D' 6>5FV6C/'*3A"!=#8P\< _]P>B3:A7HH8:&X?-(,+S[4%$-M@5'"AAW(HWY' B=(,"D)C#
M]C++<)X!5O+]AL8QS7'*Y2^P!LI%N"DHJ_F]N[NXO[,/VV$(]"$KT[]IN):Q
M5C!JN?:6P,OS/8SA!:IBXK.#.6_EE!_,?<6UQ]K_Y JT!7 91K@4*P;7I5[V
MM(P#^K^+/W;ALQ<1IK)E?N:EZ3Z,'W_QHIUL]PND-[]Z!+Z=,?<$,ZDS!;[JJ1.9$6Z $_AG%,]49V*@4K
ML\K97 >;7LKEW5_1\L,Y8C]<_*^/5[\LKR\^W-\MT 7Y[>H2W5S<7JW.[?M$
M+<_";S0:V&
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M!5G&9$N8;'XG,FK?IC3PV#N7HPI)7A:#70G&'\"\+5!/])?.++5J@F[4""GS[\E> Q&;G.\C3T0_6#%)
M^R8@!=-@]%R.)-,A/64LSUH03Q*].V]\WI'7BU=C@]0]HS$Q'DHKYJ"%RX"J(&DX2 W'D4DB53GCC[6E> S%;
M\IMTAP.>5=F*2:<7\\LJ+1F%"97@6/#:M-)B1S6)J:JZE=*"C+:,#TA,US6;'2,W$VZ;)F3UE415
MXI"+A@J#L-I:=?!K.-BF99E""CL!-Q#>"I-RSY3@$E060VOO)1Z[!(%>O"S'
M* BS;9*YD*>MP-)@M,T=2[C8;*-DC_$M9G%,+9L T!JW#H@\7*'!DN8D+8@<
M-)DQ8M73C;E^S-Y"  S(U?6E^]5+VME#02%49F /5$8!(ZYN2%LP,Y^+U;E@X6
M!U.*M(!H]*+X&A,.BH0,596_P=8V+H(/\#QP.[IH53W=4=;JN\HRLGNUCRC)
MR ]<@98/N\&:9V2JP-FRR]%[O'G J00W4BKS%="D,G"%T%AKM$0]0*'?"A(7
M"D&KE<)5%H-JQ#2TWHZ"EH#*$K1$,@B@]=9Y:$F5,@PM@$9,0^ML%+0$5):@
M)9)! *TSYZ$E5[F
M?39E^6VNJ?E*VSRW7*9NYRD]P'KLX/U?OGGUZA1MO10]T_8_H],W
MWRW>O/FWQ>OOWJ"L>"/0V^5/21K^ P<_HQ]^6+PZ?;7X\?0-.P;_X?O%FQ__
M=?'##W7CD(U"4<')A;<%51CD"C5+ 6C.9NY3[&6[= ^RFJ'&QNUFD&/^J=*B
M4<=VIK:9-P7#,7YD.0V3\EW:C9=..%P55\YFW#W(M:UBD+F *(S8=+(1)QH<2:"%$J%,:HI%MT
MWG.UG#%RH&BT+-X)$NMXP2L"U-4+2R;U!P\/%E
M8?209_)UP_[-3]D^>:"QA=<-!SCF7S=L&I47=XLKRLL\3\.'74"B57DRG-<"P:YF
M(0*RFVR&G\*BHQ@OB
MJP4Q'512(&LHO@2"ELK90YXNU6*7M?/6"1WQN<,C-7:@5Q_F:,*N(G(!8+0$47FYF% ^I P*K(5W8A=2J28C0Q%6'
MT@EP=66!(FSE4DH(4$40K GU8R7):L12#D1M,Q5+8Q'7S.9,2E":Y#PVWR-2D_V6"V9MO 2MX(*2R\*B7BG7^9B;9$=5/E
M:9I)X"A4P#]R!!A_@\>V7H2S6_R,XQU^ER1!)G_R=KBY^:/:8:ZY$TS:#)7M
M%HBU=.=E6Z 0-VD2[/P<9;2Y?;C+ ,,=NBK18G+%EN6K->/B+HGD:_U>2POK
MLCZO_%(L8X]>L3:(-G("TG#&MVZA6H .?JDH@88Y++]+DRPC?F$M3;?OM#*.
MX2Z/?1BPOZ+BSP[D3$*8W;(_HZ\B\H^O[2-V  -]M H!8+"T^Q:G'DU.NRB*
MZV> %:J$QGQY=PG_7('WJBVJ&COS@M X,%Q;*L? (].L/ENO0.&4JAPGF=6CLFPT0!K!T)08/CU34@3>R:3!YYQQFX1%VQ=Q3DFJ)!G#XA(
M+*0/"+GG\P>JIJ7-+%#5VJZA:,E0_*DT#?OVH$(/G_@ @8XY]'^,4^Q%- WU
MG1?&=&);QG#J:% E*1<4:$D1BTZN\:A+]39$_D7IO7M
MUEY8%B.EA\TOVL_4C)=1KVSD=#*V9*O$-23C/:3RP#2"VO=Z0*_1=WY:+L/D
M"J#PP>K@(=?2PGS?YU4X1@\&"OG7DSZ/')
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MTR
MS!X=(G/*=L?".W$UJ];VZ\ !_UC$]PWZ,+B;K-A=KL97ZS,O>[J,DA?(]2PY
MF86JW5(I^+K=U5Z2V"4E0(S"J8H"$,7P]:VA6C&ZSZ*\W*0)W04&;__35Q\(!
M?XV:1,3F"PO4? ,U'W%F8IIMK,Z6=W]%E]>K7^_0Y>WJ/5K=7-PN[Z\^O$/+
ML_NK7Z[NKR[N')B6IK6B@Y"9D\H''_]H5.479?7*+Z8B&$>YL8,F^%28?
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M[:M:HX;2,@0*.@SD8-025L5
M[&3B%H$1?Y?2F]?.!$@.@[S:M/7Q[L+>[<;;4T=$3^)\/]T1Z#0;ZU&[.7F'
M#I@[4'+='5_977'T7'2(6CTZ$>V<;#!JJ;*]QX&>_CF$8YYZTOE
M ZU8HZ\8!BY1*"33*J@]4=G($RUHML>LYTMN3KQ9OKZ2E
MJ+GWR[A:W&S6XIA\=Y2U'^QYA&ON8]KZV
M8[ZB>!)BQDH0VA]PQ7?HCXRF#ZD_[<=%G& >0ZETXGYLOLZDC('=>6Q+1*0$E>7^9:
M%+>Y%FS_Z]:5KFEDIG>3M]7--2ID?='+ODWKXY:KN#L2M!9M\RK.B:)">G*F
M2B\!T-JWQ %Y( ;8D)4I(HX9&T"L91"$Q2*!R!6%?C\7Q)4<$# $E=8EQY_)
MVO*)CW&071)9B[N==T])FM_C=-.\M":U+& '%NK) R4;J$;!"!'5/Z*D1?%-
M0GR2$VK4(K>[DIU(Q(V7[]*03&I$3)^X_' =$KP1 V3O@;&+VPZ8GA90^7KR
M^BBU.+/IVB",WOX,!X7GP"QGQOX.G.J@\A%^GKRLL#!W+4X'EV8:D@QD8I7;GKZ-1VDL!Z:(S@^U325
M:0\Y'',;]B/S*:[J1YL_GHCT\/'ZO^\>GEU8?EA[-C.3X=
M:45 SW*0"9G?6*_6]9.-W9<RSM7JSMNW6DUFX"R?;TE4:
M$'6G^_8;IOWG3>G92--K\4LW-N@'CD,M9_VB*:+78BT'VBW(9B/D,,)N11&(
MT49KY^SK5R]-:2W33SCUPTR:&"XGLWK.-2"%_.BG)$ UA3L'6MJR9%Y4AOG*
M5U4IMA9HNTNS'94Q3Q N.Z.M7HK^B6^-L0M1/P 89:=:Q0DRF[!+LMK2;,]H!XNE:6Y)T;];AB8%J/0,68U.$@_#5Q
MPSBH=_I7.=Z @F[P/LS'U33DXY!;T+9"[A2K3<2,T;L3%3M,TA,F:M@1=5V+
MZM2K:]J8Y4)(5+:N7G/-*V$P<3S-I
M:SI([)N9/@S-6=@J??3B\KF ,[*$3J(PJ%YTNB$0J5Z:6ZU+S^!%]Q;;
M;EAA-"UF4,,-JMA!OU&&$./HV)W! 9"?U&\%@1Z]$O/6R,*./
MNS6LW@M>Y0#2&7TS&")'WWA*&OHZ,*.B/W0,YC=&:1'D6AIJ/S:KJ1YS,]3%
M>HU9';OBZ>Q[[],M,0+-3$6=3HS/"EH2]B%9$U>/VQ-R1.E1]>QX]5[M#29\
M*ZY8F_3#^HKM>]"Q6C4'WKO=0X;_V)%AOZ"O6=R3[RT_A3*D"BF,PU+,.^<6
MZY:(-46T+=D D-8.S/<*'?1!!5* R2S,E]:&9FU"
M8O7;",-2,"?HW4+^Y11CPI]]O'16KYU^B[[email protected]F%,SXH LX6"SCBH57)P
MT7O:GGGR#H53;ANDFS[Z-!1C]IWU\@[I,HI8/='VKR"/Z\(ZL/(>.TBRH5?Z
MRE8+1$C+LKFM7SN%13T-#KUYKJL^@UE0]=E6BZF6%X=$K#7Z,)__I"$?E_Q$
M:$\VC!AU(-N>_=V:S+75R>7_C-.EP5""7T7H!EEE,3H(:#7[,1]VT)23"T:4
M]'1YVDHZZ#I9U@MR"L&C],L%+\8KUZ3KC6D@L@C-T:5+Z
MHZ6"L.$4 TEO<.4BR/S#V65*A%YJ)K5"A+[!=!FK*X;GR[?XMC
M_VGCI;\K_*&:U/YZD9<&L%:L29QQ?U M*1>(4A791%W%U7FR\<)8"W5]4@=0
MQTFCA[J"S$G<#>M)C3N9DJQZ.T#ZB)3* ;2U90  S:E$$H!& $[-=D*)8MMS
M'<:87:L:O^%M=>':IK_.;5N;?/
MWN/- TX'4*((TCB$=: P+7SG0"E,(UT&JB&@JQ%U,,Y9S_?):_H_F%
MA2 O(4$@_IK]Y)(_AXGR+L5D)9NBG*Z\G$2X!$Y# %=BR<9FS.(9+V[Z!H1?O\(3C;C$(6UZB]![QJ4X4MD-F
M/PS;E4(=AZTOCQ(*^W""*$49B!5JQ.#-9B^-P_B1%IF[>_)2#$B)%Y.8O[4L
MYIZ[HUPVI2A"K+%3:>XJ/7#7CD%*L(ZJ,B5C<#C'QRP>.DTX
M8K+CJ?9G4/,=5'VH*+G<^A0E&C0=E_/@IX:?^/AK'NP9?2LQV>"Z.M U_1(D
M251"9>.%1(D, X\CTF(G=7-4M7M 
M4 ^JACZ28#HP!Z/WWG\EZ=DNRXGG3#/%C#?4V#AT!CGFO%#Y=V>F,_$X]Q&B
M&F3KRR) RI"4SI6ED20Q2+@X0;KC%$EPQQQB5 5_4FN9#1QR- 5P!FS82XX#%S(.S^4(O
M-B^D'"M1?XF\K5+=U4 .AEX01&F$(/5>+T-F;,Z.USE;E)"8[YR
MKH1_<0C"F4VC\ZM1PFGAQ8-U?
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MA\-5W(L+B)7(" 1MT\.QX%:E5P!T84HU^&H9CKPFN_O4R_.R*J";G$A
M#Y(,&F'+30DP
MG5U_CM J%+ .K4X'UR&0;4^WO;W]3H]OX4:GO[!T &'2L1=N;<0#;S!_:O<0
MA?['/(Q8"*GF39&8*"G%
MTA; G#EVAZL&"C3[%TMK5JX!R5)#C>W-=M>2!*86?*Y=2D$2#[=PCA.,M06(
MW'HO[VG%O="+0"CIMK<'E![?DF41:8GJI@OT+DVRS.Z1-E0(ROFF^KM#.!_"
MC!#J8L!8W\!"W*.:U)6MJLQU"O>GCKE2J** &U%WW.RO2?K[57R3)C[.0'ZV
M1V#/T?8YEWA:VA2%,2H;N^5K57)4S&^+%O9M08X=H;^5 ,<"[B_#.,R>(>@EL3):*RG+V9N06
MDWGH%F^],,V6[ 5S''NQ+XL\@J@ME(Z"R,0G8F9Y^3XHHT,E(?+B +5(
M[1K).-E:?T4^Z<$!H]$ 'E\72Q-UUE?M=S@BGWI\AV.<>A%A=1ELJ/6S0A7/
M^.+3%L<9SFBZ7_M,XMU00H%;\UOJ5#+ ^
MVF]Z:"C#_ME2.^ZFO+BDTXDS9TV#$@[%4.M6#@!OO-J@YT\JG1G,MJ37EIZ2
M*,!I=O''+LSW'Y(<2U6!*XK(E
M-31DM.P-V\;<$%WD9+JGG&WI$@F .0"MC1(X2GD&"N$PF@5B5&QY7=,YA3RP
MM@;*XNBHR@'\Z65*ZG7C#BIAN9)R@#J;+CE&MV#@.I0P*>3Q(.0ZB=?Q*'7Q
M#@1<<6!86@?CI1>FOWC1#B^S#.=D.>M1&PE6\8"J,O4AU.ZL5#HR:0%R4;[=XTI&/UQKX%6*2&4V?.5P7*0L
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M?B_W&GL9IB[^:K--DV>6O*?.S9%2&4>?7(8^ZNK6J-WB-!VS?'@Q#KP$J$718;LP@I"=U9?U22:"X]'+@M-UHD)@NN6MNW*1C*P$NF
M 8@9K#7O^[O-CF7AG^-MBOVP>.H8;R-,?Z#I_)LDS<-_L-\+A9#8UG2?,%]Q
M?KK1X8K.-UVC=M\+5/=>7-II];] /2M?=,U\:OM^4XQ2C!\IFRK[GG&PKG&6
M(:\U8D'K _8=PM1&Q)7*@Q;QM\$T%EM-U <&(C2:1^U@FG
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M*EPA7Y\N$#U/
M_*Q<6-<,9_1>0S9X/(Y+G>,UNS^#LW!T;DYC=.?T?M ,R\HU6BTP:&_(6\.$
M6\/T3'[].3I+7=.?VH>.L_OC<:UE63.:'3&[#QWXUM$YRZ'QFM,KMKXWL^,S
MM "$#&#'Q]7-/T?W)C2_J?V8PO8,.ZP'M2 /ZD7MKYC69B3>F4#7>\2WF!89
M([\_2V)V57?G1?HQ1:B?,U5%1:O
MR?FWZB.-QSNK5,G $3F?TV5,R>72N?%(-
MN1$.^"=S_[-J\!BC"ZZ,Y2R3QUS.ZNCGE-:&QMTY9123G\N<,DY#UN:43J3%
M@3FEKK9C;TZ91H-'%LUQ91A-3B<'^ZGC"7B+9\[N"Q])%*U-YG>!F3FZD/FH
M$;<7/.J]+Z2JAW@JNX0.>*WK?B$&5,V1CF$ V[F'\8X<-J05'"U
MPH7A2@"FQWC0BPZ5#6A[T;?[3GF!;NV,DA6=!;)E%^K&R'/C!=M&F*O-8,7\
MNS4=+-K^4:Y?KXA@89R%/GOMW,PRM?_-8UZ-$")=/
M54*#"(9&]AA.'^ !/1^K])9&UU0%K&5$YLNVR23@ZJ#1QK120MD<)2EB!/9K
MY\(UPM5$ ZK#,JJN 84V581NH.M:4@93@K!KEVI9PE0$@II /Y;AUMI6Z0*N
M0^H&Y+K2@$'7"9;,M69F-4?O?^J,
M"XC56\K;/5:?JGT+T92K/92QH_/ !VO"C>0,A=<^9A<]N8;^?W;&"%]C/D7C
M<_3[XGN!IAP\F(.C\^3PL3567^XS]LKC1_N?)WU"T]IG+%'GHB^M8MYD#F#!
MX@QVCB0G,^ZU%%)PUY;*Y@S^!8%;!T>:\CAR:#0EUR8]#,0&^FX!;@"C3UFN
MLFQ'!RA9^\EF0UP)??\WC(E0,5FK$=_R$N9/+P4?I0_'68SS9!V6E#Y]&#&C
MWFDH"6&&;Q@]*YEZ?+CX?-EJM3YC_;/WEZ_BL[K_7TG_)0XJ7YY]P/EJ75&R
MARG9[" X4QP_/F^*\8E9J%MHF2:&J7:F%7$P5^V8Q-]MJFQ5RYB@Q\4%*LJW
MR4/Z@FOU$42_4B!_96?OO8<>R+^0Q(_%W$_NDW-[I/% P8]\&Q^.".S@Y$!1'=YZ,LZNXD)&Y V-7_&&?/]:39-6H
M&K908)6K(SP@!<%WIM-1#>P>CUMXQR)5E6#OTB23!85F^=K1&?WPF,UIX\47
MVP;.OGKOS\XNY3@_A)Z6C!'#BV',MRI!S!<'*CH-:0:K!2A.1"O!/(/T ^^R4+QL"N;0[C,'= 
MZ0(<["*\6@^O %MQJ:6?A\]AOK^6U/$YN$?#Q04.D9W?A+'>T&K=*0C0V8\5
MN5%EAD#5J2.5@29"0_<:^T10.&P"Z/N[BT_;,,5!M5N1.7\EJ7G'KY9FN#S0
MJBD/M*IJ4I6TZ$H><)]JLW&OJC\Q4L#6WH,UM;CS.$A%@Q6<*ATY<"BB:U'<
MO*9E3M.N^E[*RR9><=FDVAAMZ663,JUTPI?WU)
MKJ2KPQIH:_:ZR3@T#*"(P:BJ1GS4%R]0HFA2V]C*PZ.$/*BV->;D_"0RH0CY+NE
M)Q04J5WLNEJT$.JG0)4,]9S4M.NI)8J&_J 7-M>V@$((,UJ+G]OOIE9(TU@-7E[R3^2+DNGM 9
MV4[<*1(/E[O\*4EI.N['.,!I*R1W0S"5O=UW7R2FDZWB-M?0,>,6
M9UU;*]8RKEP*FQ$VL/23"3%S%,;&"W*>T.=MYS$V\=>.R=@D8P;-DJONFZ/F
M4VA'O]4]KF&?X[;(I\>>Z++
M["HB*WDK0@E$:]R+FN ])5C&P=\(@?TL%K @C0#HW,OGJN&CDT2FK0/4R+! 
M3 TLM8PJPI%L,KEA#&7G0*QBM+TR#[!:=W>I,9;6GE#0&+56%?_ F!4B-(Y4
MHP!II(T3#75,"I/[ET0;)BT:ZS!I\P^%":%Q&":<1E0P$:AC6IB0]OK^I$-E
M'RH=&?@7^7?:B^;<'\'G_*WY*O_0[&NE#"ZX4N_B"^"D%G1,(D_DL$<2<:O66687:Y]SKT'L(HS$.Y3=8Q;?8WZ6T),Q;+PLS]G0W!)83?\?\
ML<_$X\0=^)3]TUU.8P(+5'R$K2);GT'5=U 2H_I+B'VJ?!X>.64PL\",.^29
M#V,6_#Z0==+@0Q*GO"20.>+P;]B;3R88'\G<4_;$-BN+EHE10VSW5UJ; R8V
M.7"$\]>TJ+%@6F_W+?5>IOB/'8[]O2)7"$1MSQRD,O6!WFJ*ZK;.)/-HZ$F(
M4:B2#%X%\3)ZQ$W_1PM./WL1]2T#BT()!C7Z,'_E0T,^+@N4$#'7RGYHD2_0
MX'[ \G6 *23UZ0^X(;=O=MH Y?+^QZ'3G DV;Q&T9BZ)N0G:&S]M?XF8PC>-4C
M[<#FPDR
M=#6T)H0C5&5VL9C56U=A+H4>N1-H') *",=.X,-^FL48U4$0*=>;P0UBLMF$
MY?$X644G<4Y8(I9"E@_-TAEPQ*C9C_F-HJ:6IM$IXXE1RF7
MVV"-UZQC,(8<&>EVY":098<^<"0[[email protected]&S]..8C#6 G:4 O!Y'A"=C+
M+UYT0[#TY&5X]1"%C^RJ@>K,1;(_33<568X)O]V=>CA^3=+]:TYJ&58M $1X8W:-Q>(^7G0_A
M%JW9:\"D?8WOP)DHPH&*[J-[$BV;@_DM]J*++">,D8EEZ?N[S2ZB)1W/\998
M:5@\ N9M\&I]DR9;G.;JX,/X+HT#_0#I^TBGS2C*JX8.124.U7$?XM,H^)!;
MP/@IV67X;NOY\LL_PTU-W_@=XG8@J%\T0ZR= R$$U5#W;I,JQGFTME?K-7V=
M4*GJ@79&]3S$)_<0#6OCE(:%P]M6KV)LW9JMSG'FIR&K2= X(,72[,!^G9RW
M9..@GKP<69Q-HO Q\Q=0VR[L1P2K2N4Z;72/#NU'5++W@4Y[.LE)5\U&N^EL
M@63;%6>682OC,)[4^1J\6;])PXZ7[CQE>/J:8'5E)5XV2]D97CS*^^9N*K"TB
MC5'=V@$X@,:_O:P$#KXYW[),L;=:7WNQ[!'P=B/C/J3#81\8](]TYJ)_MN\5
M^,'L>P+12)I6>+,>K!9Z2O4/D5@"PR#W(FC0QJAH72_V78&*6 W#P%'I8/0D
M\F%'G=!J?;'91LD>XZR9=@73B)3"Z$0BYYW;]['6] FANGUKC6&Q1IN>&%+6,+H[@0BJ =5]0+Y-?TEDNU <#5GB/!R#JN6W?7DL?F9OK.4=Z^NY8\
M3#?ZZBMW+Z^\"WOMPG-ULZ)LCFMZ HA93L_D4YI')0U+^G$C85,BI^3&:BN7
MW9FPSB@U@G(V83JT -BK>+O+,Y9K?PI/(QZBL@?&01EDKKH@6"!&@DX=V+AK
MZ$6(-Y52[*+KNU'H^LXI='TW EW?.8ZN[_31-:@4N^AZ/0I=KYU"U^L1Z'KM
M.+I>ZZ-K4"GCH]&8:(YL=&GMRMMD[T7Y_I:&*[R]( $60F0V+JV2@ M.UP0T
MJE"2H%L6;RJ(+$85#I$F&9;&.QL2I+[PCENZE8:)ZV6NXO?FZ
M<0*^^?IOQ9^=R5*2#CA7>4T]V@:ALGO(V!WC_.*9_.>>?$_]-I68QCQD)/QS
ML*G;(M88T=8.!8"4NN"0!%.$.31]P#DM:'.3)K2:=?"6'NT'5_%E&'NQ3\.G
M?AX^,W]97&';D=^MMKAX?T;FH0[MV#@N#QX)[J0.YT7!IZI+]+!'7]%>41A_
MC>J.4=/S C5]HZ9S!]84LXP.*Q*U;8W.NAX3K^[/OI5/8R-]5S"E@8S>[K+C
M$)HMRPYB6=>R'%]SY/7?0\<,^OHO:GV(K@;;[,PIR]/&##9P:\=G>I"JX*VALW&Q'?W,$(;^CSG P)M#38%CP@O^A(/[Y"K+=O41#"B@#>W .*[ DG&%!A@A*BE1GJ""
MEIV[9"HKG]BF0P';3C6U %3 L)5?Q3160?&K(8J! >SD1!84I1XN2 
M2.@@5BYQ@%,O*GN_BK,=6:WY^"Q)MTE:QEXW89ZMXK))5L?RO8@TS\EZ371F
M-G'_1A$XY;AP>8Q%WZBD1'7OJ-4]*OI'J[AJEY&&J/X&:G_$8B;;G -UVURE
MRY\P\C;)CFR\B'E'M$NZF'C :+V+HCW9<177B\AFC3:%#?%7E^=79U];3IR;
MW +;/F0F\W.PDJML?CND,WGX+DV'KWE#B,P_=B23@'OQ:(>I\RZ;H[+] I44]C&HU@?W?A!0&>-3
M&DA727Q&9\!T3V$DK28C;&TVD4'(,Q>/(G-VT1J5S1%M[\"9(6#L.\D+D($W
MF,TNKR!CJ7:,H&J,&]5B9'5BK%:(\7V*JC!^O$FBD!;\15/29V
MI+[:Y5E.%B=E*1A_&0?G8;0CK27 'MNA<7R/EIRK;5]VA,J>T(>Z0A?K+$.M
M[A:L&I'/K@R67 N,&
MU_BT^-,MSL.B7D[C<\B4FV+ZP\4GFE@C>[)*HP_S.P -^;@- :5%#7%K)EJ@
MFAZ5'=A]0/[email protected]%?RF-!I(W3BT/2KC59N1S0.JK8S-R7&)R)P)']R &ZB
M%,AY+^*U(-AN!_4F]$0]'B9^4O;34^HZ JQOE#965WO1F2J6 %"I:3"PXT
M^?;)QB3V/MIWT<=EB_O".+A)DV#GLU0H05JVDL*H#Y+SSAV.MEJCLCFB[:TG
M: /UT 8-6 E3 T.8:@V@<0$#TC H:Y\5EXMLP^UT)
M("6E<2BI9>'J3904J$."*(U#Z +JJ(\S+07I(B[#_C>/R?.W 0XIV+ZG/U",
M?=_"&/G5W\_+$_VK>)VD&^45;S6),50!N.<.]D4TC5!<5B/04,1=Z
M%#$[OHE1="BB;,Y$U40CV=:U$W$P[L&;#TF.Z<%RE-"R() +;!I]6'B.!BX?
MM_QIT1:/'96[:=H%:OI OSEU74U;I?SC-J/T:;((^!,.=C3,+-@C4 '*RICT
M<*+U9>?*"^!R38[+(4O[K@:_TIU/I6
M69#.K;N?\T"-KY,^'\[&YSQ/P90@6VBBOLWF0T\T'D(36I4FA-X.G(-T+$AJ
M0)9SF2:%32>+=GK,F)NR;FE<2Y$MT6IC?*)H\\<=7=._.9,@P8UDWYD*AG&\
M'QR%-MF.>Y)>S?J^@\=@,((^WM,YL<&?$!T=1S" 9T4%G9S><_3Z,P\UNH]1\KYUQW??Y[&N__+M#0>C!D>TC0#*L!C'@
M?8)AH-O./ 9Z?'(8*/[N$@:&1I;#@'A8'F-?[H\KP,MW["+?5!GS3ST);STPI1N&G!KPT +A/A$
M0%K#ZU3E46?ZJ!T'.M<(SI E1C_+]L"XO?]EKQRR3R/Z;0<\HZDAK>7.:=D]
M6GUKC[W4A>);\]OFH,,S8)@.+2%%'GQ((IIVCR<6BM.;.63
MY1X?9.*?DQO1=<*+%MQ\[EY4..:<%Y6-Q^?E1;M6;MZ+
M#IGXD7K17C#AEX3>AV8UOXB@IORH@HGC]J2J$3;H2[DX9L,,&UL[7UK<^.V
MTN;WK=K_,#OOY\E8DN5+ZF3?\C7K6H_MLCW)GMK:8M$4+..$(A62\EAG:__[
M-DA=* E7$A2:3+Z?!M#H;C3^\9\?D_#3.TE2&D>_?.[]=/#Y$XF"
M>$2C\2^?OS]??SGY_.D___M__2__^&]?OGSZE40D\3,R^O0R_W3I9_YSX@=_
MI,OVGWH_]7XZ_<3^Y>#+-W_^I7_0._KTOWL'/_KI
M^=.73S]^_/AI!#UD>0\_!?'DTY/E&Y\_6.P_+;W]7]]NWT*WLC$_T*C-/.C
M8-V*=<-KUSL]/?V:_U?X-*4_IWG[VSCPLUQ4RG%]$G[!_M^7Y6=?V)^^]/I?
M!KV?/M+19Y#!IT__2.*0/)+73_D ?L[F4_++YY1.IB$;>/ZWMX2\_O*9IDDN
MY8-!T?P_+N-@-B%1=A:-KJ*,9O.;Z#5.)OF@/W]BW7Y_O-D8/4WCQ)\S!KZR
M__Q5WL-7&%^]$=Y$[]![G,SUAE/ZO/YO/R3QE"39G&'[,/@MZX_H
MZ&,?"-^.DM(_D-Z(Q,TM:%;Y)4D"1E=TG\^>R/)(TW_T-9WC8ZLC#>-0SIB\CCW0[:1/;T1HJO[DN;UQW9'?IP%03S+
MISHLEQ'\:U!,KP?X4?VU0ZLC"[*$Y9R^4MC/"1!V2:9Q2K-G_R747N-D'=0?
MWVVDR;!X[2SNVB9#V6G4S YN,B19^Z9VR=Y@NVJV._O7^^G9''8
M,=]%1/TT+%.C*:[74Z.>EDK[BGYW#=F21DN!O(T;\WQ544/-KO;B%:NV-AEWV]S^=>&G;]=A_*/F]E7J
MII$39N4S9<,>O=J>O,9.8S7.7[9/7.9'K=((IB4R;^$'-X8"\P.V(3):#H9U
M5#VHEX<21UY0$/XWC]Z\C0K_"V _9OS 0AU\.>HNXZW_ GU9C*0TA]Q]QAB[[
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MCT@I& &7^)TKUS0DR07 &.-+K^?4I5EG*N[B$)"'V??RG/CL1M;3
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M/7X'JX,LO=W$^C7JQSO<,B"Q =:9ZF8= 62G1\T://$GOLUK)FWF'OQ-5\Y(U+9_I)VP$@I^%&?:'S)Y<&N#;/)4Z!%BHIAT.G3P)Y@AU#9/
M.5&M+0?S3C 4G>U-U=3K#TY=S3W1V,QFGT$O7O_0:2:4&2G\&6@,M\US4*>6
MG(OYR'X81O$=1I=D/H4CM-913MK.ZQT[]*V4Y,Q&:>I143?W>BZ&(M_T.O
M[S2%T%BX(D-R!Q.>.[46.+T(_10VK-Q>%MRW5;8!,P 5TVNJ%)QR@>"YA%MC
MGRP!$U[.%7\,!ADJ0KD\"78_/A@\=W=KS%F2,!-@TW?TC4Q>2"*;M>)6WA!'
MQ(A/F6#N*N#@N=-;E^CS2D1S6WE#%.Z<"D2+X>"Y%UR7Z(M*1'-;>4.G5U)K
M$"V&@^=B<5VB+RL1S6WE#9W>[email protected](%NSJ6TF=#?''7A_%CFQN26\B
MP',+N3J39VE*M *SFQ]Z?11;K8 8/HL
MZZ/86#E,R2CE@;!U+3DCB6-B62%'EAD&_V AOG<_S,/OV86?)',:C?/\%MFY
M5Z>]UT>QT8KY%!R#M;'9NN/L7A^>WN(D>R;)A-V_621CR'9?SN=>'T56ERG;
M0BBV+CV[)_>1! 34F+T,RA6BDT5;.]]X 16C'E%XQ%EOWHMWSN[HS!P@E
MM)8_\P8HKC*8LKD#P=:-:?P-$CB\-8L4@!-0:
MN[PP4%L 5-K3'H[; H;!"4^<]-\W=V Y-YUOJ?]"0YIG:4>CW?M'&I$GW2Z\
M0Q2.+Z,8HQ$V@5:TT"-6@JT?@10W\@Y1>,2,R%3J P^C0 .,G60H5O'B/;7T
MP9\S?R!(#/Z2S #!C@QD2[U^+]XA"K>9@F+!WF (4Z HQCXTG(I2F#E6M$7>
ME7>(PA=G264TL KTQMAGAT%OXW/\@)TMH5. V\0Q0.O*IKOPB1
MX,I/*QUW1K.CF^C"GU(P%TM:+3N7*1M[1RA.9978UT0GT(96)O/!6=.G
M$1E=^4D$9FAZ%@2SR2P/:%R25QI0>GB+1I
M5P ;17Q=10Q_!E9#V^K*TB3)*-@38%BD]Z^79,J*!>>%L)Q,PM)-M;,PS$,:
MY3_I/1NM[L#K'3N;G$_!&QG-POS!QC3[1K*W>%0:8BY[K?=-3/H!P"A\'B;T
M"$PE<]AMGI^W<9H^D"1_:0I8CT9B(HB9>_\#9@PIKW3F#%7Y$PQF+
MB#^18);D5M?51Q#.@)UKT%OVFNJL8/'^=1N,V?RT]6,@.A1[JYQ:U;2U*XTV
MS^W5?4VW^VT^!*/7:26MO/Y6&1LGTWLUP$42785-5=X%P$01"U0RH9J-.C [
M\03$+N)U4DL=]1#U J)#D89J3T/D2.T_)+&_A7A9!:5< ,7=FBRLR:+U;JJB
MK=<_/G87C!<,3N_%5%5C@(9BQFER((K9Z\%LL]V3VW$O?DI&S-(C49KWZV["
MK5=&=JA='HB23OE#T[!L,]W^8.
MSO)QL##8'TD0CR/Z;P!$$AH7*,TV5\N_Z0UZ* *!-M1!M5LW(KIN&8 "F22)
M'XUS7^_Y?/W)@H6S'WXRNL\ED/Y&4F"+K]E^-VY])>>W3),^8^Y:GT)%U+,")1;D:SEH#=.Q%63/OL'_@
M?AE8C7!1_BHJWSQ?R'YT#PK./ 6P,()BTBJK@(7? 8&A2 94DZJ:XM:$T?I#
MXT8ZC+OIO9N:4,XV3L+C6WIV%JK[N(HV5"LU7;R3(*WB/XY(UJG
M.SL_X/5QO%>N0R1_6MN40\?.95R9_NXS.SU+[Y-'.GXS]208]@EB17'1K[IZ
MU81NZ=!2Y^(731.F*T<'@X6FP!^,89W/KSY($M"4/"0T((_LI+>Y(RJ-DGW\
M+ @=Q4'%7-_V)YTV'TOR=?S^]:'4Z25+[ _S>3<#/ ZLE_MD[$?TWT4)(3@+
MQB$=%0H7C=SO )]>(HB\"QE39OH,B;[>Z^+P_IBJ7L*2.0G-%;-
M:=[W( ZGAEK]&2U&);A1U"Z2%ZB^1^F4!/25DI%Z/HO:>,,>BN0^"6>BPY\4
M$9]HXP(_*(B^CA,2^.P"P.2%)!HL;S8 @> XZ,L9D]/,@\3GV+AZ3T6.N?8W
M9[FZ7;ZA(#"]94T 9SN-*SU@? *-2^\XG:17KZ\D8/G]-Q$&,__$(*UE1
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MX"?W22ZU49Z9.F,V.ZBT;>,0IKKC;5)30"FMOE1N-A
M+%W;-.2ZU-([1I*W6Y/P;4@"UMOE9RN53*^PKVNT]G 4&C%B7Q>60 /:Y8 K
M@378SB6M/!SE,ZLRSH4C8+I='K@=D,I=7-#"PW*QK [#)2@"=MOE=ML!J+=Y
MRYIY)[A"8Y5XWL8C(+M=KK>-YV\*G!*..5][)[B<;SK4BF (&&U)H@^OJ/CB
MXE.WJXH[JZVG4Q9;FB6K;N[U<"R=)F0(O-[::+N0*K1&]D2".!KYR?P"9N:8
MF8(%=_*T(:WV("XWU^2]*4/1M^>G#ISU-A3%O5!'"B6 !,F=GD5P^EI1RE
M>H^N24D][;$Q/\='W^(H>]-CE=L& *.(8MBC50+34DI2@[PN!OT<]_Y)_$2+
M5EX3@(LB8&&/53%*2^E'#9*:#_DY'K!_Z$U53@L BR(D88]2(4A+>48HWKR4
MFZNW.DE(FEV ['!X.&M:Z&9XNY#)M$9W_R,BH[., =>RQTO?@SAP!*V,Z%-9
MWSL [:S>B!OVG:Z6.J0)MDI>CAOV<07S^4P)0H$". @=3%S]E5FTZD;>
M<.#4AC6?EKJ8W%Y[X_)W36 ,?K@8[TV4SA*6)7X1)],X69@\$YJE]]'BD_0F
M6MW0AL\SFLU$11ZL]@\2=.I5UN5X5S,LB\#^E;K]&;_EAVX=AHKMOG0[=.]7
MJ/O7T<99GDE*K\$O8DT06[O*8TSN?\#A26?8._"M2@.!(VH7!\
MU6YA0*
M-E85O"Z4#%G4RE=RO?$=P$<1G*_#+@<0BC"\I>/$\CG.]7ML2HJ%;4 Z**SC
M.G0KP*$(UJ.P>W5"O[9^ F2/(G>K-1;MEN2Z4/BDID3.)JQ>1'.Z6O0/XD9Q
M]+*K/HVH:%E@;2X:RZ*<$>C\W/']D6(,JR<<-@E9>?S!PF4V2#VM1T47E
MX>-^[_4/49Q(E3(6)Y (,'7!Y?8P>PEI\#U;/!&Z0JOPFO1_?/,SDE _%&>+FW?B]8]0Y =7TXNJ>+M0
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M%H9.^D834-K+^(>J^N#FQZ#<.-(9!4RI?**;.-J5S+X3R$?I25QZ1Q'E>V]?I;;P3LA=?'4058DP_!
M&FH$M@LG?2'.\SRPKLH,4[<&4>%8=(VHY:N'-MPN> C$8M+*'5.W!E&A,+&T
M6354BFVD7;B(>$O\E+S%X>AF,DWB]]R*42<;25IY_5,4<6IM%OE*H$38A<2S
MO+K8A3^EF1^RUX*$,E,JA&%/($(4@>Z:2E()=8/>V)J=<5%VX[2>4BXX73=T89(HC M'D86 +;14/8X5!$_W6I-%2$$L8.);:=!<%L,@O9*Z&7!(8?T*)V.YF&).B-;9^ F2/(O.@GG[9E4;MY+S30A4C,F8C6=A/I:\;L$C
M">)QE!^324+C J5^L,+B[WF#'HHSBPTU4(4]K(NM"S&2FP@6';*.VB[ *Y]'
M%+8"T:"P>QOD713+5LBD"X$3 4B-YQ(E[;P!CE),2@:-B"]CZT)XA,V"^]JKS[8$DF4
MC&NT!HFAL#4JZX VQBYZR!N6%&$W:G-6-/-+P37570:@_B0N'*JJP/!BB[$$BQ8U#K1%TL
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M^Z:!F80M^>VWBP.V;VY_
M$SI^8XL#X/+'9"$[\I#0@#"^7O=ILFL.QAL,G5?3PF_.&PG34EBB_6N^I@#=
MSP?@#4> UY'&.IT_A?"M%$S22:2C \'HX!CJ5.W;@/'&&=2%&BV<806R7ZPDUVU*[X7X^5)),F^:F_8
M[VB 4*2.@&)$&CE :_^>%,]@[:?@< C+0P/['QHY:I
M  4J_1=,#2A);E-@^PD,;?ZF-SA$$ _=KRHV'O[AB5B@_\8Y!&5^4!A=C7KS
M!7PZC?H([email protected]\!JALSJ28%@IEFG)#P%YAI)0,5S4Q3CPEH=EH(J?,S39<"
MP94UXR0&\4Q#L^*?(8/=<4];2TKDF96I7:'>:SB;%
MWZ3WE&WT[1T=H$BDM<$8YPAH3T1=N,/\R!9-Q9WEU3< V[VU9X\__O:RA;8+
M-Y1S2.HR;>NO #J*/*XM+B2$EMJ^T0M\IK_[5Z!6FY/\@UM8E:DT\7
M"B36/:C^"A]FZ4U4E-=2/3G3P*\!%8@2&FIH4S..!*'$.O3TN%)&J9&0FLJX
MMC<*8!!1DL#^==ZV)+MVB[1*PL2U3Y/"O;EF:^5\;"I]1OFCP ^"=.IF-;U!
MP77H:;/*&R%/5(\T_>,Z(*([/3.5 ,P3OJ(4I_:>$<*(O1UL7*SLV!+=/PMSB$WD*:S9D(]S4+
MI(,  MV',UHR#S0$:>NRI,M2W1< -0[I*"].OBR(FMZ_WD])DO^$DQ<6MQZ?
MT(AV"UIX6\]0[W-M68Y%^9;AQH?>"8H29C)Y"F;?+HPNQ(OMUKP^19%HP*%*
MP2D72!+-)[5V?W8.T7Q J/Y+-U$T(70
M"GQ(XEJMW&W6RBX5MO%,4SQ<:,2L'TZ& GO315EFFI*R==^HT?JQ'(I]X-:XN!;V$
M#[7*+"IA(^\4Q9,#[email protected]$?Q&JMLMY:W]$Y1^*FJT*^#K$M1CAT9F>SK
M7@_'Y9@J1 O 6"MRB,=R*]RUM_*$2<[7(!!<#BPC!/E
M0H4U3'-E6Q 6+@>7#NF:J&S5I,.P;M]$[R3-F( *P,N0O#0,QF\"PD'A!=-D
MD:\"A[;J?(UGA%2Q 5"N=9+3W0
MPFBKN!8&=5@JNMIHW_H21('"SU9SVG,PU2XT=5K0&^5E#T8X-_LJFSR(!X4#
MKA;E"G2VJBPAL/-(IF6Z;WP'0D#A<3.SWW81V"KAXY[&A^5XBV@Z?:0)0HG'75%PQ=C )U,7_UQ?F2*1R<7=]HZB8VAMDVI4W
M'+9OK:@&4J OQNY"#$=$F01* M!?1:IU"!,1A6NQFD*8*Y=*$@(5,W9';B])
M2"KF/4-W,P#V=]V\=1W' WO@F36=@S5S].:/9_!E^7#'_=9I[ R2'EGTL!?H"Z<(-$!5:Y4JAUX$W[*-(
MA-$GMYIRE-&Z+6!HR4TVF8;QG)#2!7)E'4IA&Q +BM.K"8D"?YD<8A>*#3[3
MC"VT("461H!3J&(?X7X/XL!A-.QCXY!(P-)=%EP*\3O-WO)C'"MC\$:GS_%5
ME,$44FX9ACUYPV,41UD)OYH*H8/3TG48IZI2S!>U[;GQ'(&M3L'2?]U+"1;XK)U>PC'T8HD[S0@?-GR1!/(Y8UJ[.T3FM7.JG*Q=:FMG7;NEDQ6I?CS>;NW=TQU?A[80G&[JF$MWILD
M;5WI:[7>NW\49W"$P^^%6JN%@K-U$;'52GSU,:6+>L)+$36Z5N_\FC?LX;@N
M@UJ)A8*K?=VR"TH,UO\KH=DL(?M08LZO 1;\#=.-(U<2IN&*1V;HB6U+9?;XM,)G0K,B7CD F$;O.3:* DM3]_0'9
MX%8IX1K7!8SZ\0X'1ZX6#E8U(V *-/H>!7$THH52/-45
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MH:)P!5K0C.HJ)Q:,V_L,W-WJ=Y#G6PP#>YKZ 9%N5+Q/8U% RZ']Z^O+*M(2>#.=X (1?JA;?8$0-U>%>!2=P[28:E=LRA+YFQ]EQ(H
M^-H;XK#];=,HA=N-+/O92TK^G '.JW?X'XV[/X(6H. H+GO9,^ZD0#N1RLSYIUY0QQVN;WEH:H,.I$6?980
M__[UUH]DH?+U1][A$,7:4)4SO@9LX^M$.G(!:FU(+0TE)<^[34 J*(S[)E@7
MH765&9>70-*U_U1@YDM:P#[:+B>>E%0ML(XS5?D^?I($3.IC.,L\
MQG,_S.:/3!G]N2!+0=T(%+A=\6,ELSIX.Y'!J=B(\RUJV++SF=9BO$;6B23&
M];L][*7SM9>"7?+/6)VCJ6#1-NL )(8BKF=7%TRP-Y _Z*"P#TDF]Z_:0I2H
MC6%/WG#8(1N@EA!JO\/A,A'UVJ=)?JWL&_%9FE^>!;A(0761>[H:SSKS4*D5P>E"-N=J?IS/2[OZ=9+'-P)5?I=&:Q 5BH/D7A8";7ETH:0T
MSQQ<056N$1JMO<,!BC" -JL*I5 A[4(F*?>,L)I4REQQG>8@+!1Q FU>]=6"
M#[4+.9^E.;3ZU_]!20(B?YO?DG>BJCNMUP',0Q1QXWWO-DJ1=*$R-7?&["*O
MM/4(^_$.A[@.,AID&RPXJ!QM8.Y',
M:L-"N]7(?;3Z.R!_7%[WO9BW]B37B=3<"S]]8[4WX!\L3/WNAQLS?1T(D7EH
M=?L @G"M;O:40>#L-9.,K?1<#(]?7Y($\&;TG91D*U$B[O<@%A3!_KTIC$0*
MMC)\=Y5C?T'_A^5(+]GC1M 60=&IU9B*D,QR8$#A??9&DK/1OV9IIOM0M7EG
MWN'!L?,@K?*%Z8T/8<@H9F5582OBKB6,?T?B=R*;!RAJ\CCS2O!*)S--S]& 2!(K158:YN8>A"@'M16Q1T=;51
M;>Y?[#VU_ \D"HHW8F5VAGEO($H45RQ$)/-5HC)02_%OE]9R7H+V+0Y'JX>&
M'>;'%@/0,($W/_0&6]49]K\O_NZS:K_9??)(QV]*4U?<"*"@"-7P!"S='(58
M_C9OMRV- 8Z+2BKB3$W=@?B6TE_+U!TX-T;4;:Z'"
MXL*>LL^] 8Z[/B+);_*D1M(%.Y:[-.D<4.0-0:"8J#9<>76P=2$ADXOS?I:E
MF1^-:#0VI;_4%(2$PK.D0Z6!$NP@M)1_.2U>*!D"S?C(M(%K_21_%J;:N9";
MF_FCCM2TZ2Q>,#[K
M8$/X.%T^[/AUX5"-D]R0C]H,3IUFW=:DVPVDWVE3'
M8=6"->#$:?[M_M: $V'Z+8[ $U<*/PC[7S+R82ORQV3IW9LF-% %IRKW!Z)"
M<8ZW:"CHP[84Y,IPKAE7"^ /#/CJ/Z:+_YKV3!<257\@4Z?^ 0L*8;#Q#Q5I(*K?J4#4B;,;_]8#42B#KI2@4 -JO._92,
M+N+)E$1I3D_^U_1LEKW%"9_#94_7I.?SC>7GT8_&RC=Z[?\:
M4($W-[RD+(+@5U,"Z4+8K(9P=D6C?D#8_J]Y@U,4">B-:9EUI99+$N%MMGR,
M]Z^;AEA$I%?:I&T *8H 46,D[AZN-.2!,&#(&_7SC]B8^54;0(K#8'++_)8\
MW%Z-TV<>OC>?]:56@!:%'>.:_6V)N'V30)O_ZWB6&-._;N0='K3=4K#!_K9 
MNO"80&-)0J\M-6
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MJY%Q]<%\E22]!OF7;:+?:?96[M%\-;'TP\ 3BJA>'77?LQ:/+EC#S'
M)824I!>SA)$DT4)Q(V]XB&(WJZ-!*G3VW?W[.\5?Q+ <1UGAJ !K[8)E!F?+
M]V8>:?H'@O>,\F' F+[#6).,;2- @Q\?DZBX&WB)RI'@*HI
M" F%*:G)ILB6U '9"4_!#M(E3K7?0-$4A(3"BM,C4U<1>!B[X%HX"X)X%F7I
M(PD(?6<31/GZLJB)U\?Q7)(>>7SBY=BZX%1X\D,"\-Y)-"-W)%.RS?W>&R+)
MJZA!M018)RK-[RY_S_";YMO\LA7($D?FI>4=?A.?VTRZAJAG$,WW]74KKX_C
MT4HE>YJD;R/K1 9=?I3>@:IR&*-QI5>G706!1>
MN=U+V\':B"+]44FA$?-E;+9RXIQR_\W_5YPL5[E4,=UW/P9)H%C>:\UR$2Q;
M]1R<$GSG3T J&Q"5$UO8!N2"PHH7,<;G5P''5OUXIS3OJOVM1FJ/I!7(IOW[
MMQ*?@/MV^>-VC-,'DK _^&,BO=4@:09;(XIU74F@YG%]!YJ ^#H.NKW&P-,X
MI",6WU^9*"P6[J=OUV'\P\GCY*N!E,:A5:='W,SK]=Q%O"MFK_=PN#O48A6X
MM#EHNA"WMINYWNOAB%1SR%+0RH?2B7ATS?J%H8NA([O2,:V(S#KWBE8/.?S[RDK9WX_)YZJR_
M\WI]%)?3;'(JU)IMV!W*#C\;_6N69OGYB*5$!W PI"'9P/P<:TI88_EIXN> 
M$Q29,LVK8G/2LQ2>;Z <00XEA7%=Q\DC8&C^CAV$L"8PYH06TT.IO$24;_G?]?V848<2N0$(I(
MWKZ41ULD':J8LWX0F^4TKB]#LHIC&:OF/)W(+U3I=> -CU!85?M6)1/IU$XI
M0+06W43OA%7FG_^>T(QS"
MG]+,#S7\C/J=@ !1Q+^:]QZ:RD2@5*UT<^]BW[V&:J1.N\U!:"AB8J8TZRJ+
M"+% 3:J^KXQ,399'32HUH:7MO-X A5.G*<78@2K0B%9ZBSE"R^OHK":!F5IL
M-P:!H?#@-*4;?+P"!='W#*-6D(>$5<@;72Z0+.SY906F_ !@IC0Z'8)@442P
MFE(D?1D(R;)I!!L+A"9^FAU ()#X27?@PX9
MR$-P"WK/CY$VM 29ZI%.>Q ;"G^X@Z5(+ Z!%NF[QC$M1]NP;^-HG%57(DYS
M$!H*A[@#'1)*0Z!"^GYR1"JTZV=Y!+ )#6!@3.!&'JK-IB L%%[QYE5'3Q("
MM6EE$G8]F3;F! !!HW"F-Z]R-N0D4$ACUSM:W]0U9:\^-NB;,OP!$#L*%[T5
MWU0E[ *5:Z5_?FDPW+]>4B:9:)0^+$$4Y9ZB4?$'$@4D_XN&,6;0FS?$\6SXK_^XG";MS_$&2@*;20**L&<@<A(8B)F-#+;C0!/I@
MG#,^S74.AIED?PFM0!%B:48KA.&20^.<\$(KKB+';LLX"@#TVDL6C58;:RXU
M'5>0;A\@0!2A$T-OCQD\@7ZT,OO[F>V.LV2>F_I%\8O119QFWTCV%K/"<3-I
MFI%.''U[$DTDO'\D02L-#M]I8&H&DB-WD#&. )E=92B-GZ!CAB[AK=U9'_ON9S[*4U95<+E/QGZT*""V?F*FJ'Y9'MO]ZX)=/UR_/J.Q 5KI'S@_=K7.UP)P2=,@
MC&'98_L=#9ZZJU:&I
M-+"2WNE8$MI] % 4)H )+0(WEAGD-L]&5J;Q@21Y<447D_#*3R)8\59CT)AV
MHB9>_V#@:J)MCTEG8@G; ! 4R89R0?.GC@+4WJ;*/[ZRX;WX*CT8  #8D!  4              "  2C3  !ID9 0!I